STOCK TITAN

Oncotelic: $63.8K cash and going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. (OTLC) reported $250,000 in service revenue and a $2,915,974 net loss attributable to the company for the nine months ended September 30, 2026, compared with no service revenue and a $1,068,225 net loss in the same 2025 period. For the third quarter, service revenue was zero and attributable net loss was $1,110,345, versus $1,047,365 a year earlier.

At September 30, 2026, cash was $63,798 and restricted cash was $20,000; working capital was negative by approximately $16.8 million. Operating activities used $776,656 in cash during the nine months. The company reported its 45% GMP Bio interest at a fair value of $388 million, with no fair-value adjustment during the period.

Management said the company lacked sufficient cash for 12 months from the report date and that these conditions raise substantial doubt about its ability to continue as a going concern for one year. It plans to seek equity and/or debt financing, but said financing may not be available on favorable terms or at all; without adequate funding, operations may be curtailed or cease.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Major pointGoing-concern doubt concerns the company’s ability to continue for one year.
  • Major pointAttributable net loss was $2,915,974 versus $1,068,225 a year earlier.
  • Moderate pointOperating cash used was $776,656 versus $600,128 a year earlier.

Filing Explained

The note’s conversion is complete, and the additional shares reduce existing holders’ percentage ownership absent offsets.

The May 2022 note’s approximately $847,000 balance, including accrued interest and penalty, was converted in June 2026 into approximately 11.9 million common shares and was fully converted by September 30, 2026, and issuing those shares expands the share base and reduces existing holders’ percentage ownership, absent offsetting changes. At December 31, 2025, reported common shares issued and outstanding were 442,596,856, compared with 457,512,796 at September 30, 2026.

The Oncotelic–Mast Hill equity purchase agreement gives the company the right, but not the obligation, to direct purchases of up to $25 million in common stock, and the filing reports that in June 2026 it instructed a purchase of about 138,000 shares for about $6,600 in cash proceeds. The company says it plans to file a post-effective amendment to the registration statement.

Service revenue $250,000 Nine months ended September 30, 2026; no service revenue in the same 2025 period
Net loss attributable to Oncotelic ($2,915,974) Nine months ended September 30, 2026; compared with ($1,068,225) in 2025
Quarterly net loss attributable to Oncotelic ($1,110,345) Three months ended September 30, 2026; compared with ($1,047,365) in 2025
Net cash used in operating activities ($776,656) Nine months ended September 30, 2026; compared with ($600,128) in 2025
Cash $63,798 As of September 30, 2026
Negative working capital Approximately $16.8 million As of September 30, 2026
GMP Bio investment fair value $388,000,000 As of September 30, 2026; Oncotelic owns 45% of GMP Bio
Convertible debt raised $650,000 Nine months ended September 30, 2026
substantial doubt financial
"These conditions raise substantial doubt about the Company’s ability"
Level 3 financial
"classified within Level 3 of the fair value hierarchy"
Level 3 describes the lowest-confidence category in the accounting “fair value” hierarchy, covering assets or liabilities whose prices are not observable in the market and must be estimated using judgment and internal models. For investors, Level 3 items matter because they can introduce greater uncertainty and potential valuation swings—like valuing a unique antique versus checking a price tag on a supermarket shelf—so they signal higher model risk and lower liquidity.
fair value option financial
"The Company has elected the fair value option under ASC 825"
An accounting election that lets a company measure eligible financial assets and liabilities at their current market price, recording gains and losses in the income statement as those prices move. For investors it matters because choosing the fair value option makes reported profits and asset values respond immediately to market swings—like revaluing a house to today’s sale price—so it can increase earnings volatility while giving a more up‑to‑date view of value.
negative working capital financial
"The Company has a negative working capital of approximately $16.8 million"
Negative working capital happens when a company’s short-term obligations (bills, supplier invoices, debt coming due) exceed its short-term resources (cash, money owed by customers, sellable inventory). For investors it signals how easily a business can meet immediate bills — it can be a warning sign of cash stress or, in some models, an efficient operation that collects cash faster than it pays suppliers; think of a household that consistently has to borrow before payday versus one that gets paid in advance.
contingent consideration financial
"Contingent consideration liability of $2,625,000"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.
TGF-β inhibitor medical
"OT-101, a transforming growth factor-beta (TGF-β) inhibitor"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue and net loss did OTLC report for the first nine months of 2026?

OTLC reported $250,000 in service revenue and a $2,915,974 net loss attributable to the company for the nine months ended September 30, 2026, compared with no service revenue and a $1,068,225 net loss in the same 2025 period.

Why does OTLC report substantial doubt about continuing as a going concern?

Management said OTLC does not have sufficient cash for 12 months from the report date. It cited negative working capital and operating cash outflows, and said financing may not be available on favorable terms or at all. If adequate funding is unavailable, the company may curtail or cease operations.

How much convertible debt did OTLC raise during the first nine months of 2026?

OTLC raised $650,000 from the issuance of convertible debt instruments during the nine months ended September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0000908259 0000908259 2026-01-01 2026-09-30 0000908259 2026-11-13 0000908259 2026-09-30 0000908259 2025-12-31 0000908259 us-gaap:RelatedPartyMember 2026-09-30 0000908259 us-gaap:RelatedPartyMember 2025-12-31 0000908259 us-gaap:NonrelatedPartyMember 2026-09-30 0000908259 us-gaap:NonrelatedPartyMember 2025-12-31 0000908259 2026-07-01 2026-09-30 0000908259 2025-07-01 2025-09-30 0000908259 2025-01-01 2025-09-30 0000908259 us-gaap:PreferredStockMember 2025-12-31 0000908259 us-gaap:CommonStockMember 2025-12-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000908259 us-gaap:RetainedEarningsMember 2025-12-31 0000908259 us-gaap:NoncontrollingInterestMember 2025-12-31 0000908259 us-gaap:PreferredStockMember 2026-03-31 0000908259 us-gaap:CommonStockMember 2026-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000908259 us-gaap:RetainedEarningsMember 2026-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2026-03-31 0000908259 2026-03-31 0000908259 us-gaap:PreferredStockMember 2026-06-30 0000908259 us-gaap:CommonStockMember 2026-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000908259 us-gaap:RetainedEarningsMember 2026-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2026-06-30 0000908259 2026-06-30 0000908259 us-gaap:PreferredStockMember 2024-12-31 0000908259 us-gaap:CommonStockMember 2024-12-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000908259 us-gaap:RetainedEarningsMember 2024-12-31 0000908259 us-gaap:NoncontrollingInterestMember 2024-12-31 0000908259 2024-12-31 0000908259 us-gaap:PreferredStockMember 2025-03-31 0000908259 us-gaap:CommonStockMember 2025-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000908259 us-gaap:RetainedEarningsMember 2025-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2025-03-31 0000908259 2025-03-31 0000908259 us-gaap:PreferredStockMember 2025-06-30 0000908259 us-gaap:CommonStockMember 2025-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000908259 us-gaap:RetainedEarningsMember 2025-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-06-30 0000908259 2025-06-30 0000908259 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0000908259 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000908259 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0000908259 2026-01-01 2026-03-31 0000908259 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0000908259 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000908259 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2026-04-01 2026-06-30 0000908259 2026-04-01 2026-06-30 0000908259 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0000908259 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000908259 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0000908259 us-gaap:NoncontrollingInterestMember 2026-07-01 2026-09-30 0000908259 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0000908259 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000908259 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0000908259 2025-01-01 2025-03-31 0000908259 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0000908259 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000908259 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0000908259 2025-04-01 2025-06-30 0000908259 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0000908259 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000908259 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0000908259 us-gaap:PreferredStockMember 2026-09-30 0000908259 us-gaap:CommonStockMember 2026-09-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0000908259 us-gaap:RetainedEarningsMember 2026-09-30 0000908259 us-gaap:NoncontrollingInterestMember 2026-09-30 0000908259 us-gaap:PreferredStockMember 2025-09-30 0000908259 us-gaap:CommonStockMember 2025-09-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000908259 us-gaap:RetainedEarningsMember 2025-09-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-09-30 0000908259 2025-09-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2026-09-30 0000908259 OTLC:DragonOverseasCapitalLimitedMember 2026-09-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-01-01 2025-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2026-06-23 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2026-06-30 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2026-08-03 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2026-01-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoAndJulyTwoThousandAndTwentyFiveNoteMember OTLC:JVMember 2026-01-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2025-07-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoNoteMember OTLC:JVMember 2025-07-31 0000908259 OTLC:EquityPurchaseAgreementMember 2025-08-01 2025-08-31 0000908259 OTLC:JHDarbiePlacementAgreementMember OTLC:AccreditedInvestorsMember 2025-12-01 2025-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2022-05-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember 2026-06-30 0000908259 us-gaap:CommonStockMember OTLC:SecuritiesPurchaseAgreementsMember 2026-09-01 2026-09-30 0000908259 OTLC:SecuritiesPurchaseAgreementAndPurchaseAgreementMember OTLC:GoldenMountainPartnersMember 2022-01-31 0000908259 OTLC:SecuritiesPurchaseAgreementAndPurchaseAgreementMember OTLC:GoldenMountainPartnersMember 2020-06-30 0000908259 OTLC:SinceInceptionDateMember 2024-01-01 2024-12-31 0000908259 2025-01-01 2025-12-31 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-01-01 2025-12-31 0000908259 OTLC:PointRMergerAgreementMember 2026-01-01 2026-09-30 0000908259 OTLC:PointRMergerAgreementMember 2026-09-30 0000908259 OTLC:MastHillMember 2026-01-01 2026-09-30 0000908259 OTLC:LunaiBioworksIncMember 2026-09-30 0000908259 OTLC:LunaiBioworksIncMember 2026-01-01 2026-09-30 0000908259 OTLC:LunaiMember 2026-01-01 2026-09-30 0000908259 OTLC:LunaiBioworksIncMember 2026-09-30 0000908259 OTLC:LunaiBioworksIncMember 2026-09-30 0000908259 OTLC:LunaiBioworksIncMember 2026-06-30 0000908259 OTLC:LunaiBioworksIncMember 2026-04-01 2026-06-30 0000908259 OTLC:LunaiBioworksIncMember 2026-01-01 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:PointRMergerMember 2026-01-01 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:PointRMergerMember 2025-01-01 2025-12-31 0000908259 us-gaap:ConvertibleDebtSecuritiesMember 2026-07-01 2026-09-30 0000908259 us-gaap:ConvertibleDebtSecuritiesMember 2026-01-01 2026-09-30 0000908259 us-gaap:ConvertibleDebtSecuritiesMember 2025-07-01 2025-09-30 0000908259 us-gaap:ConvertibleDebtSecuritiesMember 2025-01-01 2025-09-30 0000908259 srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember 2026-09-30 0000908259 srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember 2025-12-31 0000908259 OTLC:GMPBiotechnologyLimitedMember 2026-09-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2026-01-01 2026-09-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-12-31 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-01-01 2025-12-31 0000908259 us-gaap:FairValueInputsLevel1Member OTLC:JVMember 2025-12-31 0000908259 us-gaap:FairValueInputsLevel2Member OTLC:JVMember 2025-12-31 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:JVMember 2025-12-31 0000908259 OTLC:JVMember 2025-12-31 0000908259 us-gaap:FairValueInputsLevel1Member OTLC:LunaiBioworksIncMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel2Member OTLC:LunaiBioworksIncMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:LunaiBioworksIncMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:MeasurementInputRevenueGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember srt:MinimumMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:MeasurementInputRevenueGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember srt:MaximumMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputEbitdaMultipleMember us-gaap:ValuationTechniqueDiscountedCashFlowMember srt:MaximumMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputEbitdaMultipleMember us-gaap:ValuationTechniqueDiscountedCashFlowMember srt:MinimumMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:MeasurementInputWeightedAverageCostOfCapitalMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:TerminalGrowthRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:ProductPenetrationRatesMember us-gaap:ValuationTechniqueDiscountedCashFlowMember srt:MinimumMember 2026-09-30 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:ProductPenetrationRatesMember us-gaap:ValuationTechniqueDiscountedCashFlowMember srt:MaximumMember 2026-09-30 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2026-09-30 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2026-09-30 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2025-12-31 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2025-12-31 0000908259 us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2026-09-30 0000908259 us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2026-09-30 0000908259 us-gaap:MeasurementInputSharePriceMember srt:MinimumMember 2025-12-31 0000908259 us-gaap:MeasurementInputSharePriceMember srt:MaximumMember 2025-12-31 0000908259 us-gaap:MeasurementInputExpectedTermMember 2026-01-01 2026-09-30 0000908259 us-gaap:MeasurementInputExpectedTermMember 2025-01-01 2025-12-31 0000908259 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2026-09-30 0000908259 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2026-09-30 0000908259 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2025-12-31 0000908259 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2025-12-31 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember 2026-09-30 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0000908259 OTLC:MergerAgreementMember 2019-04-30 0000908259 OTLC:MergerAgreementMember 2019-04-01 2019-04-30 0000908259 OTLC:MergerAgreementMember OTLC:PointRMember 2019-11-30 0000908259 OTLC:MergerAgreementMember OTLC:PointRMember 2022-01-01 2026-09-30 0000908259 us-gaap:InProcessResearchAndDevelopmentMember 2026-09-30 0000908259 us-gaap:InProcessResearchAndDevelopmentMember 2025-12-31 0000908259 OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember OTLC:ConvertibleDebenturesMember 2026-09-30 0000908259 OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember OTLC:ConvertibleDebenturesMember 2025-12-31 0000908259 OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember OTLC:ConvertibleDebenturesMember 2026-09-30 0000908259 OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember OTLC:ConvertibleDebenturesMember 2025-12-31 0000908259 OTLC:TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember OTLC:ConvertibleDebenturesMember 2026-09-30 0000908259 OTLC:TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember OTLC:ConvertibleDebenturesMember 2025-12-31 0000908259 OTLC:ConvertibleDebenturesMember 2026-09-30 0000908259 OTLC:ConvertibleDebenturesMember 2025-12-31 0000908259 OTLC:FivePercentConvertibleNotePayableStephenBoeschMember OTLC:FallTwoThousandNineteenNotesMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNotePayableStephenBoeschMember OTLC:FallTwoThousandNineteenNotesMember 2025-12-31 0000908259 OTLC:FivePercentConvertibleNotePayableRelatedPartyMember OTLC:FallTwoThousandNineteenNotesMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNotePayableRelatedPartyMember OTLC:FallTwoThousandNineteenNotesMember 2025-12-31 0000908259 OTLC:FivePercentConvertibleNotePayableDrSanjayJhaMember OTLC:FallTwoThousandNineteenNotesMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNotePayableDrSanjayJhaMember OTLC:FallTwoThousandNineteenNotesMember 2025-12-31 0000908259 OTLC:FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember OTLC:FallTwoThousandNineteenNotesMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember OTLC:FallTwoThousandNineteenNotesMember 2025-12-31 0000908259 OTLC:FivePercentConvertibleNotePayableBridgeInvestorsMember OTLC:FallTwoThousandNineteenNotesMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNotePayableBridgeInvestorsMember OTLC:FallTwoThousandNineteenNotesMember 2025-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember 2026-09-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember 2025-12-31 0000908259 OTLC:FivePercentConvertibleNoteAutotelicIncRelatedPartyMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNoteAutotelicIncRelatedPartyMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-12-31 0000908259 OTLC:FivePercentConvertibleNoteBridgeInvestorsMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNoteBridgeInvestorsMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-12-31 0000908259 OTLC:FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-09-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-12-31 0000908259 OTLC:SixteenPercentConvertibleNoteAccreditedInvestorsMember OTLC:MarchTwentyTwentyTwoNotesMember 2026-09-30 0000908259 OTLC:SixteenPercentConvertibleNoteAccreditedInvestorsMember OTLC:MarchTwentyTwentyTwoNotesMember 2025-12-31 0000908259 OTLC:TwoPercentageConvertibleNotesForeverProsperityMember OTLC:DebtClinicalTrialsGMPMember 2026-09-30 0000908259 OTLC:TwoPercentageConvertibleNotesForeverProsperityMember OTLC:DebtClinicalTrialsGMPMember 2025-12-31 0000908259 OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember OTLC:MayTwoThousandTwentyTwoNoteMember 2026-09-30 0000908259 OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember OTLC:MayTwoThousandTwentyTwoNoteMember 2025-12-31 0000908259 OTLC:AccruedAndUnpaidInterestMember OTLC:JHDarbiePPMTwoDebtMember 2026-09-30 0000908259 OTLC:AccruedAndUnpaidInterestMember OTLC:JHDarbiePPMTwoDebtMember 2025-12-31 0000908259 OTLC:TenPercentageConvertibleNotesAccreditedInvestorsMember OTLC:JulyTwoThousandTwentyFiveNoteMember 2026-09-30 0000908259 OTLC:TenPercentageConvertibleNotesAccreditedInvestorsMember OTLC:JulyTwoThousandTwentyFiveNoteMember 2025-12-31 0000908259 OTLC:TenPercentageConvertibleNotesAccreditedInvestorsMember OTLC:JanuaryTwoThousandTwentySixNoteMember 2026-09-30 0000908259 OTLC:TenPercentageConvertibleNotesAccreditedInvestorsMember OTLC:JanuaryTwoThousandTwentySixNoteMember 2025-12-31 0000908259 OTLC:TwelvePercentageConvertibleNotesAccreditedInvestorsMember OTLC:PacificPierTwoThousandTwentySixNoteMember 2026-09-30 0000908259 OTLC:TwelvePercentageConvertibleNotesAccreditedInvestorsMember OTLC:PacificPierTwoThousandTwentySixNoteMember 2025-12-31 0000908259 OTLC:ShortTermDebtBridgeInvestorsMember OTLC:OtherDebtMember 2026-09-30 0000908259 OTLC:ShortTermDebtBridgeInvestorsMember OTLC:OtherDebtMember 2025-12-31 0000908259 OTLC:ShortTermDebtFromCFOMember OTLC:OtherDebtMember 2026-09-30 0000908259 OTLC:ShortTermDebtFromCFOMember OTLC:OtherDebtMember 2025-12-31 0000908259 OTLC:ShortTermDebtAutotelicIncRelatedPartyMember OTLC:OtherDebtMember 2026-09-30 0000908259 OTLC:ShortTermDebtAutotelicIncRelatedPartyMember OTLC:OtherDebtMember 2025-12-31 0000908259 OTLC:ShortTermDebtFromCEOMember OTLC:OtherDebtMember 2026-09-30 0000908259 OTLC:ShortTermDebtFromCEOMember OTLC:OtherDebtMember 2025-12-31 0000908259 OTLC:ShortTermDebtAccreditedInvestorMember OTLC:OtherDebtMember 2026-09-30 0000908259 OTLC:ShortTermDebtAccreditedInvestorMember OTLC:OtherDebtMember 2025-12-31 0000908259 OTLC:TwelvePercentageConvertibleLongTermDebtNetMember OTLC:JHDarbiePPM3DebtMember 2026-09-30 0000908259 OTLC:TwelvePercentageConvertibleLongTermDebtNetMember OTLC:JHDarbiePPM3DebtMember 2025-12-31 0000908259 OTLC:BridgeInvestorMember OTLC:ConvertibleDebenturesMember 2026-09-30 0000908259 OTLC:BridgeInvestorMember 2026-09-30 0000908259 OTLC:BridgeInvestorMember OTLC:ConvertibleDebenturesMember 2025-12-31 0000908259 OTLC:BridgeInvestorMember 2025-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:BridgeInvestorMember us-gaap:ConvertibleDebtMember 2019-04-30 0000908259 OTLC:FallTwoThousandNineteenDebtFinancingMember 2019-12-01 2019-12-31 0000908259 OTLC:FallTwoThousandNineteenDebtFinancingMember 2019-12-31 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember OTLC:DrVuongTrieuMember 2019-12-31 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember OTLC:DrVuongTrieuMember 2019-12-31 2019-12-31 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember OTLC:DrSanjayJhaMember 2019-12-31 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember OTLC:DrVuongTrieuMember us-gaap:RelatedPartyMember 2019-12-31 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember OTLC:ChulhoParkMember us-gaap:RelatedPartyMember 2019-12-31 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember OTLC:AmitShahMember us-gaap:RelatedPartyMember 2019-12-31 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember OTLC:TwoAccreditedInvestorsMember 2019-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2026-09-30 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember 2026-07-01 2026-09-30 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember 2026-01-01 2026-09-30 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember 2025-07-01 2025-09-30 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:FallTwoThousandNineteenNotesMember 2025-01-01 2025-09-30 0000908259 OTLC:GMPNoteMember 2020-06-30 0000908259 OTLC:GMPNoteTwoMember 2021-09-30 0000908259 OTLC:OctoberPurchaseAgreementMember OTLC:ConvertiblePromissoryNoteMember 2021-10-31 0000908259 OTLC:JanuaryPurchaseAgreementMember OTLC:ConvertiblePromissoryNoteMember 2022-01-31 0000908259 OTLC:UnsecuredConvertibleNotePurchaseAgreementsMember 2021-10-31 0000908259 OTLC:GoldenMountainPartnersLLCMember 2026-09-30 0000908259 OTLC:GoldenMountainPartnersLLCMember 2025-12-31 0000908259 OTLC:GoldenMountainPartnersLLCMember 2026-07-01 2026-09-30 0000908259 OTLC:GoldenMountainPartnersLLCMember 2026-01-01 2026-09-30 0000908259 OTLC:GoldenMountainPartnersLLCMember 2025-07-01 2025-09-30 0000908259 OTLC:GoldenMountainPartnersLLCMember 2025-01-01 2025-09-30 0000908259 OTLC:NotePurchaseAgreementMember 2021-08-31 0000908259 OTLC:NotePurchaseAgreementMember 2021-08-01 2021-08-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-07-01 2026-09-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-01-01 2026-09-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-07-01 2025-09-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-01-01 2025-09-30 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:FourthManLLCMember 2022-03-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:FiveInstitutionalInvestorsMember 2022-03-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:FourthManLLCMember 2023-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:FourthManLLCMember 2026-04-01 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:FourthManLLCMember 2026-09-30 0000908259 OTLC:PlacementAgentMember OTLC:SecuritiesPurchaseAgreementMember 2026-01-01 2026-09-30 0000908259 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:BlueLakeMember 2025-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:BlueLakeMember 2026-04-01 2026-04-30 0000908259 OTLC:FourthManConvertibleNoteMember 2026-07-01 2026-09-30 0000908259 OTLC:FourthManConvertibleNoteMember 2026-01-01 2026-09-30 0000908259 OTLC:FourthManConvertibleNoteMember 2025-07-01 2025-09-30 0000908259 OTLC:FourthManConvertibleNoteMember 2025-01-01 2025-09-30 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:OneInstitutionalInvestorsMember 2022-05-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2026-06-30 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2026-06-01 2026-06-30 0000908259 OTLC:MayTwoThousandAndTwentyTwoMastFinancingMember 2026-07-01 2026-09-30 0000908259 OTLC:MayTwoThousandAndTwentyTwoMastFinancingMember 2026-01-01 2026-09-30 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember 2025-07-31 0000908259 us-gaap:WarrantMember OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember 2025-07-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember 2025-07-31 2025-07-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember OTLC:JVMember 2025-07-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember 2026-01-01 2026-09-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember 2026-07-01 2026-09-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember 2026-01-01 2026-09-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember 2025-12-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember 2025-01-01 2025-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember 2026-01-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember 2026-01-23 0000908259 us-gaap:WarrantMember OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember 2026-01-31 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember 2026-01-01 2026-01-31 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember OTLC:JVMember 2025-07-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember 2026-01-01 2026-09-30 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember 2026-07-01 2026-09-30 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember 2026-01-01 2026-09-30 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember 2026-06-30 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember 2026-06-23 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember OTLC:SecuritiesPurchaseAgreementMember 2026-06-23 2026-06-23 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember 2026-06-23 2026-06-23 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember 2026-01-01 2026-09-30 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember 2026-07-01 2026-09-30 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember 2025-01-01 2025-12-31 0000908259 OTLC:PacificPierAugustTwentyTwentySixFinancingtMember 2026-08-03 0000908259 OTLC:PacificPierAugustTwentyTwentySixFinancingtMember 2026-08-03 2026-08-03 0000908259 OTLC:PacificPierAugustTwentyTwentySixFinancingtMember 2026-01-01 2026-09-30 0000908259 OTLC:PacificPierAugustTwentyTwentySixFinancingtMember 2026-07-01 2026-09-30 0000908259 OTLC:AutotelicIncMember 2025-01-01 2025-01-01 0000908259 OTLC:AutotelicIncMember 2025-12-31 0000908259 OTLC:AutotelicIncMember 2026-09-30 0000908259 OTLC:AutotelicIncMember 2026-01-01 2026-09-30 0000908259 srt:ChiefFinancialOfficerMember 2025-01-01 0000908259 srt:ChiefFinancialOfficerMember 2025-01-01 2025-12-31 0000908259 srt:ChiefFinancialOfficerMember 2026-09-30 0000908259 srt:ChiefExecutiveOfficerMember 2023-12-01 2023-12-31 0000908259 srt:ChiefExecutiveOfficerMember 2025-12-31 0000908259 srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0000908259 srt:ChiefExecutiveOfficerMember 2026-09-30 0000908259 OTLC:BridgeInvestorsAndOthersMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNoteAccreditedInvestorsMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-09-30 0000908259 OTLC:FivePercentConvertibleNoteAccreditedInvestorsMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-12-31 0000908259 OTLC:AugustTwoThousandAndTwentyOneMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2026-09-30 0000908259 OTLC:AugustTwoThousandAndTwentyOneMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-12-31 0000908259 OTLC:FourthManLLCMember OTLC:SixteenPercentCouponMarchTwoThousandTwentyThreeMember OTLC:MarchTwentyTwentyTwoNotesMember 2026-09-30 0000908259 OTLC:FourthManLLCMember OTLC:SixteenPercentCouponMarchTwoThousandTwentyThreeMember OTLC:MarchTwentyTwentyTwoNotesMember 2025-12-31 0000908259 OTLC:FourthManLLCMember OTLC:MarchTwentyTwentyTwoNotesMember 2026-09-30 0000908259 OTLC:FourthManLLCMember OTLC:MarchTwentyTwentyTwoNotesMember 2025-12-31 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember OTLC:MastHillMember 2026-09-30 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember OTLC:MastHillMember 2025-12-31 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember 2026-09-30 0000908259 OTLC:MayTwoThousandTwentyTwoNoteMember 2025-12-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember OTLC:TenPercentCouponAugustTwoThousandTwentySixMember 2026-09-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember OTLC:TenPercentCouponAugustTwoThousandTwentySixMember 2025-12-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastFinancingMember 2026-09-30 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember OTLC:TenPercentCouponJanuaryTwoThousandTwentySevenMember 2026-09-30 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember OTLC:TenPercentCouponJanuaryTwoThousandTwentySevenMember 2025-12-31 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember 2026-09-30 0000908259 OTLC:JanuaryTwoThousandAndTwentySixMastFinancingMember 2025-12-31 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember OTLC:TwelvePercentCouponJuneTwoThousandTwentySixMember 2026-09-30 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember OTLC:TwelvePercentCouponJuneTwoThousandTwentySixMember 2025-12-31 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember 2026-09-30 0000908259 OTLC:PacificPierJuneTwentyTwentySixFinancingtMember 2025-12-31 0000908259 OTLC:PacificPierAugustTwentyTwentySixFinancingtMember OTLC:TwelvePercentCouponJuneTwoThousandTwentySixMember 2026-09-30 0000908259 OTLC:PacificPierAugustTwentyTwentySixFinancingtMember OTLC:TwelvePercentCouponJuneTwoThousandTwentySixMember 2025-12-31 0000908259 OTLC:PacificPierAugustTwentyTwentySixFinancingtMember 2026-09-30 0000908259 OTLC:PacificPierAugustTwentyTwentySixFinancingtMember 2025-12-31 0000908259 OTLC:OtherShortTermAdvancesMember srt:ChiefFinancialOfficerMember 2026-09-30 0000908259 OTLC:OtherShortTermAdvancesMember srt:ChiefFinancialOfficerMember 2025-12-31 0000908259 OTLC:OtherShortTermAdvancesMember OTLC:BridgeInvestorsAndOthersMember 2026-09-30 0000908259 OTLC:OtherShortTermAdvancesMember OTLC:BridgeInvestorsAndOthersMember 2025-12-31 0000908259 OTLC:OtherShortTermAdvancesMember OTLC:AutotelicIncMember 2026-09-30 0000908259 OTLC:OtherShortTermAdvancesMember OTLC:AutotelicIncMember 2025-12-31 0000908259 OTLC:OtherShortTermAdvancesMember srt:ChiefExecutiveOfficerMember 2026-09-30 0000908259 OTLC:OtherShortTermAdvancesMember srt:ChiefExecutiveOfficerMember 2025-12-31 0000908259 OTLC:OtherShortTermAdvancesMember OTLC:AccreditedInvestorMember 2026-09-30 0000908259 OTLC:OtherShortTermAdvancesMember OTLC:AccreditedInvestorMember 2025-12-31 0000908259 OTLC:OtherShortTermAdvancesMember 2026-09-30 0000908259 OTLC:OtherShortTermAdvancesMember 2025-12-31 0000908259 OTLC:JVMember 2026-09-30 0000908259 OTLC:JVMember 2026-09-30 0000908259 OTLC:GMPBioMember 2026-09-30 0000908259 OTLC:DragonOverseasMember 2026-09-30 0000908259 OTLC:GoldenMountainPartnersMember 2026-09-30 0000908259 OTLC:JVMember 2026-01-01 2026-09-30 0000908259 OTLC:JVMember 2025-01-01 2025-09-30 0000908259 OTLC:GMPBiotechnologyLimitedMember 2025-12-31 0000908259 OTLC:JHDarbiePlacementAgreementMember OTLC:AccreditedInvestorsMember 2023-07-01 2024-01-31 0000908259 us-gaap:WarrantMember OTLC:AccreditedInvestorsMember 2024-01-31 0000908259 us-gaap:WarrantMember OTLC:AccreditedInvestorsMember 2025-12-31 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember us-gaap:CommonStockMember 2026-09-30 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember us-gaap:ConvertibleDebtMember 2026-01-01 2026-09-30 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember us-gaap:ConvertibleDebtMember 2025-01-01 2025-09-30 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2026-01-01 2026-09-30 0000908259 OTLC:SubscriptionAgreementsTwoMember OTLC:AccreditedInvestorsMember us-gaap:RelatedPartyMember 2026-09-30 0000908259 OTLC:SubscriptionAgreementsTwoMember OTLC:AccreditedInvestorsMember us-gaap:RelatedPartyMember 2025-12-31 0000908259 OTLC:SubscriptionAgreementsTwoMember 2026-09-30 0000908259 OTLC:SubscriptionAgreementsTwoMember 2025-12-31 0000908259 us-gaap:MeasurementInputExpectedTermMember OTLC:JHDarbiePlacementAgreementTwoMember 2026-09-30 0000908259 us-gaap:MeasurementInputPriceVolatilityMember OTLC:JHDarbiePlacementAgreementTwoMember 2026-09-30 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember OTLC:JHDarbiePlacementAgreementTwoMember 2026-09-30 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember OTLC:JHDarbiePlacementAgreementTwoMember 2026-09-30 0000908259 us-gaap:MeasurementInputExpectedTermMember OTLC:JHDarbieSubscriptionAgreementMember 2026-09-30 0000908259 us-gaap:MeasurementInputPriceVolatilityMember OTLC:JHDarbieSubscriptionAgreementMember srt:MinimumMember 2026-09-30 0000908259 us-gaap:MeasurementInputPriceVolatilityMember OTLC:JHDarbieSubscriptionAgreementMember srt:MaximumMember 2026-09-30 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember OTLC:JHDarbieSubscriptionAgreementMember srt:MinimumMember 2026-09-30 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember OTLC:JHDarbieSubscriptionAgreementMember srt:MaximumMember 2026-09-30 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember OTLC:JHDarbieSubscriptionAgreementMember 2026-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember OTLC:AccreditedInvestorsMember 2025-12-01 2025-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:SubscriptionAgreementsMember 2025-12-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember OTLC:OneConvertiblePromissoryNoteMember 2025-12-01 2025-12-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember OTLC:OneConvertiblePromissoryNoteMember 2025-12-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember us-gaap:WarrantMember 2025-12-01 2025-12-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember us-gaap:WarrantMember 2025-12-31 0000908259 OTLC:JHDarbiePPMThreeDebtMember OTLC:SubscriptionAgreementsMember 2025-12-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember srt:MinimumMember 2024-05-01 2024-05-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember srt:MaximumMember 2024-05-01 2024-05-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2024-05-01 2024-05-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2024-05-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2025-12-01 2025-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:AccreditedInvestorsMember 2025-12-01 2025-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:NewSubscriptionAgreementsMember 2025-12-31 0000908259 OTLC:NewSubscriptionAgreementsMember OTLC:JHDarbiePPMThreeDebtMember 2025-12-31 2025-12-31 0000908259 OTLC:NewSubscriptionAgreementsMember OTLC:JHDarbiePPMThreeDebtMember 2025-12-31 0000908259 OTLC:JHDarbiePPMThreeDebtMember OTLC:NewSubscriptionAgreementsMember 2026-01-01 2026-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2026-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2026-01-01 2026-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember OTLC:OneConvertiblePromissoryNoteMember 2026-01-01 2026-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember OTLC:OneConvertiblePromissoryNoteMember 2026-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2025-01-01 2025-12-31 0000908259 OTLC:JHDarbieSubscriptionAgreementMember us-gaap:CommonStockMember 2026-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember 2025-01-01 2025-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember us-gaap:ConvertibleDebtMember 2026-07-01 2026-09-30 0000908259 OTLC:JHDarbieSubscriptionAgreementMember us-gaap:ConvertibleDebtMember 2026-01-01 2026-09-30 0000908259 OTLC:SubscriptionAgreementsMember OTLC:JHDarbiePPMThreeDebtMember us-gaap:RelatedPartyMember 2026-09-30 0000908259 OTLC:SubscriptionAgreementsMember OTLC:JHDarbiePPMThreeDebtMember us-gaap:RelatedPartyMember 2025-12-31 0000908259 OTLC:SubscriptionAgreementsTwoMember OTLC:JHDarbiePPMThreeDebtMember 2026-09-30 0000908259 OTLC:SubscriptionAgreementsTwoMember OTLC:JHDarbiePPMThreeDebtMember 2025-12-31 0000908259 OTLC:ServiceAgreementMember us-gaap:IntellectualPropertyMember OTLC:LunaiBioworksIncMember 2026-04-17 2026-04-17 0000908259 OTLC:MergerAgreementMember OTLC:LunaiBioworksIncMember 2026-04-26 0000908259 OTLC:MergerAgreementMember OTLC:LunaiBioworksIncMember OTLC:SeriesBConvertiblePreferredStockMember 2026-05-01 0000908259 OTLC:MergerAgreementMember OTLC:LunaiBioworksIncMember OTLC:SeriesBConvertiblePreferredStockMember 2026-05-01 2026-05-01 0000908259 OTLC:MergerAgreementMember OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember 2026-05-01 0000908259 OTLC:MergerAgreementMember OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember 2026-05-01 0000908259 OTLC:MergerAgreementMember OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember 2026-05-01 2026-05-01 0000908259 OTLC:AssetTransferAgreementMember OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember 2026-04-30 0000908259 OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember 2026-09-30 0000908259 OTLC:LunaiBioworksIncMember us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-09-30 0000908259 OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember us-gaap:RelatedPartyMember 2025-07-01 2025-09-30 0000908259 OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0000908259 OTLC:VuongTrieuMember OTLC:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember 2019-04-30 0000908259 OTLC:VuongTrieuMember OTLC:SecuritiesPurchaseAgreementMember 2019-04-30 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember 2019-04-01 2019-04-30 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember 2019-04-30 0000908259 OTLC:FallTwoThousandAndNineteenNoteMember OTLC:VuongTrieuMember 2019-04-01 2019-04-30 0000908259 OTLC:VuongTrieuMember 2025-01-01 0000908259 OTLC:VuongTrieuMember 2025-12-31 0000908259 OTLC:VuongTrieuMember 2026-09-30 0000908259 OTLC:VuongTrieuMember srt:MaximumMember OTLC:SeriesAConvertiblePreferredStockMember 2025-11-01 2025-11-30 0000908259 us-gaap:CommonStockMember OTLC:VuongTrieuMember 2025-11-01 2025-11-30 0000908259 OTLC:VuongTrieuMember srt:MaximumMember OTLC:SeriesAConvertiblePreferredStockMember 2026-01-01 2026-01-31 0000908259 us-gaap:CommonStockMember OTLC:VuongTrieuMember 2026-01-01 2026-01-31 0000908259 OTLC:DrVuongTrieuMember 2025-12-31 0000908259 OTLC:DrVuongTrieuMember 2026-09-30 0000908259 OTLC:AutotelicIncMember OTLC:AugustTwoThousandAndTwentyOneNoteMember 2025-01-01 0000908259 OTLC:AutotelicIncMember OTLC:AugustTwoThousandAndTwentyOneNoteMember 2026-09-30 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2026-07-01 2026-09-30 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2026-01-01 2026-09-30 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2025-07-01 2025-09-30 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2025-01-01 2025-09-30 0000908259 OTLC:StevenKingMember OTLC:TermSheetAgreementMember 2024-04-01 2024-04-30 0000908259 OTLC:EquityPurchaseAgreementMember us-gaap:WarrantMember 2025-08-31 0000908259 us-gaap:CommonStockMember OTLC:EquityPurchaseAgreementMember 2025-08-01 2025-08-31 0000908259 OTLC:EquityPurchaseAgreementMember 2025-08-31 0000908259 2026-01-01 2026-01-31 0000908259 2026-04-01 2026-04-30 0000908259 2026-05-01 2026-05-31 0000908259 2026-05-31 0000908259 2026-06-01 2026-06-30 0000908259 OTLC:PacificPierMember 2026-06-01 2026-06-30 0000908259 OTLC:PacificPierMember 2026-08-01 2026-08-31 0000908259 OTLC:FourthManLLCMember 2025-03-01 2025-03-31 0000908259 OTLC:SpecialPurchaseAgreementsMember 2026-07-31 0000908259 OTLC:SpecialPurchaseAgreementsMember 2026-08-31 0000908259 OTLC:ValorNationMember 2025-08-01 2025-08-31 0000908259 OTLC:MastHillFundLPMember 2025-08-31 0000908259 OTLC:MastHillFundLPMember 2025-08-01 2026-08-31 0000908259 2025-09-01 2025-09-30 0000908259 OTLC:SeriesAConvertiblePreferredStockMember 2026-09-30 0000908259 OTLC:VuongTrieuMember srt:MaximumMember OTLC:SeriesAConvertiblePreferredStockMember 2025-01-01 2025-12-31 0000908259 OTLC:RestrictedStockAwardsMember OTLC:DrVuongTrieuMember 2026-01-01 2026-09-30 0000908259 OTLC:RestrictedStockAwardsMember OTLC:DrVuongTrieuMember 2026-07-01 2026-09-30 0000908259 OTLC:RestrictedStockAwardsMember OTLC:DrVuongTrieuMember 2025-01-01 2025-12-31 0000908259 OTLC:DrVuongTrieuMember 2026-01-01 2026-09-30 0000908259 us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0000908259 us-gaap:PreferredStockMember 2025-01-01 2025-12-31 0000908259 OTLC:JeffersonCapitalMember 2025-08-01 2025-08-31 0000908259 OTLC:JeffersonCapitalMember 2026-09-30 0000908259 OTLC:ValorNationMember 2025-01-01 2025-12-31 0000908259 OTLC:BoxCapitalIncMember 2025-12-01 2025-12-31 0000908259 OTLC:BoxCapitalIncMember 2026-07-01 2026-09-30 0000908259 OTLC:BoxCapitalIncMember 2026-01-01 2026-09-30 0000908259 OTLC:TwoThousandSeventeenEquityIncentivePlanMember srt:MaximumMember 2026-09-30 0000908259 OTLC:ExercisePriceOneMember 2026-01-01 2026-09-30 0000908259 OTLC:ExercisePriceOneMember 2026-09-30 0000908259 OTLC:ExercisePriceTwoMember 2026-01-01 2026-09-30 0000908259 OTLC:ExercisePriceTwoMember 2026-09-30 0000908259 OTLC:ExercisePriceThreeMember 2026-01-01 2026-09-30 0000908259 OTLC:ExercisePriceThreeMember 2026-09-30 0000908259 OTLC:ExercisePriceOneMember us-gaap:WarrantMember 2026-09-30 0000908259 OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2026-09-30 0000908259 OTLC:ExercisePriceThreeMember us-gaap:WarrantMember 2026-09-30 0000908259 OTLC:ExercisePriceFourMember us-gaap:WarrantMember 2026-09-30 0000908259 OTLC:ExercisePriceFiveMember us-gaap:WarrantMember 2026-09-30 0000908259 OTLC:MergerAgreementMember OTLC:PointRMergerMember 2026-01-01 2026-09-30 0000908259 OTLC:MergerAgreementMember OTLC:PointRMergerMember 2026-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended September 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period from _________ to _________

 

Commission file number: 000-21990

 

Oncotelic Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   13-3679168
(State or other jurisdiction of
incorporation or organization)
 

(I.R.S. Employer

Identification No.)

 

29397 Agoura Road Suite 107

Agoura Hills, CA

  91301
(Address of principal executive offices)   (Zip Code)

 

(650) 635-7000

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock   OTLC   OTCQB

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” a “smaller reporting company” and an “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
       
Non-accelerated filer ☒ Smaller reporting company ☒
       
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 13, 2026, there were 457,512,796 shares of the registrant’s common stock outstanding.

 

 

 

 

 

 

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026

 

TABLE OF CONTENTS

 

      Page
       
PART I. FINANCIAL INFORMATION   3
       
ITEM 1. Financial Statements (unaudited)   3
       
  Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025   3
       
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025   4
       
  Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025   5
       
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025   7
       
  Notes to Condensed Consolidated Financial Statements   8
       
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   44
       
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk   59
       
ITEM 4. Controls and Procedures   59
       
PART II. OTHER INFORMATION   61
       
ITEM 1. Legal Proceedings   61
       
ITEM 1A. Risk Factors   61
       
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds   61
       
ITEM 3. Defaults Upon Senior Securities   61
       
ITEM 4. Mine Safety Disclosures   61
       
ITEM 5. Other Information   61
       
ITEM 6. Exhibits, Financial Statement Schedules   62
       
SIGNATURES   63

 

2

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

   September 30,   December 31, 
   2026   2025 
         
ASSETS          
Current assets:          
Cash  $63,798   $88,857 
Restricted cash   20,000   20,000 
Accounts receivable   2,057    51,324 
Prepaid and other current assets   1,186,671    1,038,071 
           
Total current assets   1,272,526    1,198,252 
           
In process R&D   1,101,760    1,101,760 
Goodwill, net of impairment   2,788,230    2,788,230 
Investment in equity securities   650,000    - 
Investment in GMP Bio at fair value   388,000,000    388,000,000 
Total assets  $393,812,516   $393,088,242 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable and accrued liabilities  $2,437,517   $2,571,123 
Accounts payable to related party   349,655    348,111 
Contingent consideration   2,625,000    2,625,000 
Derivative liability on notes   228,452    350,044 
Convertible and short-term debt, net of costs   8,209,614    8,225,669 
Convertible debt and short-term debt - related party, net of costs   4,192,897    4,023,331 
           
Total current liabilities   18,043,135    18,143,278 
           
Convertible long-term debt, net of costs   1,922,616    1,663,405 
Deferred income tax liability   111,550,000    111,550,000 
Total non current liabilities   113,472,616    113,213,405 
           
Total liabilities   131,515,751    131,356,683 
           
Commitments and contingencies (Note 15)   -    - 
           
Stockholders’ equity:          
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 50,900 and 24,388 shares issued and outstanding, respectively   509    244 
Common stock, $0.01 par value; 750,000,000 shares authorized; 457,512,796 and 442,596,856 issued and outstanding, respectively   4,575,125    4,425,968 
Additional paid-in capital   50,569,866    47,095,219 
Accumulated equity   208,323,190    211,239,164 
           
Total Oncotelic Therapeutics, Inc. stockholders’ equity   263,468,690    262,760,595 
Non-controlling interests   (1,171,925)   (1,029,036)
           
Total stockholders’ equity   262,296,765    261,731,559 
Total liabilities and stockholders’ equity  $393,812,516   $393,088,242 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three AND NINE MONTHS ended SEPTEMBER 30, 2026 and 2025

(Unaudited)

 

   2026   2025   2026   2025 
   For the Three Months Ended
September 30,
   For the Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
                 
Service Revenue  $-   $-   $250,000   $- 
                     
Operating expenses:                    
Research and development  $1,622   $426   $2,762   $1,020 
General and administrative   231,053    490,547    3,176,863    657,019 
Total operating expenses   232,675    490,973    3,179,625    658,039 
                     
Loss from operations   (232,675)   (490,973)   (2,929,625)   (658,039)
Other income (expense):                    
Gain on derecognition of non-financial asset   -    -    1,100,000    - 
Loss on change in fair value of equity investment   (750,000)   

-

    (450,000)   - 
Interest expense, net   (286,727)   (231,338)   (900,830)   (642,917)
Gain (loss) on change in fair value of derivative on debt   108,804    (392,058)   121,592    32,772 
Total other expense   (927,923)   (623,396)   (129,238)   (610,145)
Net loss before non-controlling interests   (1,160,598)   (1,114,369)   (3,058,863)   (1,268,184)
Net loss attributable to non-controlling interests   (50,253)   (67,004)   (142,889)   (199,959)
Net loss attributable to Oncotelic Therapeutics, Inc.  $(1,110,345)  $(1,047,365)  $(2,915,974)  $(1,068,225)
                     
Basic and diluted net loss per share attributable to common stock  $(0.00)  $(0.00)  $(0.01)  $(0.00)
Basic and diluted weighted average common stock outstanding   457,224,483    426,435,213    449,556,679    414,315,703 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026

(Unaudited)

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Interests   Equity 
                   Additional             
   Preferred Stock   Common Stock   Paid-in   Accumulated   Non-controlling   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Equity   Interests   Equity 
                                 
Balance at January 1, 2026   24,388   $244    442,596,856   $4,425,968   $  47,095,219   $211,239,164   $(1,029,036)  $  261,731,559 
                                         
Preferred shares issued for services   26,512    265    -    -    2,588,227    -    -   2,588,492 
Shares and warrants issued in connection with debt conversion   -    -    1,600,446    16,002    114,764    -    -   130,766 
Net loss   -    -    -    -    -    (2,193,776)   (45,500)  $(2,239,276)
Balance at March 31, 2026   50,900   $509    444,197,302   $4,441,970   $49,798,210   $209,045,388   $(1,074,536)  $262,211,541 
                                         
Common shares issued upon conversion of debt   -    -    11,877,507    118,775    728,695    -    -   847,470 
Common shares issued with debt   -    -    800,000    8,000    24,727    -    -   32,727 
Shares issued in connection with equity purchase agreement   -    -    137,987    1,380    5,250    -    -   6,630 
Net Income (Loss)   -    -    -   -   -   388,147   (47,136)  341,011 
Balance at June 30, 2026   50,900   $509    457,012,796   $4,570,125   $50,556,882   $209,433,535   $(1,121,672)  $263,439,379 
                                         
Common shares issued with debt   -    -    500,000    5,000    12,984    -    -   17,984 
Net Loss   -    -    -   -    -   (1,110,345)  (50,253)  (1,160,598)
Balance at September 30, 2026   50,900   $509    457,512,796   $4,575,125   $50,569,866   $208,323,190   $(1,171,925)  $262,296,765 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025

(Unaudited)

 

                   Additional             
   Preferred Stock   Common Stock   Paid-in   Accumulated   Non-controlling   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Interests   Equity 
                                 
Balance at January 1, 2025   -   $-    407,289,888   $4,072,899   $  42,219,400   $(38,040,668)  $(774,119)  $     7,477,512 
Common shares issued upon partial conversion of debt   -    -    1,002,832    10,028    60,170    -    -   70,198 
Net loss   -    -    -    -    -    (298,716)   (65,548)  (364,264)
Balance at March 31, 2025   -   $-    408,292,720   $4,082,927   $42,279,570   $(38,339,384)  $(839,667)  $7,183,446 
                                         
Net Income(Loss)   -    -    -   -   -   277,856   (67,407)  210,449 
Balance at June 30, 2025   -    -    408,292,720   $4,082,927   $42,279,570   $(38,061,528)  $(907,074)  $7,393,895 
                                         
Common shares issued upon partial conversion of debt   -    -    4,516,082    45,161    270,965    -    -   316,126 
Shares and warrants issued in connection with debt, equity purchase agreement and services   -    -    26,637,516    266,375    1,214,473    -    -   1,480,848 
Net Loss   -        -    -    -   (1,047,365)  (67,004)  (1,114,369)
                                         
Balance at September 30, 2025   -   $-    439,446,318   $4,394,463   $43,765,008   $(39,108,893)  $(974,078)  $8,076,500 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

6

 

 

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026, AND 2025

(Unaudited)

 

   2026   2025 
   For the Nine Months Ended September 30, 
   2026   2025 
Cash flows from operating activities:          
Net loss  $(3,058,863)  $(1,268,184)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation   2,435,646    183,742 
Amortization of debt discount and deferred finance costs   442,556    135,573 
Gain on derecognition of non-financial asset   (1,100,000)   

-

 
Loss on change in fair value of equity investment   450,000    

-

 
Common shares issued in connection with debt conversion   130,766    

-

 
Gain on change in fair value of derivative on debts   (121,592)   (32,772)
Changes in operating assets and liabilities:          
Accounts receivable   49,266    

-

 
Prepaid and other current assets   (148,600)   19,407 
Accounts payable and accrued liabilities    142,621    360,565 
Accounts payable to related party   1,544    1,541 
Net cash used in operating activities   (776,656)   (600,128)
           
Cash flows from financing activities:          
Proceeds from sales of common stock under equity purchase agreement   6,630    - 
Net proceeds from convertible debt   650,000    478,000 
Proceeds from short term loans, others   147,922    445,000 
Repaid to related party/others   (52,955)   - 
Net cash provided by financing activities   751,597    923,000 
           
Net increase (decrease) in cash   (25,059)   322,872 
           
Cash and restricted cash - beginning of period   108,857    106,128 
           
Cash and restricted cash - end of period  $83,798   $429,000 
           
Supplemental cash flow information:          
Cash paid for:          
Interest paid  $228,669   $285,260 
Non-cash investing and financing activities:          
Common stock issued in connection with debt  $181,477   $- 
Common shares issued upon conversion of debt  $847,470   $386,324 
Common shares and warrants issued in connection with debt, equity purchase agreement and services  $

-

   $1,480,848 
Equity investment in exchange for non-financial asset  $1,100,000   $- 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

7

 

 

ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Description of Business

 

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) was originally incorporated in the State of New York in 1988 as OXiGENE, Inc. The Company reincorporated in the State of Delaware in 1992, changed its name to Mateon Therapeutics, Inc. (“Mateon”) in 2016, and subsequently changed its name to Oncotelic Therapeutics, Inc. in November 2020. The Company conducts business through Oncotelic and its wholly owned subsidiaries, including Oncotelic, Inc., PointR Data, Inc. (“PointR”), Pet2DAO, Inc. (“Pet2DAO”), and EdgePoint AI, Inc. (“EdgePoint”), a consolidated subsidiary with non-controlling interests. (Collectively, “Oncotelic,” “we,” “our,” or “the Company”). Further detail on prior mergers and corporate history is provided in our prior Annual Reports on Form 10-K filed with the Securities and Exchange Commission (“SEC”).

 

The Company is principally focused on the development of immuno-oncology therapeutics, including OT-101, a transforming growth factor-beta (“TGF-β”) inhibitor being advanced for difficult-to-treat cancers and viral respiratory diseases. OT-101 is being developed through our joint venture (“JV”) with Dragon Overseas Capital Limited (“Dragon”) and GMP Biotechnology Limited (“GMP Bio”), affiliates of Golden Mountain Partners (“GMP”).

 

The Company entered into a JV with Dragon to form GMP Bio in March 2022. The Company’s ownership interest in GMP Bio is 45%, while that of Dragon is 55%. GMP Bio and the Company will focus to further expand the development of OT-101 for various oncology indications like pancreatic cancer, melanomas, gliomas etc. as also for viral infections like COVID-19. This path is being evaluated as a monotherapy, as well as combination therapies in conjunction with other drugs like checkpoint inhibitors. The JV is also developing five other nanoparticles for various cancer therapies. The pharmaceutical development of OT-101, our nano-particle platform and other artificial intelligence (“AI”) development is being advanced through our JV. In addition, the JV has also set up a FDA certified cGMP development and manufacturing facility in San Diego, California which is capable of drug development and manufacture of Phase 1 clinical trial materials.

 

During the year ended December 31, 2025, GMP Bio completed an independent third-party valuation by an offshore independent valuation firm, which preliminarily estimated the potential value of the drug pipeline under development at approximately $2.3 billion. This valuation was non-binding, forward-looking, and based upon a number of assumptions including the successful achievement of clinical, regulatory, and commercial milestones. That valuation was interpreted not to be a current measure of fair value under the United States Generally Accepted Accounting Principles (“U.S. GAAP”).

 

8

 

 

Oncotelic hired the services of a separate, ASC-compliant valuation firm to perform a valuation of GMP Bio under U.S. GAAP standards. The results of this valuation that indicated a change in the value of the Company’s holdings in GMP Bio have been incorporated into this, consistent with the Company’s fair value reporting under U.S. GAAP. In establishing the valuation of the Company’s interest in GMP Bio, the Company relied on the inputs from the ASC-Compliant valuation of GMP Bio; and applied certain parameters like lack of marketability, lack of control discounts and other standard discounts, specific to the Company to establish the value of its holdings in GMP Bio. The Company relied on the inputs by the JV valuation, however, certain parameters like lack of marketability, lack of control discounts and other standard discounts, specific to the Company, have been applied to the independent valuation done by the Company to derive the ASC-compliant valuation. As the circumstances related to the JV have not materially changed since December 31, 2025 till the date of this filing, the Company qualitatively assessed and determined that no additional fair value adjustment was required and hence, the Company has not recorded a change in value of the Company’s interest in the JV. In the future, the Company will appropriately adjust the fair value of the Company’s interest in GMP Bio, at the end of reporting periods, and when key value inflection points are met or the Company observes conditions that require the fair value of the Company’s interest in GMP Bio to be adjusted.

 

The JV initiated Phase 2 and Phase 3 trials for OT-101 in high-grade glioma, pancreatic cancer, and other indications. The JV is also sponsoring investigator-initiated clinical studies in additional oncology applications. In addition, the JV is developing five additional therapeutic candidates, which, if successfully developed and approved, are anticipated to contribute significant revenues, income and meaningful long-term value to both the JV and the Company.

 

In addition to the development of OT-101 (also referred to as Sapu-002), the JV is advancing the development of five additional therapies:

 

  a. Sapu-001 – A paclitaxel-based taxane therapy, which can address cancers like breast cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer
  b. Sapu-003 – An everolimus formulation, which can address renal cell cancer, neuroendocrine tumors and tuberous sclerosis complex (renal angiomyolipoma and subependymal giant cell astrocytoma)
  c. Sapu-004 – A carboplatin formulation, which can address small cell lung cancer, head and neck cancer and testicular cancer
  d. Sapu-005 – A palbociclib formulation, which would address HR+, HER2- breast cancer
  e. Sapu-006 – A docetaxel formulation, which can address prostate cancer and gastric cancer.

 

Each of these therapies, and the various cancers they address, have shown they are increasing in terms of incidences and that opens up the avenue to be able to generate revenues ranging from several millions of dollars to several hundreds of millions of dollars, if successfully developed and commercialized.

 

Although no assurances can be given, GMP Bio currently intends to conduct an initial public offering of the JV, at a future date, on either the Hong Kong Exchange or other stock exchange. For more information on the JV, refer to Note 6 of the unaudited Notes to the Condensed Consolidated Financial Statements.

 

The Company’s core scientific focus is the development of its proprietary self-immunization protocol (“SIP™”), designed to stimulate a patient’s immune system to recognize and target tumors without requiring tumor extraction or antigen identification. The SIP™ platform is supported by more than three decades of RNA-based research and is being applied initially to oncology, and other diseases driven by TGF-β overexpression.

 

Separately from the JV, the Company plans to develop OT-101 for select animal-health indications and is evaluating the use of digital assets and blockchain-based technologies to support that platform. The Company acquired apomorphine for potential uses in Parkinson’s disease, erectile dysfunction, and female sexual dysfunction. The Company continues to evaluate advancement opportunities for OXi4503 (for acute myeloid leukemia and myelodysplastic syndromes) and CA4P (in combination with checkpoint inhibitors for metastatic melanoma). The development of any of these products will be subject to the availability of resources to develop them.

 

In April 2026, the Company announced that it had entered into a strategic partnership with TechForce Robotics, Inc. (“TechForce”) to advance the commercialization of its PDAOAI-enabled, GMP-compliant robotics platform. This milestone reflects the culmination of several years of research and development efforts, resulting in an integrated platform designed to combine Oncotelic’s proprietary PDAOAI capabilities with TechForce’s robotics hardware and manufacturing expertise. The system under development is designed to operate within GMP-regulated environments and is intended to enable automated material handling, real-time monitoring, and PDAOAI-enhanced compliance workflows across pharmaceutical manufacturing and related applications. For more information on the partnership with TechForce, refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 15, 2026.

 

9

 

 

Agreement and Plan of Merger with Lunai Bioworks Inc.

 

In April 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lunai Bioworks, Inc. (“Lunai”), a Delaware corporation, Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings Incorporated, a Delaware corporation (“Holdings”). In connection with the Merger Agreement, the Company entered into an IP Assignment Agreement with Holdings, pursuant to which it agreed to contribute and assign certain assets relating to the intellectual property of the Company (collectively, the “Intellectual Property Assets”) to Holdings. For more discussion on the transactions with Lunai, refer to Note 9 of these Notes to Condensed Consolidated Financial Statements.

 

Fundraising

 

Pacific Pier June 2026 Note

 

On June 23, 2026, the Company entered into a Securities Purchase Agreement (the “June 2026 Pacific Pier SPA”), with Pacific Pier Capital II, LP (“Pacific Pier”), pursuant to which Company issued a convertible promissory note in the aggregate gross principal amount of $178,410 (the “June 2026 Pacific Pier Note”). The June 2026 Pacific Pier Note is convertible into shares of the Company’s common stock par value $0.01 per share (“Common Stock”).

 

Pacific Pier August 2026 Note

 

On August 3, 2026, the Company entered into a Securities Purchase Agreement (the “August 2026 Pacific Pier SPA”), with Pacific Pier, pursuant to which Company issued a convertible promissory note in the aggregate gross principal amount of $178,410 (the “August 2026 Pacific Pier Note”). The August 2026 Pacific Pier Note is convertible into shares of the Company’s Common Stock.

 

For more information on both Pacific Pier financings of the Company, refer to Note 5 of the Notes to the Condensed Consolidated Financial Statements.

 

Mast Hill January 2026 Note

 

In January 2026, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of approximately $0.4 million that is convertible into shares of the Company’s Common Stock. Proceeds from this note are to be utilized for corporate expenses. This note, the May 2022 Note and the July 2025 Note are securitized against all the assets of the Company, excluding the 45% ownership of the Company in the JV.

 

For more information on the debt financing of the Company, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements.

 

Mast Hill July 2025 Note

 

In July 2025, the Company entered into a Securities Purchase Agreement with Mast Hill, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of approximately $0.6 million, which is convertible into shares of the Company’s Common Stock. This note was utilized for corporate expenses. This note, and the May 2022 Note were securitized against all the assets of the Company, excluding the 45% ownership of the Company in the JV.

 

For more information on the debt financing of the Company, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements.

 

10

 

 

Mast Hill Equity Purchase Agreement

 

In August, 2025, the Company entered into an Equity Purchase Agreement (the “Mast EPA”) and a Registration Rights Agreement (the “Mast Registration Rights Agreement”) with Mast, pursuant to which the Company shall have the right, but not the obligation, to direct Mast, to purchase up to $25 million (the “Maximum Commitment Amount”) in shares of the Company’s Common Stock in multiple tranches. The Company instructed Mast Hill in June 2026 to purchase approximately 138,000 shares of Common Stock for cash proceeds of approximately $6,600 and incurred a cost of approximately $1,500 against the sale of the Company’s Common Stock. The Company plans to file a post-effective amendment to the registration statement with the SEC at the earliest.

 

For more information on the Mast EPA, refer to Note 11 of the Notes to the unaudited Condensed Consolidated Financial Statements.

 

Jefferson Capital Ventures, LLC and Valor Nation, Inc Independent Contractor Agreements

 

In August 2025, the Company entered into independent contractor agreements (“ICA”) with Jefferson Capital Ventures, LLC (“Jefferson”) and Valor Nation, Inc. (“Valor”) for providing certain consulting and advisory services. Further on December 31, 2025, the Company reported modifying the threshold of the first milestone contained within the ICA with Jefferson, to earn certain RSAs of shares the Company’s Common Stock upon the achievement of certain corporate milestones. For more information on the ICA and modification, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. In connection with the uplisting of the Company’s Common Stock to a nationally recognized stock exchange, the Company filed an initial application with Nasdaq in July 2026 and is in the process of responding to the Nasdaq’s queries.

 

Private Placement 3 & JH Darbie Financing

 

In December 2025, the Company completed the conversion of the debt of forty-seven (47) accredited investors from the JH Darbie Financing from our prior private placement (“PPM-2”) into the new subscription agreements under the new financing (“PPM-3”) in three tranches, which resulted in conversion of approximately $2.2 million. JH Darbie and the Company are parties to a May 2024 placement agent agreement (“Placement Agreement”), pursuant to which JH Darbie had the right to sell/convert a minimum of 10 Units and a maximum of 200 Units on a best-efforts basis. Two of the investors did not participate in PPM-3 and their 7 units for a total of approximately $0.2 million were converted into short term loan to the Company, of which $70,000 was paid off during the nine months ended September 30, 2026. For more information on the PPM-3 Financing, refer to Note 8 of these Notes to the Condensed Consolidated Financial Statements.

 

May 2022 Note

 

In May 2022, the Company entered into a Securities Purchase Agreement with Mast Hill, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of approximately $0.7 million, which note is convertible into shares of the Company’s Common Stock. The May 2022 Note was extended till December 2026. In June 2026, Mast Hill converted the balance of the May 2022 Note, including accrued interest and penalty, of approximately $847,000 into approximately 11.9 million shares of the Company’s Common Stock. As of September 30, 2026, this note is fully converted.

 

For more information on the debt financing of the Company, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements.

 

Forever Prosperity (previously GMP) Note purchase agreements and unsecured notes

 

Between June 2020 and January 2022, the Company entered into various purchase agreements and promissory notes with GMP, cumulatively totaling $4.5 million. Such notes were assigned to Forever Prosperity, LLC, an affiliated entity of GMP. For more information on the GMP debt financing, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements.

 

11

 

 

Mosaic ImmunoEngineering, Inc. Term Sheet

 

In April 2024, the Company entered into a binding term sheet (the “Term Sheet”) with Mosaic Immuno Engineering, Inc. (“Mosaic”). For more information on the Term Sheet, refer to the Current Report on Form 8-K filed with the SEC on April 29, 2024. In August 2024, Mosaic and the Company mutually agreed to extend the date of the Term Sheet to expire at the earlier of (1) the signing of definitive agreements or (2) December 31, 2024. In December 2024, the Company and Mosaic further extended the term of the term-sheet to expire at the earlier of (1) the signing of definitive agreements or (2) June 30, 2025. Both Mosaic and the Company are in discussions as to the future of this Term Sheet and how to proceed on this front.

 

Joint Development, Manufacturing and Licensing Agreement with TechForce Robotics

 

In March 2026, the Company entered into a Joint Development, Manufacturing, and Licensing Agreement (the “TechForce Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation. The TechForce Agreement establishes a framework for the joint development, and manufacturing of AI-enabled, GMP-compliant robotic systems for use in pharmaceutical and related manufacturing environments. The integrated product to be developed (the “Product”) combines TechForce’s robotic hardware with the Company’s proprietary PDAOAI Platform.

 

Principles of Consolidation

 

The unaudited condensed consolidated financial statements include the accounts of Oncotelic, its wholly owned subsidiaries, Oncotelic Inc., PointR, and EdgePoint our consolidated non-controlled interest entity. Intercompany accounts and transactions have been eliminated in consolidation. The Company’s investment in GMP Bio is recorded and reported as a minority investment in equity securities.

 

The Company also holds an equity investment in Lunai. The Company has determined that it does not have a controlling financial interest in Lunai and does not exercise significant influence over its operating or financial policies. Accordingly, the investment is not consolidated and is not accounted for under the equity method. The investment is accounted for in accordance with the applicable guidance for equity securities in ASC 321 and is included in “Investment in equity securities” in the accompanying unaudited condensed consolidated balance sheet.

 

Basis of Presentation

 

The accompanying interim unaudited condensed consolidated financial statements as of September 30, 2026 and for the three and nine months ended September 30, 2026, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission including Form 10-Q and Article 8 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2025, and the notes thereto, which are included in the Company’s 2025 Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 15, 2026. In management’s opinion, all normal, and recurring adjustments necessary for a fair statement, have been included. The results for the three and nine months ended September 30, 2026, are not necessarily indicative of the results for the year ending December 31, 2026.

 

Liquidity and Going Concern

 

The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Prior to December 31, 2024, the Company incurred net losses of approximately $38.0 million. During the year ended December 31, 2025, the Company recorded net income of approximately $249.3 million, primarily due to an increase in fair value of the Company’s ownership in GMP Bio of approximately $365.4 million and offset by deferred taxes of approximately $111.6 million. During the nine months ended September 30, 2026, the Company has incurred a loss of approximately $3.1 million. The Company has a negative working capital of approximately $16.8 million at September 30, 2026, of which approximately $2.6 million contingent liability of issuance of common shares of the Company to PointR shareholders upon achievement of certain milestones in accordance with the PointR Merger Agreement. The Company recorded negative cash flows from operations for the nine months ended September 30, 2026, of approximately $0.8 million. Barring the funding raised during the nine months ended September 30, 2026, through Mast Hill and Pacific Pier, and short-term funding from related parties, the Company has not been able to raise any substantial funding during the past few years from other third parties. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. Management expects to incur lower costs and losses in the foreseeable future, as a majority of the costs related with the development of OT-101 will be incurred by the JV, but the Company also recognizes the need to raise capital to remain viable. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

12

 

 

The Company’s long-term plans include continued development of its current pipeline of products, in addition to continue the development of OT-101 which is exclusively out-licensed to the JV and the JV will be responsible for the funding required to support the development in entirety, to generate sufficient revenues, through either technology transfer or product sales, or raise additional financing to cover its anticipated expenses. Until the Company is able to generate sufficient revenues from its current pipeline, the Company plans on funding its operations through the sale of equity and/or the issuance of debt, combined with or without warrants or other equity instruments. During the nine months ended September 30, 2026, the Company raised an aggregate amount of $0.65 million from the issuance of convertible debt instruments.

 

Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern. Also, management cannot guarantee any potential debt or equity financing will be available on favorable terms or at all. As such, management does not believe the Company has sufficient cash for twelve months from the date of this report. If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations or cease operations completely.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

The preparation of financial statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates.

 

The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and related valuation allowance, and fair value of financial instruments.

 

Cash and Restricted Cash

 

As of September 30, 2026, and December 31, 2025, the Company held all its cash in banks in the United States of America. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2026, and December 31, 2025. Restricted cash consists of certificates of deposits held at banks as collateral for various purposes.

 

Debt issuance Costs and Debt discount

 

Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument are offset against the associated proceeds in the determination of the instrument’s initial net carrying amount.

 

13

 

 

Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying balance sheets if related to the issuance of debt or presented as a reduction of additional paid in capital if related to the issuance of an equity instrument. The Company applies the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction.

 

If the Company amends the terms of its convertible notes, the Company reviews and applies the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments, evaluates and concludes whether the terms of the agreements were or were not substantially different as of a particular reporting date and accounts the transaction as a debt modification or a troubled debt restructuring.

 

Fair Value of Financial Instruments

 

The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement.

 

The three levels of the fair value hierarchy defined by ASC 820 are as follows:

 

● Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.

 

● Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.
   
● Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.

 

The Company did not have any Level 1 or Level 2 assets or liabilities at September 30, 2026 and December 31, 2025.

 

14

 

 

Investment in equity securities

 

The Company holds equity investments in GMP Bio and Lunai Bioworks Inc. Neither investment results in a controlling financial interest requiring consolidation. The Company’s investment in GMP Bio is subject to the guidance in ASC 323, Investments - Equity Method and Joint Ventures, due to the Company’s ability to exercise significant influence. The Company has elected the fair value option under ASC 825, Financial Instruments, for its investment in GMP Bio. The Company’s investment in Lunai Bioworks Inc. is accounted for under ASC 321, Investments - Equity Securities. Accordingly, both investments are carried at fair value on the unaudited Condensed Consolidated Balance Sheets, and changes in fair value are recognized in earnings in the period incurred. Unrealized gains and losses resulting from changes in the fair value of these investments are reported within other income (expense), net, on the unaudited Condensed Consolidated Statements of Operations. Below is the change in the fair value of the Company’s equity investments for the nine months ended September 30, 2026, and the Audited Consolidated Statements of Operations for the year ended December 31, 2025:

 

  

Beginning
Period

Fair Value

   Adjustment
to Fair
Value
   Ending
Period Fair
Value
 
September 30, 2026               
Investment in JV GMP Bio (ASC 323)  $388,000,000   $-   $388,000,000 
Investment Lunai (ASC 321)   1,100,000    (450,000)   650,000 
Total  $389,100,000   $(450,000)  $388,650,000 

 

  

Beginning
Period

Fair Value

   Adjustment
to Fair
Value
   Ending
Period Fair
Value
 
December 31, 2025               
Investment in JV GMP Bio (ASC 323)  $22,653,225   $365,346,775   $388,000,000 
Total  $22,653,225   $365,346,775   $388,000,000 

 

The table above sets forth a summary of the recording of the initial value of the long-term value of investment in equity securities of GMP Bio, based on a third-party valuation report, and changes in the fair value of such equity securities, if such change occurs, as a Level 3 fair value as of September 30, 2026 and December 31, 2025. During the year ended December 31, 2025, there was a change in the long-term value of the Company’s investment in equity securities of GMP Bio and as such has been recorded as above. No similar change in fair value has been recorded in the long-term value of the GMP Bio investment during the nine months ended September 30, 2026, as the Company did not observe any qualitative or quantitative conditions required to record any further changes to the fair value. For more information, see Change in Fair Value of Equity Securities of GMP Bio below.

 

In addition, the Company recorded a $1.1 million initial non-cash gain in exchange for a non-financial asset and an approximately $0.5 million loss from the change in the fair value of the Company’s equity securities in Lunai received during the nine months ended September 30, 2026. No similar gains or losses were recorded during the comparable periods in prior year. For more information, see Note 9 – Lunai Bioworks Transactions below.

 

Change in Fair Value of Equity Securities of GMP Bio

 

In March 2022, the Company entered into the JV with Dragon, contributing a license agreement for rights to OT-101for the territory within the United States of America with Sapu Holdings, LLC, a wholly owned subsidiary of GMP Bio and a license agreement for rights to OT-101 for the rest of the world with GMP Bio. For more information on the JV and the related agreements, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. As of the effective date of the formation of the JV, the Company received a 45% ownership interest in the JV. The combined enterprise value of GMP Bio, on the date of the formation of the JV, was approximately $50.4 million, comprising of the fair value of the Company’s investment in GMP Bio of approximately $22.7 million and the total original capital contributions by Dragon Overseas of approximately $27.7 million.

 

The investment in GMP Bio had been accounted for under the fair value method of accounting. Similarly, during the year ended December 31, 2025, the Company determined that a remeasurement of its investment to fair value was appropriate. All the factors described below allowed the Company to form a basis for a triggering event of significant development for the JV and justified the JV, and consequently the Company, to reassess the fair value of the JV.

 

For more information on the developments in the JV, refer to Note 6 to these condensed consolidated financial statements below.

 

15

 

 

Fair Value Hierarchy – GMP Bio

 

The Company’s investment in the JV is classified within Level 3 of the fair value hierarchy under ASC 820 Fair Value Measurement due to the use of significant unobservable inputs, including projected cash flows and discount rates.

 

The fair value measurement was determined on a recurring basis as of September 30, 2026, and December 31, 2025. There were no transfers between Levels 1, 2, or 3 during the period.

 

The following table presents the fair value of the Company’s investment in the JV by level within the fair value hierarchy as of September 30, 2026 and December 31, 2025:

 

SCHEDULE OF FAIR VALUE OF INVESTMENT HIERARCHY

   Level 1   Level 2   Level 3   Total 
Fair value of investment in JV   -    -   $388,000,000   $388,000,000 

 

Quantitative Information about significant unobservable inputs (Level 3):

 

SCHEDULE OF QUANTITATIVE INFORMATION ABOUT SIGNIFICANT UNOBSERVABLE INPUTS

Valuation Technique   Unobservable Input   Range
Discounted Cash Flow   Revenue growth rate   (1)% to 400%
Discounted Cash Flow   EBIT margin   (146)% to 33%
Discounted Cash Flow   Discount rate (WACC)   21.4%
Discounted Cash Flow   Terminal growth rate   3%
Discounted Cash Flow   Product penetration rates   1% to 35%, depending on the product

 

For a detailed discussion on the significant level 3 unobservable inputs, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

Fair Value Hierarchy – Lunai

 

The Company’s equity investment in Lunai is classified within Level 3 of the fair value hierarchy under ASC 820 Fair Value Measurement due to the use of significant unobservable inputs, including lack of marketability and liquidity conditions and contractual limitation conditions. The fair value of the investment is determined using a market approach that considers the quoted market price of Lunai’s publicly traded common stock, adjusted to reflect the specific rights, preferences, and restrictions associated with the Series B preferred stock. Because significant unobservable inputs are used in determining fair value, the investment is classified as a Level 3 asset within the fair value hierarchy. The Company received convertible preferred stock of Lunai, with a stated value of $12.5 million. For financial reporting, the fair value of these shares was determined using a market approach based on the market capitalization value of the underlying common stock on an as-converted basis. This baseline value was then adjusted downward to reflect significant unobservable inputs, specifically a discount for lack of marketability and discounts for contractual restrictions.

 

The fair value measurement initially determined at the time of acquisition in April 2026 and was remeasured as of September 30, 2026. No corresponding transactions were recorded during the year ended December 31, 2025. There were no transfers between Levels 1, 2, or 3 during the period.

 

The following table presents the fair value of the Company’s equity investment in Lunai Bioworks by level within the fair value hierarchy as of September 30, 2026:

 

   Level 1   Level 2   Level 3   Total 
Fair value of equity investment in Lunai   -    -   $650,000   $650,000 

 

16

 

 

Quantitative Information about significant unobservable inputs (Level 3)

 

The Company first attributed a portion of the value of the market capitalization of Lunai common stock, based on a fully diluted basis including the preferred shares and common shares. The market capitalization of Lunai was the only observable input available and used in the fair market value of the Company’s investment in preferred shares of Lunai Bioworks.

 

The Company then considered the below factors that impacted the liquidity and marketability of the underlying equity interest along with existing contractual restrictions associated with the Lunai Preferred Stock on the date of the closing of the Lunai transaction and then on September 30, 2026.

 

Sensitivity and Measurement Uncertainty

 

The fair value of the Company’s investment in Lunai is based on significant unobservable inputs and, as a result, is subject to substantial measurement uncertainty. Changes in key assumptions could result in a different fair value. For example, a 10 percent increase in the discount rate could result in a decrease in the estimated fair value of approximately $0.1 million.

 

Lack of liquidity and marketability

 

The Company’s ownership of the convertible preferred shares of Lunai, even if converted into common shares of Lunai, is faced with liquidity and marketability limitations. The common stock of Lunai is fairly thinly traded. Further the preferred shares have Rule 144 restrictions and are restricted in book entry form, have no DTC eligibility, require shareholders’ approval prior to conversion amongst other conditions. The Company attributed a 35% discount due to all these factors.

 

Contractual Risks

 

The Company believes that it is exposed to certain concentrations of credit risk related to its investment in the Lunai preferred shares, such as beneficial ownership limitation, suspended conversion, cancellation of the shares if there were an IP clawback, cancellation of shares in the event of indemnification claims among other conditions. The Company attributed a 10% discount for these limitations.

 

Based on the above limitations, the Company recorded an initial fair value of $1.1 million for the investment in Lunai on the date of the Lunai merger transaction, recorded a fair value gain of $0.3 million for the three months ended June 30, 2026, and further recorded a loss in the value of $0.75 million during the nine months ended September 30, 2026, based on changes to the fair value inputs. The Company will continue to record the fair value of its investment in future periods on a similar basis and report the change a in fair value through the unaudited condensed consolidated statement of operations.

 

For more information on Lunai, refer to Note 9 – Lunai Bioworks Transactions to these Notes to the unaudited Condensed Consolidated Financial Statements below.

 

Derivative Liability Related to 2019 Bridge Financing

 

The Company has certain derivative liabilities associated with its 2019 bridge financing Convertible Notes (see Note 5), consisting of conversion feature derivatives at September 30, 2026 and December 31, 2025, and are Level 3 fair value measurements. The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities, due to the conversion feature, classified as Level 3 for the below periods:

 

   September 30,
2026
   December 31,
2025
 
Balance at January 1, 2026 and 2025  $350,044   $703,617 
Change in fair value   (121,592)   (353,573)
Balance at September 30, 2026 and December 31, 2025  $228,452   $350,044 

 

17

 

 

As of September 30, 2026, and December 31, 2025, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consist, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of September 30, 2026 and December 31, 2025:

 

    September 30,
2026
    December 31,
2025
 
Risk free interest     3.68% - 4.20 %     3.48% - 4.03 %
Market price of share   $ 0.02 - 0.04     $ 0.04 - 0.08  
Life of instrument in years     0.01       0.01  
Volatility     108.70%-116 %     114.47%-139.5 %
Dividend yield     0 %     0 %

 

A contingent consideration liability of $2,625,000 for shares of the Company, issuable to PointR’s shareholders recorded and associated with the PointR Merger, is also classified as Level 3 fair value measurements. The Company initially recorded the contingency based on a valuation conducted by a third-party valuation expert. The valuation was based on a probability of the completion of certain milestones by PointR for the shareholders to earn additional shares. The Company evaluated the probability of the earning of the milestones and concluded that the probability of achievement of the milestones had not changed, primarily due to the shifting of focus by the Company to develop AI technologies for the COVID-19 pandemic as well as other AI technologies, utilizing the same basis technologies. As such, the Company did not record any change to the valuation as of September 30, 2026.

 

If and when the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period when the transfers occur. For the period ended September 30, 2026, there were no transfers of financial assets or financial liabilities between the hierarchy levels.

 

Net Loss Per Share

 

Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive.

 

For the three and nine months ended September 30, 2026, and 2025, respectively, no equivalent shares of the Common Stock were included as the Company incurred losses during the said periods, because addition of such stock equivalents in the computation would have been anti-dilutive.

 

Stock-Based Compensation

 

The Company applies the provisions of ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and non-employees, including employee stock options, in the statements of operations.

 

For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised.

 

18

 

 

For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital.

 

For shares issued in connection with provision of services, the Company estimates the cost of the shares at the price of the Company’s stock on the date of issuance and records that cost as a stock-based compensation cost.

 

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the three and nine months ended September 30, 2026 and 2025, there were no impairment losses recognized for long-lived assets.

 

Intangible Assets

 

The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the intangible asset’s carrying amount exceeds its fair value, an impairment loss is recognized for the difference. For the three and nine months ended September 30, 2026 and 2025, there were no impairment losses recognized for intangible assets. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed.

 

Goodwill

 

Goodwill represents the excess of the purchase price of an acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level, or more frequently if events or changes in circumstances indicate that the asset might be impaired.

 

The goodwill impairment test may be initiated by performing an optional qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that it is not more likely than not that the fair value is less than the carrying amount, further quantitative testing is not required. Otherwise, a quantitative impairment test is performed by comparing the fair value of the reporting unit with its carrying amount. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. For the three and nine months ended September 30, 2026, no impairment was recognized toward goodwill. For more information on goodwill and impairment, refer to Note 3 to these Notes to the unaudited Condensed Consolidated Financial Statements.

 

19

 

 

Derivative Financial Instruments Indexed to the Company’s Common Stock

 

We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants based on the price of our Common Stock as of December 31 each year, which is as inherently subjective as it is for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Condensed Consolidated Statements of Operations.

 

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging” (“ASC 815”).

 

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.”

 

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“OID”) under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note.

 

ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event occurs that is not within the entity’s control could or would require net cash settlement, then the contract shall be classified as an asset or a liability.

 

Variable Interest Entity (VIE) Accounting

 

The Company evaluates its ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC 810, Consolidations. These evaluations can be complex and involve Management judgment as well as the use of estimates and assumptions based on available historical information, among other factors. Based on these evaluations, if the Company determines that it is the primary beneficiary of a VIE, the entity is consolidated into the financial statements. At September 30, 2026 and December 31, 2025, the Company identified EdgePoint as the Company’s sole VIE. At September 30, 2026 and December 31, 2025, the Company’s ownership percentage of EdgePoint was 29%, respectively. The VIE’s net assets were less than $0.1 million at September 30, 2026 and December 31, 2025.

 

20

 

 

Investments - Equity Method

 

The Company accounts for equity method investments at cost, adjusted for the Company’s share of the investee’s earnings or losses, which are reflected in the unaudited condensed consolidated statements of operations. The Company periodically reviews the investments for other than temporary declines in fair value below cost and more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares shall be included in the result from other income. Refer to Note 6 to these Notes to the unaudited Condensed Consolidated Financial Statements.

 

Joint Venture agreement

 

We have equity interest in unconsolidated arrangement that is primarily engaged in the business of drug discovery, development, and commercialization, including but not limited to development and commercialization of TGF-beta therapeutics as well as establishing and operating contract development and manufacturing organization (“CDMO”) facilities and capabilities. The Company first reviews the arrangement to determine if it meets the definition of an accounting joint venture pursuant to ASC 323-10-20. In order to meet the definition of a joint venture, the arrangement must have all of the following characteristics, (i) the arrangement is organized within a separate legal entity, (ii) the entity is under the joint control of the venturers, (iii) the venturers must be able to exercise joint control through their equity investments, (iv) the qualitative characteristics of the entity, including its purpose and design must be consistent with the definition of a joint venture.

 

We consolidate arrangements that are considered to be VIEs where we are the primary beneficiary. We analyze our investments in joint ventures to determine if the joint venture is considered a VIE and would require consolidation. We (i) evaluate the sufficiency of the total equity investment at risk, (ii) review the voting rights and decision-making authority of the equity investment holders as a group and whether there are limited partners (or similar owning entities) that lack substantive participating or kick out rights, guaranteed returns, protection against losses, or capping of residual returns within the group and (iii) establish whether activities within the venture are on behalf of an investor with disproportionately few voting rights in making this VIE determination.

 

To the extent that we own interests in a VIE and we (i) have the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) have the obligation or rights to absorb losses or receive benefits that could potentially be significant to the VIE, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent that we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary.

 

To the extent that our arrangements do not qualify as VIEs, they are consolidated if we control them through majority ownership interests or if we are the managing entity (general partner or managing member) and our partner does not have substantive participating rights. Control is further demonstrated by our ability to unilaterally make significant operating decisions, refinance debt, and sell the assets of the joint venture without the consent of the non- managing entity and the inability of the non-managing entity to remove us from our role as the managing entity.

 

We use the equity method of accounting for those arrangements where we exercise considerable influence but do not have control. Under the equity method of accounting, our investment in each arrangement is included on our unaudited condensed consolidated balance sheet; however, the assets and liabilities of the joint ventures for which we use the equity method are not included on our unaudited condensed consolidated balance sheet.

 

When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed when its derecognition criteria are met. The equity method investment we retain in such partial sale transactions is noncash consideration and is measured at fair value. As a result, the accounting for a partial sale will result in the recognition of a full gain or loss.

 

21

 

 

When circumstances indicate there may have been a reduction in the value of an equity investment, we evaluate whether the loss in value is other than temporary. If we conclude it is other than temporary, we recognize an impairment charge to reflect the equity investment at fair value.

 

The Company elected the fair value option under the fair value option Subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that the fair value option is most appropriate for a company in the biotechnology industry, The fair value option is more appropriate for companies that are involved in extensive and usually very expensive research and development efforts, which are not appropriately reflected in the market value or reflective of the true value of the development activities of the Company.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers.

 

Under ASC 606, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.

 

At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

 

While the Company entered into the transactions with Lunai and recorded service revenue of approximately $0.3 million, the Company does not anticipate generating revenues from rendering services to other third-party customers for the development of certain drug products and/or in connection with certain out-licensing agreements, at least in the near future. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either (i) upon achievement of certain pre-defined milestones when there is no obligation of the Company to achieve any performance obligations in connection with the said pre-defined milestones, or (ii) upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations.

 

The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized.

 

Research & Development Costs

 

In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred.

 

Recent Accounting Pronouncements

 

Recently Adopted

 

In December 2023, the FASB issued ASU 2023-09, “Improvements to Tax Disclosures” (Topic 740). The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures through changes to the rate reconciliation and the income taxes paid information disclosed. The ASU is effective prospectively for fiscal years beginning after December 15, 2024, with retrospective application and early adoption permitted. The Company adopted this ASU on a prospective basis as of December 31, 2025.

 

22

 

 

Not Yet Adopted

 

In November 2024 and January 2025, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures” (Subtopic 220-40) “Disaggregation of Income Statement Expenses” and ASU 2025-01 “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures” (Subtopic 220-40): Clarifying the Effective Date”. The new guidance is intended to enhance transparency and disclosures by requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The ASU is effective for the first annual reporting periods after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is in the process of evaluating the impact that the adoption of this ASU will have on its financial statements and related disclosures.

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. ASU 2025-11 clarifies the applicability of ASC 270, Interim Reporting, and the form and content of interim financial statements. In addition, ASU 2025-11 requires entities to disclose material events occurring since the last annual reporting period. ASU 2025-11 will be effective for interim periods beginning January 1, 2028, and can be applied on a prospective or retrospective basis. The Company is in the process of evaluating the impact of this guidance on its financial statements; however, the Company does not expect that it will have a material impact on its consolidated financial statements.

 

All other newly issued, but not yet effective, accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

 

NOTE 3 - ACQUISITIONS, GOODWILL AND INTANGIBLE ASSETS

 

Goodwill from 2019 Reverse Merger with Oncotelic and Merger with PointR

 

The Company completed the reverse merger with Oncotelic Inc. (“Merger”) in April 2019. The Company completed the merger with PointR Data Inc (“PointR Merger”) in November 2019. For more details on the two mergers, refer to our 2020 Annual Report on Form 10-K for the year ended December 31, 2020 filed by the Company on April 15, 2021.

 

The Oncotelic merger gave rise to Goodwill of approximately $4.9 million. Upon the non-financial sale of our asset as contribution to our equity method investment, we derecognized the balance of the carrying value of our goodwill of approximately $4.9 million from the Oncotelic Merger in accordance with our policy and authoritative accounting guidance.

 

Further, we added goodwill of approximately $16.2 million upon the completion of the Merger with PointR. Since 2022, we recorded impairments of approximately $13.4 million, as we observed our market capitalization being negatively impacted as compared to the book value of our net assets.

 

We have one operating segment and reporting unit. Accordingly, our review of goodwill impairment indicators was performed at the entity-wide level. In performing our annual impairment assessment, we determined if we should qualitatively assess whether it was more likely than not the fair value of goodwill was less than its carrying amount (the qualitative impairment test). The factors we considered in the assessment included our market capitalization, general macroeconomic conditions, conditions specific to the industry and market and whether there had been sustained declines in our share price. If we concluded, it was more likely than not, the fair value of the reporting unit was less than its carrying amount, or elected not to use the qualitative impairment test, a quantitative impairment test would be performed.

 

We have used our market capitalization as an indicator of fair value. While we believe the fair value measurement need not be based solely on the quoted market price of an individual share of our Common Stock, and that we also could consider the impact of a control premium in measuring the fair value of its reporting unit. In the absence of any other valuation metrics, the Company believed using a control premium utilized would not be appropriate under the current circumstances. We also considered some other market comparables’ trends in our stock price as well as the industry over a period of two successive quarters and prospective quarter to evaluate whether the fair value of our reporting unit was greater than our carrying amount. No impairment to goodwill was required to be recorded for the year ended December 31, 2025. The Company evaluated if it needed to record any goodwill impairment as of September 30, 2026, based solely on the market capitalization of the Company and concluded that no impairment was required to be recorded for the three and nine months ended September 30, 2026.

 

23

 

 

A summary of our goodwill as of September 30, 2026, and December 31, 2025, is shown below:

 

   September 30,
2026
   December 31,
2025
 
Balance at January 1, 2026 and 2025  $2,788,230   $2,788,230 
Less: Goodwill impairment    -    - 
Balance at September 30, 2026 and December 31, 2025  $2,788,230   $2,788,230 

 

Goodwill is tested for impairment annually as of December 31, or more frequently if events or changes in circumstances, such as a sustained decline in our market capitalization, indicate that it is more likely than not that the fair value of a reporting unit is below its carrying amount. If an interim evaluation indicates that an impairment exists, a quantitative test is performed, and any resulting impairment loss is recognized in the period identified

 

In-Process Research & Development (“IPR&D”) Summary

 

The IPR&D assets were acquired in the PointR Merger during the year ended December 31, 2019. Since January 2021, the Company has determined that the IPR&D should be reported as an indefinitely lived asset and therefore will evaluate, on an annual basis, for any impairment on the IPR&D and will record an impairment if identified. The balance of IPR&D as of September 30, 2026, and December 31, 2025, was $1,101,760. For more information on the IPR&D, please refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. The Company did not record any impairment as of September 30, 2026 and December 31, 2025.

 

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities consist of the following amounts:

 

  

September 30,

2026

   December 31,
2025
 
         
Accounts payable  $1,732,329   $1,638,713 
Accrued liabilities   705,188    932,410 
Total accounts payable and accrued liabilities  $2,437,517   $2,571,123 

 

  

September 30,

2026

   December 31,
2025
 
         
Accounts payable – related party  $349,655   $348,111 

 

24

 

 

NOTE 5 – CONVERTIBLE DEBENTURES, NOTES AND OTHER DEBT

 

As of September 30, 2026, and December 31, 2025, convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts:

 

 

  

September 30,

2026

  

December 31,

2025

 
Current Debt          
Convertible debentures          
10% Convertible note payable, due April 23, 2022 – Bridge Investor  $35,556   $35,556 
10% Convertible note payable, due April 23, 2022 – Related Party   164,444    164,444 
10% Convertible note payable, due August 6, 2022 – Bridge Investor   200,000    200,000 
Convertible note payable   400,000    400,000 
Fall 2019 Notes          
5% Convertible note payable – Stephen Boesch   142,708    138,958 
5% Convertible note payable – Related Party   335,608    326,233 
5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)   335,128    325,753 
5% Convertible note payable – CEO & CFO – Related Parties   109,834    106,759 
5% Convertible note payable – Bridge Investors   225,022    218,722 
Convertible note payable    1,148,300    1,116,425 
August 2021 Convertible Notes          
5% Convertible note – Autotelic Inc– Related Party   314,427    305,052 
5% Convertible note – Bridge investors   469,758    455,751 
5% Convertible note – CFO – Related Party   94,336    91,522 
Convertible note payable   878,521    852,325 
March 2022 Notes          
16% Convertible Notes – Accredited Investors   63,956    58,531 
           
Debt for Clinical Trials – Forever Prosperity ( Formerly GMP)          
2% Convertible Notes – Forever Prosperity   4,997,562    4,930,247 
           
May 2022 Note          
16% Convertible Notes – Accredited Investors   -    809,492 
           
J.H. Darbie PPM-2 Debt          
Accrued and Unpaid Interest – PPM-2   21,117    102,795 
           
July 2025 Note          
10% Convertible Note – Accredited Investor   625,512    465,261 
           
January 2026 Note          
10% Convertible Note - Accredited Investor   368,886    - 
           
Pacific Pier 2026 Notes          
12% Convertible Note – Accredited Investor   289,806    - 
           
Other Debt          
Short-term debt – Bridge investors   210,000    210,000 
Short-term debt from CFO – Related Party   86,050    86,050 
Short-term debt – Autotelic Inc. – Related Party   3,157,801    2,992,874 
Short-term Debt from CEO – Related Party   155,000    175,000 
Short-term loan from accredited investor   -    50,000 
Total Short-Term Other Debt   3,608,851    3,513,924 
Total convertible and short-term debt, net  $8,209,614   $8,225,669 
Total convertible debt and short-term debt – related party, net  $4,192,897   $4,023,331 

 

  

September 30,

2026

  

December 31,

2025

 
         
Long-term debt - 12% convertible long-term debt, net – JH Darbie PPM-3  $1,922,616   $1,663,405 

 

25

 

 

Convertible Debentures

 

As of September 30, 2026, the Company had a derivative liability of approximately $228,452 and recorded a change in fair value of approximately $122,000 on the Convertible Debentures issued in 2019 to our CEO and a bridge investor. As of December 31, 2025, the Company had a derivative liability of approximately $350,000 and recorded a change in fair value of approximately $353,600 during the year ended December 31, 2025, on the Convertible Debentures issued in 2019 to our CEO and a bridge investor.

 

Bridge Financings

 

Notes with Officer and Bridge Investor

 

In April 2019, the Company entered into a Securities Purchase Agreement (the “Bridge SPA”) with our CEO and the Bridge Investor with a commitment to purchase convertible notes in the aggregate of $400,000. For more information on the Bridge SPA, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. In April 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #1 (“Tranche #1”) with the Bridge Investor. For more information on Tranche #1, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. In August 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #2 (“Tranche #2”) with the Bridge Investor. For more information on Tranche #2, refer to 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

Fall 2019 Debt Financing

 

In December 2019, the Company closed its Fall 2019 Debt Financing, raising an additional $500,000 bringing the gross proceeds of all debt financings under the Fall 2019 Debt Financing to $1,000,000. The Company entered into those certain Note Purchase Agreements (the “Fall 2019 Note Purchase Agreements”) with certain accredited investors and the officers of the Company for the sale of convertible promissory notes (the “Fall 2019 Notes”). The Company completed the initial closing under the Fall 2019 Note Purchase Agreements in November 2019. The Company issued Fall 2019 Notes in the principal amount of $250,000 to each of Dr. Vuong Trieu, the Company’s Chief Executive Officer, and Stephen Boesch, in exchange for gross proceeds of $500,000. In connection with the second and final closing of the Fall 2019 Debt Financing, the Company issued Fall 2019 Notes to additional investors including $250,000 to Dr. Sanjay Jha, through his family trust, the former CEO of Motorola and COO/President of Qualcomm. The Company also offset certain amounts due to Dr. Vuong Trieu, the Company’s Chief Executive Officer, Chulho Park, the Company’s then Chief Technology Officer, and Amit Shah, the Company’s Chief Financial Officer, all related parties as Officers of the Company, and converted such amounts due into the Fall 2019 Notes. $35,000 due to Dr. Vuong Trieu, $27,000 due to Chulho Park and $20,000 due to Amit Shah were converted into convertible debt under the Fall 2019 Notes. The Company also issued a total of the Fall 2019 Notes of $168,000 to two accredited investors.

 

All the Fall 2019 Notes provided for interest at the rate of 5% per annum and are unsecured. For more information on the Fall 2019 Debt Financing, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026. There was no activity during the nine months ended September 30, 2026 and 2025. The total unamortized principal amount of the Fall 2019 Notes was $850,000 as of September 30, 2026, and December 31, 2025. Further, the Company recorded interest expense of approximately $10,600 and $32,000 on these Fall 2019 Notes for the three and nine months ended September 30, 2026, and 2025, respectively. The total amount outstanding under the Fall 2019 Notes, net of discounts for both periods, respectively.

 

26

 

 

Forever Prosperity (Formerly GMP) Notes

 

In June 2020, the Company secured $2 million in debt financing, evidenced by a one-year convertible note (the “GMP Note”) from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and was personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of the Company. In September 2021, the Company secured a further $1.5 million in debt financing, evidenced by a one-year convertible note (the “GMP Note 2”) from GMP, to fund the same clinical trial evaluating OT-101 against COVID- 19 bearing 2% annual interest. In October 2021, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “October Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $0.5 million. Further, in January 2022, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “January Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $0.5 million. Cumulatively, these four Notes are referred to as the “GMP Notes”. The GMP Notes carry an interest rate of 2% per annum and mature on the earlier of (a) the one- year anniversary of the date of the Purchase Agreement, or (b) the acceleration of the maturity by GMP upon occurrence of an Event of Default (as defined below). All Notes contain a voluntary conversion mechanism whereby GMP may convert the outstanding principal and accrued interest under the terms of all the GMP Notes into shares of Common Stock (the “Conversion Shares”), at the consolidated closing bid price of the Company’s Common Stock on the applicable OTC Market as of the date the Company receives a Notice of Conversion from GMP. Prepayment of the GMP Notes may be made at any time by payment of the outstanding principal amount plus accrued and unpaid interest. As of September 30, 2026, the GMP Notes are in default, however Forever Prosperity has not called for the repayment of the debt and both parties are in discussion to extend the term of the note, which, if both parties are in agreement, would cure the default. The total principal outstanding on all the GMP notes, inclusive of accrued interest, was approximately $5.0 million and $4.9 million, as of September 30, 2026, and December 31, 2025, respectively. During the three and nine months ended September 30, 2026, and 2025, the Company incurred approximately $22,700 and $67,300 of interest expense, respectively, on all the 4 notes. For a more detailed discussion on the Forever Prosperity Notes, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

August 2021 Notes

 

In August 2021, the Company entered into Note Purchase Agreements with Autotelic - a related party, our CFO – a related party, and certain accredited investors (the “August 2021 investors”), whereby the Company issued four convertible notes in the aggregate principal amount of $698,500 convertible into shares of common stock of the Company for net proceeds of approximately $691,000. The convertible notes carry a five (5%) percent coupon and mature one year from issuance. The majority of the August 2021 investors have the right, but not the obligation, not more than five days following the maturity date, to convert all, but not less than all, the outstanding and unpaid principal plus accrued interest into the Company’s common stock, at a conversion price of $0.18. The August 2021 Note Holders has waived the default in the maturity of the August 2021 Notes and as such there is no event of default and also agreed to extend the date of maturity of the August 2021 Notes to December 31, 2026. The Company determined that the economic characteristics and risks of the embedded conversion option are not clearly and closely related to the economic characteristics and risks of the debt host instrument. Further, the Company determined that the embedded conversion feature meets the definition of a derivative but met the scope exception to the derivative accounting required under ASC 815 for certain contracts involving a reporting entity’s own equity.

 

The August 2021 convertible notes, inclusive of accrued interest, consist of the following amounts:

 

   September 30,   December 31, 
   2026   2025 
Autotelic - Related party convertible note, 5% coupon December 2026  $314,427   $305,052 
CFO - Related party convertible note, 5% coupon December 2026   94,336    91,522 
Accredited investors convertible note, 5% coupon December 2026   469,758    455,751 
Total August 2021 convertible notes  $878,521   $852,325 

 

During the three and nine months ended September 30, 2026 and 2025, respectively, the Company recognized approximately $8,700 and approximately $26,200 of interest expense on the August 2021 Investors notes, of which approximately $4,000 and approximately $12,100 are attributable to related parties. At September 30, 2026 and December 31, 2025, accrued interests on these convertible notes totaled approximately $0.2 million.

 

27

 

 

March 2022 Financing

 

In March 2022, the Company entered into a Securities Purchase Agreement with Fourth Man, pursuant to which the Company issued convertible promissory note in the aggregate principal amount of $0.25 million, convertible into shares of common stock of the Company. The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. As of December 31, 2023, this note was in default and Fourth Man has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s Common Stock at an initial conversion price established at a fixed rate of $0.10, and subsequently corrected to $0.07 based on the terms of the Securities Purchase Agreement and Fourth Man Note. The Company granted a total number of 1,250,000 warrants convertible into an equivalent number of the Company common shares at a strike price of $0.20 up to five years after issuance. The Placement agent was also granted a total of 125,000 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $0.20 up to five years after issuance, as part of a finder’s fee agreement.

 

The March 2022 Fourth Man convertible note, including accrued interest and net of debt discount, consist of the following amounts:

 

   September 30,
2026
   December 31,
2025
 
         
Fourth Man Convertible note, 16% coupon March 2023 inclusive of accrued interest and default provision  $63,956   $58,531 
Unamortized debt discount   -    - 
Convertible note, net  $63,956    58,531 

 

During the year ended December 31, 2025, the Company converted approximately $150,000 in principal and approximately $54,100 in accrued interest and legal fees into 2,991,270 shares of common stock. The note includes a default amount calculated at 125% of the unpaid principal and accrued interest. As the Company failed to repay the note at the original maturity date, the Company has recorded an estimated default penalty of approximately $70,000. In April 2026, the Company issued 300,000 shares to Fourth Man in exchange for a one-time waiver of their right to adjustment of conversion price of their March 2022 note.

 

The Company recognized approximately $2,500 and $7,500 of interest for the three and nine months ended September 30, 2026, respectively. Similarly, the Company recognized approximately $7,100 and $23,800 of interest during the three and nine months ended September 30, 2025.

 

May 2022 Mast Financing

 

In May 2022, the Company entered into a securities purchase agreement with Mast Hill, whereby the Company issued one convertible note in the aggregate principal amount of $605,000 convertible into shares of common stock of the Company (“May 2022 Mast Note”). In June 2026, Mast Hill fully converted the balance of their note of approximately $847,000, including principal, accrued interest, default penalty and legal fees, into 11,877,507 common shares of the Company. For more information on the May 2022 Mast Note, refer to our 2025 Annual Report on form 10K filed with the SEC on April 15, 2026.

 

The May 2022 Mast Financing, net of debt discount, consisted of the following amounts:

 

   September 30,
2026
   December 31,
2025
 
Mast Hill Convertible note, 12% coupon inclusive of accrued interest and penalty  $-   $809,492 
Total May 2022 convertible note, net  $-   $809,492 

 

The Company recognized $0 and approximately $36,000 of interest related to the May 2022 Mast Financing in the three and nine months ended September 30, 2026, respectively.

 

The Company recognized approximately $0 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants during the three and nine months ended September 30, 2026, respectively.

 

28

 

 

July 2025 Mast Financing

 

In July of 2025, the Company entered into a securities purchase agreement with Mast Hill, whereby the Company issued a secured convertible note in the aggregate principal amount of $560,000 convertible into shares of Common Stock of the Company (“July 2025 Mast Note”). The July 2025 Mast Note carries a twelve (12%) percent coupon and a default coupon of 18% and mature at the earliest of one year from issuance or upon event of default. Mast Hill has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s Common Stock at a conversion price established at a fixed rate of $0.07. The July 2025 Mast Note is secured against the assets of the Company, excluding any assets assigned to the JV. In connection with the July 2025 Mast Note, the Company granted a total number of 2,000,000 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $0.15 up to five years after issuance. The Company also issued 2,250,000 of the Company’s common stock as commitment shares to Mast. Mast has agreed to extend the July 2025 Mast Note through the end of January 2027. The July 2025 Mast Note, and the May 2022 Note were securitized against all the assets of the Company, excluding the 45% ownership of the Company in the JV, however, Mast Hill fully converted their May 2022 Note. As of September 30, 2026, the Company assessed that certain variable rate financing convertible notes from another lender have resulted in technical deficiencies in the July 2025 Mast Note. If such deficiencies were confirmed by either of the lenders and remain uncured, that could, among other remedies, require an additional financial obligation of approximately $0.3 million for the July 2025 Mast Note. The Company has not recorded such liability, as the lenders have not sought any available remedies under their agreements or notes. The Company will continue to monitor communications and actions by noteholders and will recognize such liability in the period in which such obligation becomes probable and reasonably estimable. The Company recognized approximately $14,000 and $42,000 of accrued interest during the three and nine months ended September 30, 2026. It recognized $9,500 of accrued interest during the same period in 2025. The Company recognized approximately $16,000 and $118,000 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs and fair value allocated to the warrants and the commitment shares during the three and nine months ended September 30, 2026, as opposed to $34,600 during the same periods in 2025.

 

The July 2025 Mast Note, net of debt discount, consists of the following amounts:

   

  

September 30,

2026

  

December 31,

2025

 
         
Mast Hill Convertible note, inclusive of accrued interest 12% coupon due January 2027, gross  $625,512   $583,512 
Less: debt discount recorded   (203,833)   (203,833)
Amortization of debt discount   203,833    85,582 
Convertible notes, net  $625,512   $465,261 

 

January 2026 Mast Financing

 

In January of 2026, the Company entered into a securities purchase agreement with Mast, whereby the Company issued one convertible note in the aggregate principal amount of $398,333 convertible into shares of common stock of the Company (“2026 Mast Note”). The 2026 Mast Note carries a ten (10%) percent coupon and a default coupon of 18% and mature at the earliest of one year from issuance or upon event of default. Mast has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the 2026 Mast Note into the Company’s common stock at a conversion price established at a fixed rate of $0.07. The note is secured against the assets of the Company, excluding any assets assigned to the JV. The Company granted Mast an aggregate of 1,422,613 warrants convertible into an equivalent number of the Company common shares at a strike price of $0.15 up to five years after issuance. The Company also issued 1,600,446 shares of the Company’s Common Stock as commitment shares to Mast. The 2026 Mast Note was securitized against all the assets of the Company, excluding the 45% ownership of the Company in the JV. As of September 30, 2026, the Company assessed that certain variable rate financing convertible notes from another lender have caused technical deficiencies in those notes and impacted deficiencies in the 2026 Mast Note. If such deficiencies were confirmed by either of the lenders and remain uncured, that could, among other remedies, require an additional financial obligation of approximately $0.2 million for the 2026 Mast Note. The Company has not recorded such liability, as the lenders have not sought any available remedies under their agreements or notes. The Company will continue to monitor communications and actions by noteholders and will recognize such liability in the period in which such obligation becomes probable and reasonably estimable. The Company recognized approximately $10,000 and $27,000 of accrued interest during the three and nine months ended September 30, 2026, respectively. There was no similar expense during the same period in 2025. The Company recognized approximately $45,000 and $122,700 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs and fair value allocated to the warrants and the commitment shares during the three and nine months ended September 30, 2026.

 

29

 

 

The convertible note under the 2026 Mast Note, net of debt discount, consists of the following amounts:

 

  

September 30,

2026

  

December 31,

2025

 
         
Mast Hill Convertible note, inclusive of accrued interest 10% coupon January 2027, gross  $425,561   $- 
Less Debt discount recorded   (179,102)   - 
Amortization debt discount   122,427    - 
Convertible notes, net  $368,886   $- 

 

Pacific Pier June 2026 Financing

 

In June 2026, the Company entered into the 2026 Pacific Pier SPA with Pacific Pier, whereby the Company issued the June 2026 Pacific Pier Note in the aggregate principal amount of $178,410 convertible into shares of common stock of the Company. The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. Pacific Pier has the right at any time on or following the date that is six (6) calendar date months after the issue date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at the lesser of a fixed rate of $0.06 or 85% of the lowest traded price of the Common stock on the principal market on any trading day during the ten (10) trading days prior to the respective conversion date, therefore considered as variable rate financing note. The Company also issued 500,000 of the Company’s common stock as commitment shares to Pacific Pier. As of September 30, 2026, the Company assessed that the variable rate financing convertible note has caused technical deficiencies in other notes, that need to be notified by the other lender to be deemed deficient. If the other lender does not notify the Company for a deficiency, the June 2026 Pacific Pier Note would not be considered deficient under the provisions of the note. However, if such deficiencies were confirmed by the other lenders and remain uncured, that could, among other remedies, require an additional financial obligation of approximately $0.1 million to approximately for this note. The Company has not recorded such liability, as the other lenders have not sought any available remedies under their agreements or notes. The Company will continue to monitor communications and actions by noteholders and will recognize such liability in the period in which such obligation becomes probable and reasonably estimable. The Company recognized approximately $5,300 and $5,700 of accrued interest during the three and nine months ended September 30, 2026, respectively. There was no similar expense during the same period in 2025. The Company recognized approximately $12,500 and $13,500 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs and fair value allocated to the commitment shares during the three and nine months ended September 30, 2026.

 

The June 2026 Pacific Pier convertible note, net of debt discounts, consists of the following amounts:

 

  

September 30,

2026

  

December 31,

2025

 
         
Pacific Pier Convertible note, inclusive of accrued interest 12% coupon, gross  $184,173   $- 
Less debt discount recorded   (50,336)   - 
Amortization debt discount   13,549    - 
Total June 2026 Pacific Pier convertible note, net  $147,386   $- 

 

Pacific Pier August 2026 Financing

 

On August 3, 2026, the Company entered into another Share Purchase Agreement (“SPA”) with Pacific Pier, whereby the Company issued the August 2026 Pacific Pier Note in the aggregate principal amount of $178,410 convertible into shares of common stock of the Company. The convertible notes carry a twelve (12%) percent coupon and a default coupon of 16% and mature at the earliest of one year from issuance or upon event of default. Pacific Pier has the right at any time, on or following the date that is six (6) calendar date months after the issue date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at the lesser of a fixed rate of $0.06, subject to standard anti-dilution provision or 85% of the lowest traded price of the Common Stock on the principal market on any trading day during the ten (10) trading days prior to the respective conversion date. The Company also issued 500,000 of the Company’s common stock as commitment shares to Pacific Pier. As of September 30, 2026, the Company assessed that the variable rate financing convertible note has caused technical deficiencies in other notes, that need to be notified by the other lender to be deemed deficient. If the other lender does not notify the Company for a deficiency, the current note would not be considered deficient under the provisions of the note. However, if such deficiencies were confirmed by the other lenders and remain uncured, that could, among other remedies, require an additional financial obligation of approximately $0.1 million to approximately for this note. The Company has not recorded such liability, as the lenders have not sought any available remedies under their agreements or notes. The Company will continue to monitor communications and actions by noteholders and will recognize such liability in the period in which such obligation becomes probable and reasonably estimable. The Company recognized approximately $3,300 of accrued interest during the three and nine months ended September 30, 2026. There was no similar expense during the same periods in 2025. The Company recognized approximately $7,000 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs and fair value allocated to the commitment shares during the three and nine months ended September 30, 2026.

 

30

 

 

The August 2026 Pacific Pier convertible note, net of debt discounts, consists of the following amounts:

 

  

September 30,

2026

  

December 31,

2025

 
         
Pacific Pier Convertible note, inclusive of accrued interest 12% coupon, gross  $181,695   $- 
Less Debt discount recorded   (46,393)   - 
Amortization debt discount   7,118    - 
Total August 2026 Pacific Pier convertible note, net  $142,420   $- 

 

 

Other short-term advances

 

Other short-term advances consist of the following amounts obtained from various employees and related parties:

 

Other Advances 

September 30,

2026

  

December 31,

2025

 
Short-term advance from CFO – Related Party  $86,050   $86,050 
Short-term advances – bridge investors & others   210,000    210,000 
Short-term advances – Autotelic Inc. – Related Party   3,157,801    2,992,874 
Short-term advance – CEO – Related Party   155,000    125,000 
Short-term advance – Accredited investor   -    50,000 
Short term advance   $3,608,851   $3,513,924 

 

As of January 1, 2025, approximately $2 million was outstanding and payable to Autotelic. During the year ended December 31, 2025 Autotelic Inc. provided additional short-term funding of approximately $1.0 million to the Company. During the nine months ended September 30, 2026 Autotelic Inc. provided additional short-term funding of $165,000 to the Company. As such, approximately $3.2 million was outstanding and payable to Autotelic at September 30, 2026.

 

As of January 1, 2025, approximately $76,000 was outstanding and payable to the Company’s CFO. During the year ended December 31, 2025, the CFO provided additional short-term funding of $10,000. As such, approximately $86,000 was outstanding and payable to the Company’s CFO at September 30, 2026.

 

In December 2023, the Company received $50,000 from the Company’s CEO. In December 2025, the amount due from PPM-2 payable to the CEO of $125,000 was converted into a short-term loan. During the nine months ended September 30, 2026 the Company repaid $20,000 to the CEO. As such, approximately $155,000 was outstanding and payable to the Company’s CEO at September 30, 2026. As of September 30, 2026, approximately $210,000 was outstanding as short-term advances from certain bridge investors.

 

NOTE 6 – JOINT VENTURE WITH GMP BIO AND AFFILIATES, EQUITY METHOD INVESTMENT

 

On March 31, 2022, the Company entered into (i) an agreement to form the JV with Dragon, GMP Bio, both affiliates of GMP, (ii) a license agreement for rights to OT-101for the territory within the United States of America with Sapu Holdings, LLC, a wholly owned subsidiary of GMP Bio and (iii) a license agreement for rights to OT-101 for the rest of the world with GMP Bio. For more information on the JV and the related agreements, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023.

 

As of the effective date of the formation of the JV, the Company received a 45% ownership interest in the JV. The combined enterprise value of GMP Bio was approximately $50.4 million, comprising of the fair value of the Company’s investment in GMP Bio of approximately $22.7 million and the total original capital contributions by Dragon Overseas of approximately $27.7 million. The JV was initially funded by equity contributions from Dragon under the terms of the joint venture agreement. In May 2025, GMP Bio and Golden Mountain Partners, an affiliate of Dragon, entered into a note purchase agreement and promissory note pursuant to which Golden Mountain Partners agreed to loan funds to the JV sufficient to meet its operating expenses for 2025 and beyond. The loans are made as monthly advances, bear interest at the Wall Street Journal “Prime” rate and mature on December 31, 2026. Amounts due under the promissory note are convertible into equity of the JV at the election of Golden Mountain Partners at a price equal to 80% of the price for shares issued in connection with an equity financing of $20 million or more, or otherwise at a mutually agreed price. As of September 30, 2026, the JV had approximately $24.3 million in assets, recorded approximately $25.3 million in liabilities, including loans of approximately $18.5 million, and incurred approximately $15.5 million and $9.7 million in operational expenses for the nine months ended September 30, 2026 and September 30, 2025, respectively.

 

31

 

 

The JV has initiated phase 2 and 3 clinical trials for OT-101 in both high-grade glioma and pancreatic cancer. In late 2023, the JV initiated a plan to start evaluating various nanoparticles that could treat various cancers. In this regard, the JV identified a total of 4 compounds, in addition to OT-101, which had the potential of significant revenue generation for the JV. In the same year, the JV signed a lease agreement to set up a GMP manufacturing facility in San Diego (“SD”), California. The main purpose of this facility was to initially commence an aggressive formulation development of newly planned nanoparticle platform (“Nano Platform”). The GMP manufacturing facility was initiated in January 2024. Upon the initiation of this facility by the JV, the JV commenced the development work on two of the four identified compounds, as well as other activities, in tandem with the development of OT-101. The JV has since completed the formulation development of one of the products and is moving to complete the formulation development for the three additional products. The JV is also working on improved formulations for OT-101 with new nanoparticle sizes. The JV also has started clinical development for OT-101 for pancreatic cancer. Significant progress has been made in the development of the products and the JV anticipates to complete the formulation development work in 2026 and pushing to initiate clinical trials for the various compounds. In late 2024, the GMP facility in San Diego was issued a Drug Manufacturing License by the State of California Department of Public Health and Food and Drug Branch. Further, in late 2024, the JV identified a sixth candidate as a compound for development for the JV and has already started to work on the formulation development of that compound as well. All developmental and manufacturing, including for Phase 1 clinical trial materials, will be performed at the SD site. The Company successfully completed a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101, an antisense therapeutic targeting TGFβ2, with CKIs and recombinant IL-2. The Phase 1 trial (ClinicalTrials.gov ID: NCT04862767) investigated the safety and tolerability of OT-101 in combination with recombinant IL-2 in patients with advanced or metastatic solid tumors. The combination showed a tolerable safety profile at the planned dosing schedule, with no unexpected safety signals identified. Based on the favorable safety data, Oncotelic plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers.

 

The Company elected the fair value option under subsection of Section 825-10-15 to account for its equity-method investment in the JV as the Company believes that it the most appropriate method to properly value the Company and record a change in value when and upon conducting a fair value assessment. As of December 31, 2025, as the development and IPO operations of the JV are proceeding as planned, the Company assessed the fair value of its investment in the JV. The Company also utilized the services of an ASC-compliant third party valuation firm to validate the Company’s assessment. Based on the Company’s assessment and report, and considering the Company’s 45% ownership in the JV, the Company proceeded to record an increase in fair value of the Company’s ownership interest in GMP Bio of approximately $365.4 million.As of September 30, 2026, the Company assessed and determined that, while there was a marginal change in the timeline for the IPO and the development program, the fair value of the Company’s investment in the JV had not materially changed and hence no additional fair value adjustment was required during the three and nine months ended September 30, 2026. As such, the Company has not recorded a change in value of the Company’s interest in the JV.

 

A summary of the change in the fair value of our investment in GMP Bio, is shown below:

 

   September 30,
2026
   December 31,
2025
 
Balance at beginning of period  $388,000,000   $22,653,225 
Add: change in fair value of investment in GMP Bio   -    365,346,775 
Balance at end of period  $388,000,000   $388,000,000 

 

For detailed and more information on the fair value of our investment in GMP Bio, refer to Note 2 to the unaudited Condensed Consolidated Financial Statements: Change in Fair Value of Equity Securities of GMP Bio.

 

32

 

 

NOTE 7 - PRIVATE PLACEMENT -2 (PPM-2) AND JH DARBIE FUNDING

 

During the period between July 2023 to January 2024, the Company entered into a series of subscription agreements including forty-eight accredited investors, whereby the Company issued and converted a total of 94 Units from a previous offering, which resulted in conversion of $2.35 million of old debt into new debt to the Company (the “PPM-2 Financing”). The Company did not receive any cash proceeds through the PPM-2 Financing. In December 2025, the Company converted the debt of forty-six accredited investors from PPM-2 into the new subscription agreements under the new financing (“PPM-3”- See Note 8 below) in three tranches, which resulted in conversion of approximately $2.2 million of the PPM-2 debt into the PPM-3 debt. For more information on PPM-2, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

The PPM2 - JH Darbie Financing, net of debt discounts, consisted of the following amounts:

 

  

September 30,

2026

  

December 31,

2025

 
Accrued interest          
Accrued, returned and unpaid interest  $21,117   $102,795 
Total PPM-2 Darbie Financing, net of discounts  $21,117   $102,795 

 

All warrants sold in this offering had an exercise price of $0.12 per share of the Company stock, subject to adjustment, are exercisable immediately and expire two years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values:

 

Expected Term   2 years 
Expected volatility   173%
Risk-free interest rates   4.29%
Dividend   0.00%

 

The Company recorded approximately $318,000 as an initial debt discount related to the four tranches of PPM 2. The Company recognized amortization expense related to the debt discount and debt issuance costs of $0 and approximately $101,000 for the nine months ended September 30, 2026 and 2025, respectively, which is included in interest expense in the statements of operations. During the nine months ended September 30, 2026 and 2025, the Company incurred $0 and approximately $276,000 of interest expense related to the convertible notes.

 

NOTE 8 – PRIVATE PLACEMENT -3 (“PPM-3”) AND JH DARBIE FUNDING

 

In December 2025, the Company entered into a series of subscription agreements with certain accredited investors pursuant to the JH Darbie Financing, whereby the Company issued and converted a total of 87 Units from the previous PPM-2, into the current subscription agreements under the PPM-3, which resulted in conversion of approximately $2.2 million of the PPM-2 to PPM-3 the Company did not receive any cash proceeds through the December 2025 conversions, with each Unit consisting of:

 

  ● One 12% unsecured convertible promissory note (the “Note”) of principal amount of $25,000 and convertible into up to 250,000 shares of the Company’s common stock (par value of $0.01) based on a conversion price of $0.10 per share.
     
  ● 250,000 warrants to purchase an equivalent number of shares of the Company’s common stock at a strike price of $0.12 per share (“Oncotelic warrant”) with a contractual term of two years.

 

33

 

 

In December 2025, in a series of three tranches, the Company converted the debt of forty-seven (47) accredited investors from PPM-2 (See Note 7 above) into the current subscription agreements under the PPM-3, which resulted in conversion of $2,175,000 of old debt into new debt to the Company. The Company did not receive any cash proceeds through the conversions. JH Darbie and the Company are parties to a May 2024 placement agent agreement (“Agreement”) pursuant to which JH Darbie had the right to sell a minimum of 10 Units and a maximum of 200 Units on a best-efforts basis. Initial placement agent fees of $25,000 were paid to JH Darbie in June 2024. Subsequently, the Company paid JH Darbie an amount of $326,250 for processing the three tranches of the Financing. Based on the placement agent agreement, JH Darbie was entitled to a non-refundable $25,000 fee to start the due diligence process and 2% due diligence fees and 13% commissions on all subsequent conversions or new funding. In addition, the Company is to provide warrant coverage equal to 10 % of all of the units sold to JH Darbie. As the Company converted an aggregate of 87 units, JH Darbie was entitled to earn a total of 2,175,000 warrants. A total of 2 investors holding 7 units under the PPM-2 opted not to participate in the PPM-3 and approximately $0.2 million of notes were converted into short-term loan to the Company. During the nine months ended September 30, 2026, $70,000 of this loan was repaid.

 

In connection with the consummation of the PPM-3 financing, the Company entered into Registration Rights Agreements granting certain registration rights with respect to the shares of the Company’s Common Stock issued in connection with the financing, as well as the shares of the Company’s Common Stock issuable upon exercise of the Warrants. The issuance of the Units is exempt from the registration requirements of the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506 of Regulation D promulgated thereunder. The shares of common stock and warrants and any shares of common stock issuable upon exercise of the warrants, have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.

 

The December 2025 JH Darbie Financing, net of debt discounts, consists of the following amounts:

 

  

September 30,

2026

  

December 31,

2025

 
Convertible promissory notes          
Subscription agreements - accredited investors  $1,922,616   $1,663,405 
Total convertible promissory, net of discounts  $1,922,616   $1,663,405 

 

The Company incurred approximately $0.3 million of issuance costs, consisting of incremental costs related to the issuance of the various instruments bundled in the offering.

 

Concurrently with the sale of the Units, JH Darbie was granted a total of 2,175,000 stock warrants, exercisable over a two-year period.

 

The terms of convertible notes are summarized as follows:

 

  ● Term: through December 31, 2027
  ● Coupon: 12%
  ● Convertible at the option of the holder at any time into the Company’s common stock
  ● Conversion price is set at $0.10 per share subject to standard anti-dilution provision.

 

34

 

 

Management reviewed the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments and concluded that the terms of the agreements were substantially different and accounted for the transaction as a debt extinguishment. The transaction resulted in a loss from debt extinguishment of approximately $1.2M, which is presented in other expense in the condensed consolidated statements of operations for the year ended December 31, 2025.

 

The estimated volume weighted grant date fair value of approximately $0.053 per share associated with the warrants to purchase up to 21,750,000 shares of common stock issued in this offering, or a total of approximately $1.2M, was recorded to additional paid-in capital. All warrants sold in this offering have an exercise price of $0.12 per share of the Company stock, subject to adjustment, are exercisable immediately and expire two years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation pricing model using the following input values:

 

Expected Term   2 years  
Expected volatility     127.9% - 132.2 %
Risk-free interest rate     3.47% - 3.52 %
Dividend     0.00 %

 

The Company recorded an initial debt discount of approximately $511,600 for the year ended December 31, 2025. The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $181,000 and $0 for the nine months ended September 30, 2026 and 2025, respectively, which is included in interest expense in the statements of operations. During the three and nine months ended September 30, 2026, the Company incurred approximately $71,500 and $200,500 of interest expense related to the convertible notes. There was no similar expense during the same periods in 2025.

 

NOTE 9. LUNAI BIOWORKS TRANSACTIONS

 

Intellectual Property Development and Services Agreement with Lunai Bioworks, Inc.

 

On April 17, 2026, the Company and Lunai Bioworks, Inc., a Delaware corporation (“Lunai”) entered into an intellectual property development and services agreement (“IP Services Agreement”), whereby the Company was to perform intellectual property development and business development services relating to a Nose-to-Brain (“N2B”) delivery platform. This includes applications in biodefense, Alzheimer’s disease (“AD”), and broader central nervous system (“CNS”) indications and excludes Parkinson’s disease and sexual dysfunction. The work shall focus on direct-to-CNS delivery to bypass the blood-brain barrier. The scope of services included scientific development, IP execution, technical data delivery, business development support and broadened biodefense focus. In connection with these services, Lunai agreed to compensate the Company a total compensation of $250,000, of which $62,500 was payable upon signing of the IP Services Agreement, $62,500 upon filing of provisional patents and $125,000 payable upon the execution of a biodefense and neurodegenerative platform IP acquisition agreement by Lunai, which was the agreement and plan for merger with Lunai, described below. The Company has completed all its obligations under the IP Services Agreement, invoiced Lunai for the services and recognized the revenue under the IP Services Agreement during the nine months ended September 30, 2026 for an aggregate amount of $250,000, which was recorded as service revenue in the unaudited condensed consolidated statement of operations for the three and nine months ended September 30, 2026. No similar services revenue was recorded in the three and nine months ended September 30, 2025.

 

Agreement and Plan of Merger with Lunai

 

On April 27, 2026, Oncotelic Inc., a wholly owned subsidiary of the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lunai, Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings Incorporated, a Delaware corporation (“Holdings”), and the holders of all of the issued and outstanding capital stock of Holdings, namely Oncotelic Inc. and Pelerin Therapeutics Inc., a corporation existing under the laws of the Province of British Columbia, Canada (“Pelerin” and, together with Oncotelic Inc., the “Holders”). Pursuant to the Merger Agreement, Holdings merged with and into Merger Sub in a triangular merger (the “Merger”), with Merger Sub continuing as the surviving corporation and as a wholly owned subsidiary of Lunai. The Merger was completed on May 1, 2026. Immediately prior to the effective time of the Merger, all of the issued and outstanding capital stock of Holdings was owned 62.5% by Oncotelic Inc. and 37.5% by Pelerin. The sole assets of Holdings at the effective time of the Merger consisted of a multi-jurisdictional patent portfolio (collectively, and as further defined in the Merger Agreement, the “Patents”), which the Holders had contributed to Holdings prior to the effective time. In consideration for the Merger, on May 1, 2026 Lunai issued to the Holders an aggregate of eight (8) shares of a newly designated series of preferred stock of Lunai, designated as “Series B Convertible Preferred Stock” (the “Series B Preferred Stock”), having an aggregate stated value (the “Stated Value”) of $20,000,000. The Series B Preferred Stock was allocated five (5) shares to Oncotelic Inc. (representing 62.5% of the Series B Preferred Stock and an aggregate Stated Value of $12,500,000). For more information on the Merger Agreement, refer to our Current Report on Form 8-K filed with the SEC on May 5, 2026.

 

35

 

 

IP Assignment Agreement

 

In connection with the Merger Agreement, on April 27, 2026, Oncotelic Inc. entered into an IP Assignment Agreement with Holdings, pursuant to which it agreed to contribute and assign certain assets relating to the intellectual property of the Company (collectively, the “Intellectual Property Assets”) to Holdings. For more information on the Merger Agreement, refer to our Current Report on Form 8-K filed with the SEC on May 5, 2026.

 

IP Grant-back Agreement

 

Further, on April 27, 2026, the Company and Holdings entered into an Intellectual Property Assignment and Grant-back Agreement (the “IP Grant-back Agreement”). The IP Grant-back Agreement grants back to the Company a perpetual, irrevocable, royalty-free, exclusive, non-terminable, and non-cancellable license to make, have made, use, offer to sell, sell, and otherwise exploit the Intellectual Property Assets in all fields of use except the Biodefense Field and the Alzheimer’s Disease Field as defined in the IP Grant-back Agreement, giving Holdings exclusive use of the Intellectual Property Assets in those fields. For more information on the Merger Agreement, refer to our Current Report on Form 8-K filed with the SEC on May 5, 2026.

 

Asset Transfer Agreement

 

Further, on April 30, 2026, Oncotelic Inc. on behalf of the Company, and Autotelic Inc. (“Autotelic”) entered into an asset transfer agreement (the “Asset Transfer Agreement”) pursuant to which Autotelic agreed to transfer all the rights, title and interest to certain assets (“Assets”), described below and owned by Autotelic to Oncotelic Inc. This Asset Transfer Agreement was entered into by both parties to effectuate the Merger Agreement. Dr. Trieu, Chairman and CEO of Oncotelic Therapeutics, Inc., is a partial owner and control person in Autotelic Inc. Autotelic Inc. currently owns less than 10% of the Company. The Assets transferred pursuant to the Asset Transfer Agreement include Peptide Y (including all variants, analogs, derivatives); Parathyroid Hormone (“PTH”), including PTH 1-34, PTH 1-84, and derivatives; Insulin (including intranasal and other formulations); Apomorphine (including intranasal and other formulations); Carbetocin (including intranasal and other formulations); any associated combination therapies, including multi-agent CNS, AD, metabolic, endocrine, or biodefense applications; and all delivery platforms, including nasal, injectable, and device-based systems and includes all patents, patent applications, know-how, trade secrets, data, formulations, manufacturing processes, regulatory filings, and all related rights associated with the Assets. In consideration for the transfer of the Assets, the Company shall issue equity of ten percent (10%) of the fully diluted outstanding shares of the Company, issuable on an uplisting of its capital stock to NYSE/NASDAQ. No cash was paid for the Asset Transfer Agreement.

 

The consideration payable to Autotelic is contingent on the Company uplisting its Common Stock to a nationally recognized stock exchange. Such shares of the Company have not been issued to Autotelic as of the date of this filing and are not legally due to be issued until the uplisting of the Company’s stock onto a nationally recognized stock exchange. If the uplisting does not occur, then the shares would not be issuable, and neither would the transaction with Lunai be invalidated.

 

Even though the Company received the Series B Preferred Stock from Lunai with a stated value of $12.5 million, the Company initially recorded $1.1 million as a fair value for its investment in Lunai upon the exchange of the Company’s non-financial asset, which had zero carrying basis. The Company measures the fair value of these shares at every quarter end. At September 30, 2026, the Company recorded a loss in fair value of its equity investment of approximately $0.5 million, which is presented in change in fair value equity investment in the Company’s unaudited condensed consolidated statement of operations for the nine months ended September 30, 2026. Such decrease in the fair value of the Company’s investment was attributable to the decrease in the market capitalization of Lunai. For more information on the fair value of the investment in Lunai, refer to Fair Value Hierarchy – Lunai above.

 

36

 

 

NOTE 10 - RELATED PARTY TRANSACTIONS

 

Master Service Agreement with Autotelic Inc.

 

In October 2015, Oncotelic entered into a Master Service Agreement (the “MSA”) with Autotelic Inc., a related party that is partly owned by the Company’s CEO Vuong Trieu, Ph.D. Dr. Trieu, a related party, is a control person in Autotelic Inc. Autotelic Inc. currently owns less than 10% of the Company. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services.

 

Expenses related to the MSA were approximately $500 and $1500 for the three and nine months ended September 30, 2026 and 2025, respectively.

 

License Agreement with Autotelic Inc.

 

In September 2021, the Company entered into an exclusive License Agreement with Autotelic. For more information on the exclusive license Agreement with Autotelic, refer to our 2025 Annual Report on Form 10-K filed with SEC on April 15, 2026.

 

Notes Payable and Short-Term Loan – Related Parties

 

In April 2019, the Company issued a convertible note to Dr. Trieu totaling $164,444, including OID of $16,444, receiving net proceeds of $148,000, which was used by the Company for working capital and general corporate purposes. The Company issued a Fall 2019 Note to Dr. Trieu in the principal amount of $250,000. Dr. Trieu also offset certain amounts due to him in the amount of $35,000 and was converted into the Fall 2019 debt. As of January 1, 2025, Dr Trieu had provided a short-term loan of $50,000 to the Company. During the year ended December 31, 2025, Dr. Trieu converted his holding in PPM-2 of $125,000 into a short-term loan with the Company. During the nine months ended September 30, 2026, the Company repaid $70,000 of this short-term loan. As such, the balance due and payable to Dr. Trieu, on the short term loan, as of September 30, 2026, and December 31, 2025, was $105,000 and $175,000, respectively.

 

In November 2025, the Company entered into a restricted stock agreement (the “RSA-1”) with Dr. Trieu, to provide incentive compensation for his extra-ordinary efforts and time to raise capital and successful achievement of certain milestones. The RSA-1 provides for a grant of up to approximately 24,388 shares of our unissued Series A Convertible preferred stock (“Preferred Stock”), subject to achievement of certain milestones. Each share of Preferred Stock is convertible into 1,000 shares of the Company’s Common Stock and votes with the Common Stock on an as converted basis.

 

In January 2026, the Company entered into another restricted stock agreement (the “RSA-2”) with Dr. Trieu, to provide incentive compensation for his extra-ordinary efforts and time to raise capital and successful achievement of certain milestones. The restricted stock agreement provides for a grant of up to 26,512 shares of our Preferred Stock, subject to achievement of certain milestones. Each share of Preferred Stock is convertible into 1,000 shares of the Company’s Common Stock and votes with the Common Stock on an as converted basis.

 

As of December 31, 2025, Dr. Trieu had earned 12,196 shares of Preferred Stock. As of September 30, 2026, Dr. Trieu earned an additional 8,131 shares of Preferred Stock.

 

37

 

 

As of January 1, 2025, approximately $2 million was outstanding and payable to Autotelic. During the year ended December 31, 2025, Autotelic Inc. provided additional short-term funding of approximately $1.0 million to the Company. During the nine months ended September 30, 2026, Autotelic Inc. provided additional short-term funding of approximately $165,000 to the Company. As such, approximately $3.2 million was outstanding and payable to Autotelic at September 30, 2026.

 

Contingent shares issuable to Autotelic

 

The Company is contingently obligated to issue equity of ten percent (10%) of the fully diluted outstanding shares of the Company, issuable on an uplisting of its capital stock to NASDAQ. No cash was paid for the Asset Transfer Agreement. For more information, refer to Note 9 – Lunai Bioworks Transactions: Asset Transfer Agreement and Note 15 – Commitment and Contingencies: Autotelic Asset Transfer Consideration.

 

Artius Consulting Agreement

 

In March 2020, the Company and Artius Bioconsulting, LLC (“Artius”), for which Mr. King is the Managing Member, entered into an amendment to the Consulting Agreement dated December 1, 2018, under which Artius agreed to serve as a consultant to the Company for services related to the Company’s business from time to time. For more information on this Agreement, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

No expense was recorded during the three or nine months ended September 30, 2026 and 2025 related to this Agreement.

 

Mosaic ImmunoEngineering, Inc.

 

In April 2024, the Company entered into a Term Sheet with Mosaic. For more information on the Term Sheet, refer to Note 1 of this Quarterly Report. Steven King, our Board member, is the CEO of Mosaic. The Company had advanced $40 thousand to Mosaic in accordance with the terms of the Term Sheet, and Mosaic has repaid the amount, with interest to the Company as of December 31, 2024. In addition, the Company, on behalf of our JV, had entered into an agreement with Mosaic to provide consulting services related to CMC activities for the JV. The expenses for these services have been paid for by the JV. As such, the Company has not recorded any expenses or accounts payable in this regard during the three months ended September 30, 2026 or 2025, related to this Agreement.

 

Maida Consulting Agreement

 

Effective May 5, 2020, the Company and Dr. Maida entered into an independent consulting agreement, commencing April 1, 2020, under which Dr. Maida will assist the Company in providing medical expertise and advice from time to time in the design, conduct and oversight of the Company’s existing and future clinical trials. For more information on this Agreement, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

Effective April 1, 2022, Dr. Maida’s compensation has been borne by the JV. No expense was recorded during the three and nine months ended September 30, 2026, and 2025 related to this Agreement.

 

NOTE 11 - EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (MAST HILL)

 

In August of 2025, the Company entered into an Equity Purchase Agreement (“EPA”) and Registration Rights Agreement with Mast Hill. Under the terms of the EPA, the Company issued warrants to purchase 3,350,000 shares of Common Stock to Mast Hill. Further, under the terms of the EPA, Mast Hill agreed to purchase from the Company up to $25,000,000 of the Company’s Common stock upon effectiveness of a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission and subject to certain limitations and conditions set forth in the Equity Purchase Agreement. The Registration Rights Agreement provided that the Company would (i) file the Registration Statement with the SEC by October 1, 2025: and (ii) use its best efforts to have the Registration Statement declared effective by the Commission at the earliest possible date (in any event, within 90 after days after the execution date of the definitive agreements). The Company filed the initial Form S-1 with the SEC on November 21, 2025 and the SEC declared the S-1 effective on December 23, 2025. The Company filed a prospectus on Form 424B3 with the SEC on December 23, 2025.

 

38

 

 

Following effectiveness of the Registration Statement, and subject to certain limitations and conditions set forth in the EPA, the Company shall have the discretion to deliver put notices to the Investor and the Investor was obligated to purchase shares of the Company’s Common Stock based on the investment amount specified in each put notice. The minimum amount that the Company can put to the Investor in each put notice is $5,000 and the maximum amount is up to the lesser of $0.5 million or twenty percent (20%) of the average daily trading value of the Company’s Common stock. Pursuant to the EPA, the Investor is not permitted to purchase, and the Company may not put shares of the Company’s Common Stock to the Investor that would result in the Investor’s beneficial ownership of the Company’s outstanding Common Stock exceeding 4.99%. The price of each put share shall be equal to ninety seven percent (97%) of the market price, which is defined as the lesser of (i) closing bid price of the Common stock on the trading date immediately preceding the respective put date, or (ii) the lowest closing bid price of the Common Stock during the seven (7) trading days immediately following the clearing date associated with the applicable put notice. The Registration Statement is not currently effective, and the Company does not have the right to deliver additional put notices to the Investor unless and until an effective registration covering the underlying Common Stock is declared effective by the SEC.

 

In connection with the EPA, the Company issued 3,350,000 warrants to Mast Hill and recorded a fair value deferred finance cost of approximately $122,000.

 

During the nine months ended September 30, 2026, the Company sold a total of 137,987 shares of Common Stock at $0.04 for total gross proceeds of $6,630, and incurred issuance costs of approximately $1,500.

 

NOTE 12 - STOCKHOLDERS’ EQUITY

 

The following transactions affected the Company’s Stockholders’ Equity:

 

Issuance of Common Stock during the nine months ended September 30, 2026

 

In January 2026, the Company issued 1,600,446 of the Company’s Common Stock as commitment shares to Mast Hill in connection with a Note purchase agreement.

 

In April 2026, the Company issued 300,000 shares to Fourth Man in exchange for one time waiver of their right to adjustment of conversion price of their March 2022 note.

 

In May 2026, the Company sold 137,987 registered shares of Common Stock at $0.04 to Mast Hill in connection with EPA.

 

In June 2026, the Company issued 11,877,507 shares of Common Stock to Mast Hill in connection with the note conversion of their May 2022 Note.

 

In June 2026, the Company issued 500,000 shares of Common Stock to Pacific Pier in connection with the new Pacific Pier Note.

 

In August 2026, the Company issued 500,000 shares of Common Stock to Pacific Pier in connection with the second Pacific Pier Note.

 

Issuance of Common Stock during the nine months ended September 30, 2025

 

In March 2025, Fourth Man partially converted approximately $68,000 of their debt, including accrued interest plus $1,750 for legal fees. In connection with the partial Note conversion, the Company issued 1,002,832 shares of Common Stock to Fourth Man.

 

In July 2025, the Company issued 2,250,000 shares of Common stock as commitment shares to Mast Hill as part of the secured convertible note purchase agreement.

 

In August 2025, the Company issued 20,322,930 shares of Common stock as service fees to Jefferson Capital as part of the independent contractor agreement. A copy of the independent contractor agreement was submitted to the SEC on a Current Report on Form 8-K on August 12, 2025.

 

39

 

 

In August 2025, the Company issued 4,064,586 shares of Common stock as service fee to Valor Nation as part of the independent contractor agreement. A copy of the independent contractor agreement was submitted to the SEC on a Current Report on Form 8-K on August 12, 2025.

 

In August 2025, Mast Hill partially converted approximately $264,000 of accrued interest. In connection with the partial Note conversion, the Company issued 3,860,000 shares of Common Stock to Fourth Man.

 

In September 2025, Fourth Man issued notice to the Company to partially convert approximately $44,000 of their debt, including accrued interest and fee of approximately $2,000. As the Company had received the request for conversion prior to close of business of the quarter ending September 30, 2025 and was obligated to issue such shares to Fourth Man, the Company recorded 656,082 shares of Common stock as ‘Equity to be issued” to Fourth Man.

 

The Company has outstanding convertible promissory notes, preferred stock, warrants and stock options that are potentially convertible into or exercisable for shares of the Company’s Common Stock, subject to the applicable terms and conditions of the respective agreements and instruments. Based on the outstanding balances, contractual conversion and exercise provisions as of September 30, 2026, the aggregate number of common shares potentially issuable upon conversion or exercise of these dilutive instruments exceeds the number of authorized but unissued shares of common stock. Accordingly, if all such instruments were converted or exercised in accordance with their respective terms, the aggregate number of shares required would exceed the Company’s currently authorized but unissued common shares. The Company has also ensured to reserve the shares with the Company’s stock transfer agent for contractually obligated share issuances. The potential shortfall does not represent an immediate obligation to issue additional shares, as conversion and exercise are subject to the applicable contractual terms and conditions. Based on the holdings by management, affiliated persons and certain other large investors, the Company believes it would be able to obtain shareholder approval to increase its authorized common shares based on provisions acceptable. The Company will continue to monitor its authorized share capacity relative to its outstanding convertible and equity-linked instruments.

 

NOTE 13 – PREFERRED STOCK

 

The Company has authorized 15,000,000 shares of Convertible Preferred Stock, par value $0.01 per share, of which, 5,000,000 shares have been designated as Series A Convertible Preferred Stock (the “Preferred Stock”).

 

In November 2025, the Company entered into RSA-1 with Dr. Vuong Trieu, our CEO, and granted him 24,388 shares of our Preferred Stock, which were subject to a vesting schedule upon achievement of certain corporate milestones and subject to forfeiture if any or all the milestones were not achieved. As of December 31, 2025, 24,388 shares of the Company’s Preferred Stock were issued to Dr. Trieu, but Dr. Trieu would earn the Preferred Shares as and when he achieved certain milestones. As of December 31, 2025, Dr. Trieu had earned 12,196 shares of Preferred Stock. As of September 30, 2026, Dr. Trieu earned an additional 8,131 shares of Preferred Stock. Each share of Preferred Stock is convertible into 1,000 shares of the Company’s Common Stock, and votes with the Common Stock on an as converted basis.

 

In January 2026, the Company entered into RSA-2 with Dr. Trieu, to provide incentive compensation for his extraordinary efforts and time to raise capital and successful achievement of certain milestones. The restricted stock agreement provides for a grant of up to 26,512 shares of our Preferred Stock, subject to achievement of certain milestones. Each share of Preferred Stock is convertible into 1,000 shares of the Company’s Common Stock upon conversion and votes with the Common Stock on an as converted basis. Dr. Trieu achieved the first milestone and earned 4,426 shares of Preferred Stock.

 

   Shares   Amount 
Balance at January 1, 2026   24,388   $244 
Issuance of preferred stock   26,512    265 
Balance at September 30, 2026   50,900   $509 

 

   Shares   Amount 
Balance at January 1, 2025   -   $- 
Issuance of preferred stock   24,388    244 
Balance at December 31, 2025   24,388   $244 

 

For the January 2026 grant, The Company calculated the grant date fair value of the Preferred Stock for the RSA issued to Dr. Trieu as approximately $2.1 million, recorded stock-based compensation of approximately $0 and $1.7 million for the three months and nine months ended September 30, 2026 and had approximately $0.5 million of unamortized expense to be recognized in future periods as and when the milestones are achieved.

 

The Company calculated the grant date fair value of the Preferred Stock for the RSA issued to Dr. Trieu in 2025 as approximately $2.1 million, recorded stock-based compensation of approximately $1.6 million during the year ended December 31, 2025, and had approximately $0.5 million of unamortized expense to be recognized in future periods as and when the milestones are achieved. As of September 30, 2026, the performance milestone that would have triggered the vesting of 4,063 Preferred shares was not deemed probable. During the three and nine months ended September 30, 2026, the Company did not record any stock-based compensation and had approximately $0.5 million of unamortized expense.

 

40

 

 

NOTE 14 – STOCK-BASED COMPENSATION

 

Compensation for services

 

In August 2025, the Company issued 20,322,930 shares of Common stock as service fees of approximately $1.2 million, as the grant date fair value of the Common Shares to Jefferson Capital, as part of the independent contractor agreement. Jefferson is due to earn certain shares out of the shares issued based on certain milestones, as described in Note 1 to this Report. The Company has not recognized any stock-based compensation during the three and nine months ended September 30, 2026, and had approximately $0.3 million of unamortized expense remaining.

 

In August 2025, the Company issued 4,064,586 shares of Common stock as service fee of approximately $0.2 million to Valor Nation as part of the independent contractor agreement, as the grant date fair value of the Common Shares to Valor Nation. Valor Nation is due to earn the shares issued based over the service period of the agreement. The Company recognized approximately $0.2 million as stock-based expense during the year ended December 31, 2025, and had approximately $0 unamortized expense to be recognized over the remainder of the period of the services.

 

In December 2025, the Company issued 1,818,182 shares of Common stock as service fee of approximately $0.2 million to Outside the Box Capital, Inc. as part of the service agreement, as the grant date fair value of the Common Shares to Outside the Box Capital Inc. Outside the Box Capital Inc. is due to earn the shares issued based over the service period of the Agreement. The Company recognized approximately $0.1 million as stock-based compensation during the three and nine months ended September 30, 2026, and had $0 unamortized expense.

 

Options

 

As of September 30, 2026, the Company had options to purchase Common Stock that were outstanding under three stock option plans – the 2017 Equity Incentive Plan (the “2017 Plan”), the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2005 Stock Plan (the “2005 Plan”). No further awards may be granted under the 2005 Plan, although options previously granted remain outstanding in accordance with their terms. Under the 2017 Plan, up to 2,000,000 shares of the Company’s Common Stock may be issued to directors, officers, employees or consultants pursuant to awards granted in the form of non-qualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Under the 2015 and 2005 Plans, taken together, no further shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of incentive stock options, non-qualified stock options, restricted and unrestricted stock awards, and other stock-based awards.

 

41

 

 

The Company’ stock option activity for both qualified and unqualified stock options, is summarized as follows:

    

       Weighted 
       Average 
For the nine months ended September 30, 2026  Options   Exercise Price 
Outstanding at January 1, 2026   23,802,761   $0.15 
Expired or cancelled   (6,297,040)   - 
Outstanding at September 30, 2026   17,505,721    0.14 
Exercisable at September 30, 2026   9,698,221   $0.16 

 

The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at September 30, 2026:

   

Exercise prices  

Outstanding

Options

  

Weighted-

Average

Remaining Life

(In Years)

  

Weighted-

Average

Exercise

Price

  

Exercisable

Options

 
                  
$0.10 to $0.15    12,275,000    5.5   $0.12    4,467,500 
$0.16 to $0.21    3,680,721    4.8    0.16    3,680,721 
$0.22 to $0.37    1,550,000    1.2    0.28    1,550,000 
      17,505,721    5.0   $0.14    9,698,221 

 

The compensation expense attributed to the issuance of the options is recognized as they vest. The employee stock option plan stock options are generally exercisable for ten years from the grant date and vest over various terms from the grant date to three years.

 

As of September 30, 2026, there was no unamortized stock compensation cost related to the stock options granted during the year ended December 31, 2023. Of the approximately 10 million unvested stock options, the vesting criteria for 7.3 million options is still being evaluated as on the date of this Report, as those options are subject to individual milestone achievements. The Company amortized $0 stock compensation expense during the three and nine months ended September 30, 2026 and 2025 on the 2021 and 2022 grants. For more information on the stock options, refer to 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

Warrants

 

The Company has issued warrants in connection with the various financings conducted by the Company. For more information on the warrant issuances, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

The issuance of warrants to purchase shares of the Company’s Common Stock, including those attributed to debt issuances, as of September 30, 2026 and 2025, respectively are summarized as follows:

 

       Average 
For the nine months ended September 30, 2026  Shares   Exercise Price 
Outstanding at January 1, 2026   59,415,289   $0.13 
Issued   1,422,613    0.15 
Exercised / cancelled   -    - 
Outstanding at September 30, 2026   60,837,902   $0.13 

 

42

 

 

       Average 
For the nine months ended September 30, 2025  Shares   Exercise Price 
Outstanding at January 1, 2025   31,890,289   $0.13 
Issued during the nine months ended September 30, 2025   5,350,000    0.15 
Outstanding at September 30, 2025   37,240,289   $0.13 

 

The following table summarizes information about warrants outstanding and exercisable at September 30, 2026:

 

    Outstanding and exercisable 
Exercise Price  

Number

Outstanding

  

Weighted-

Average

Remaining Life

in Years

  

Weighted-

Average

Exercise

Price

  

Number

Exercisable

 
$0.13    961,539    0.25   $0.13    961,539 
$0.20    4,373,750    0.67   $0.20    4,373,750 
$0.12    46,555,000    1.25   $0.12    46,555,000 
$0.12    2,175,000    4.25   $0.12    2,175,000 
$0.15    6,772,613    4.00   $0.15    6,772,613 
      60,837,902    1.64   $0.13    60,837,902 

 

NOTE 15– COMMITMENTS AND CONTINGENCIES

 

Leases

 

Currently, the Company is leasing the office located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 on a month-to-month basis until such time a new office is identified. The Company believes the office is sufficient for its current operations.

 

PointR Merger Consideration

 

The total purchase price in the PointR Merger of $17,831,427 included $2,625,000 of contingent consideration of shares issuable to PointR shareholders, upon achievement of certain milestones. For more information on the PointR Merger Contingent Consideration, refer to our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

Autotelic Asset Transfer Consideration

 

As noted in Note 9 – Lunai Bioworks Transactions, Oncotelic Inc. on behalf of the Company, and Autotelic entered into the Asset Transfer Agreement, pursuant to which Autotelic agreed to transfer all the rights, title and interest to certain Assets In consideration for the transfer of the Assets, the Company shall issue equity of ten percent (10%) of the fully diluted outstanding shares of the Company, issuable on an uplisting of its capital stock to NYSE/NASDAQ. Such shares of the Company have not been issued to Autotelic as of the date of this filing and are not due to be issued till the uplisting of the Company’s stock onto a nationally recognized stock exchange. If the uplisting does not occur, then the shares would not be issuable and neither would the transaction with Lunai be invalidated. For more information, refer to Note 9 – Lunai Bioworks Transactions.

 

Other claims

 

From time to time, the Company may become involved in in legal proceedings, claims and regulatory matters arising in the ordinary course of business. Such matters are subject to uncertainties, and outcomes are not predictable with assurance. As of September 30, 2026, the Company was not a party to any legal proceedings, and management is not aware of any pending or threatened claims or contingencies that, individually or in the aggregate, are probable of resulting in a material loss to the Company’s unaudited condensed consolidated financial statements. Accordingly, no accrual for loss contingencies has been recorded as of September 30, 2026.

 

NOTE 16 – SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date the unaudited condensed consolidated financial statements were issued. Based on this evaluation, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements.

 

43

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q for the period ended September 30, 2026 (this “Quarterly Report” or “Report”) contains statements that are, or may be deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Any statements contained in or incorporated by reference into this Quarterly Report, that are not statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “assumption” or the negative of these terms or other comparable terminology. Statements concerning: our expectations on the timing, success of the JV’s product approvals, commercialization of the JVs products and results of operations of the JV: our expectations on the timing, success, or valuation our JV’s planned initial public offering; the timing, success or continuing valuation of our equity interest in the JV; our ability to secure future debt or equity financing needed to meet operating costs; the timing, costs and other limitations involved in obtaining regulatory approval for any product candidate; the expected efficacy of our product candidates compared to competitive products; anticipated results of our research and development programs as well as preclinical and clinical trials; expected market size, market acceptance for our product candidates; our ability to enter into future partnerships, joint ventures or other corporate transactions, ability of us being able to obtain additional resources, including debt or equity funding, and the expected benefits to be derived from those transactions; the anticipated impact of regulatory and legislative changes in the United States and foreign countries on our product candidates and operations; anticipated trends in revenues, operating expenses or financial position and results of operations; and our estimates regarding anticipated operating income or losses, future performance, future revenues and projected expense; are all forward-looking statements.

 

Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed or implied in the forward-looking statements. Factors that might cause such differences include, but are not limited to, the factors included in “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on April 15, 2026 and the other registration statements and reports that we file with the Securities and Exchange Commission (“SEC”).

 

The forward-looking statements contained in this Quarterly Report are based on our current expectations and beliefs concerning future developments and their potential effects on us. We undertake no obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

Readers should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements.

 

Corporate History

 

Oncotelic Therapeutics, Inc. (“Oncotelic”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through Oncotelic and its wholly owned subsidiaries, Oncotelic, Inc., a Delaware corporation, PointR Data, Inc. (“PointR”), a Delaware corporation, Pet2DAO Inc., a Delaware corporation and EdgePoint AI, Inc. (“EdgePoint”), a Delaware Corporation for which there are non-controlling interests, (Oncotelic, Oncotelic Inc., PointR, Pet2DAO and EdgePoint are collectively called the “Company” or “We”). The Company completed a reverse merger with Oncotelic Inc in April 2019, a merger with PointR in November 2019 and formed a subsidiary EdgePoint in February 2020. For more information on these mergers, 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026.

 

44

 

 

Company Overview

 

The Company is a clinical stage biopharmaceutical company developing drugs for the treatment of cancer. The Company’s proprietary product candidates have shown promising clinical activity in phase 2 trials for the treatment of gliomas and pancreatic cancers. The Company aims to translate its unique insights, which span more than three decades of original work using RNA therapeutics, into the deployment of antisense as a RNA therapeutic for diseases which are caused by TGF-β overexpression, starting with cancer and expanding to Duchenne Muscular Dystrophy and others. OT-101, the Company’s lead product candidate, is being developed as a broad-spectrum anti-cancer drug that can also be used in combination with other standard cancer therapies to establish an effective multi-modality treatment strategy for difficult-to-treat cancers.

 

Since April 2022, the Company has conducted the vast majority of its development efforts for OT-101 through a joint venture (the “JV”), namely GMP Biotechnology Limited (“GMP Bio”), with Dragon Overseas Capital (“Dragon”). In connection with the formation of the JV, the Company contributed license rights OT-101 for both U.S. and the rest of the world, in exchange for a 45% equity interest in GMP Bio, and Dragon agreed to provide approximately $27.6 million of research and development funding in exchange for a 55% ownership stake in GMP Bio. The Company accounts for its holdings in GMP Bio as an equity investment under the fair value option. Accordingly, the Company accounts for only its change in fair value in the Company’s investment in GMP Bio, and the income and expenses of the JV are not consolidated in the Company’s financial statements.

 

For more information on, refer to Recent Joint Venture Developments below.

 

Recent Joint Venture Developments

 

The JV’s principal activities centered on the commercialization of OT-101 for certain oncology indications in the US and looking at other territories as well. In March 2025, the JV successfully completed a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101, an antisense therapeutic targeting Transforming Growth Factor Beta 2 (“TGFβ2”), with checkpoint inhibitors (“CKIs”) and recombinant IL-2 (aldesleukin) (“IL-2”). The Phase 1 trial (ClinicalTrials.gov ID: NCT04862767) investigated the safety and tolerability of OT-101 in combination with recombinant IL-2 in patients with advanced or metastatic solid tumors. The combination showed a tolerable safety profile at the planned dosing schedule, with no unexpected safety signals identified. Based on the favorable safety data, the JV plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers. The JV is also sponsoring investigator-initiated studies for OT-101 for other oncology indications including lung cancer (non-small cell lung cancer(“NSCLC”) and Mesothelioma (“MPM”) and has started clinical development for OT-101 for pancreatic cancer. Over ten patent families have been filed exploiting the central role of TGFB2 as prognostic indicator for cancer survival and one patent family for the intracranial delivery device of brain cancer with issued patents in China and Germany.

 

In addition to OT-101, the JV has developed a nanoparticle platform (“Nano Platform”) that entails the formulation of products in new nanoparticle sizes. The JV anticipates that the Nano Platform may offer superior platform for the absorption of water insoluble drugs across a broad spectrum of cancers. The JV is working on improved formulations for OT-101 with new nanoparticle sizes. In addition, the JV has identified five additional compounds as product candidates on the Nano Platform, including the following:

 

  ● The JV has completed the formulation development of the first product, everolimus for injection. The JV has initiated a global clinical trial for that product, including open patient enrollment in Australia. The JV hopes to complete the Phase 1 trial and to move to a Phase 3 noninferiority trial against Affinitor. Phase 3 trial is slated to initiate within one year with completion and submission for marketing approval no less than three years thereafter.
     
  ● The JV is developing palbociclib for injection on the Nano Platform and expects to file the investigational new drug (“IND”) and to initiate a Phase 1 trial in 2026.

 

45

 

 

  ● The JV is developing docetaxel and paclitaxel for injection on the Nano Platform and expects to file the IND to initiate a Phase 1 trial for this product candidate in 2026. These are expected to go through the 505(b)2 bioequivalence pathway for a more rapid entrance into the market
     
  ● In addition, the JV has also identified developing carboplatin and intends to begin the development as soon as the other products clinical trials are under way.

 

The Nano or DeciparticleTM platform has proven robust and is being expand to other drug candidates through partnering. The platform is protected by more than 15 patent families covering chemical composition, manufacturing, and method of use.

 

The JV built a GMP manufacturing facility in San Diego, California (the “San Diego Facility”). In late 2024, the San Diego Facility was issued a Drug Manufacturing License by the State of California Department of Public Health and Food and Drug Branch. A significant portion of the manufacturing for the Nano Platform, including the development of Phase I clinical trial materials, is conducted at the San Diego Facility. Evaluation of larger commercial scale manufacturing is ongoing.

 

In early 2025, the Company entered into a strategic partnership with Shanghai Medicilon, Inc. (“Medicilon”) to access its industry-leading rapid IND development platform to support up to 20 IND projects, including INDs developed by the JV. All six of the compounds that the JV is developing are planned to be initiated under these INDs, and are focused on next-generation anticancer agents.

 

The JV was initially funded by equity contributions from Dragon under the terms of the joint venture agreement. That equity funding commitment has been fully paid as of September 30, 2026. In May 2025, GMP Bio and Golden Mountain Partners, an affiliate of Dragon, entered into a note purchase agreement and promissory note pursuant to which Golden Mountain Partners agreed to loan funds to the JV sufficient to meet its operating expenses for 2025 and beyond. The loans are made as monthly advances, bear interest at the Wall Street Journal “Prime” rate, and matures on December 31, 2026. Amounts due under the promissory note are convertible into equity of the JV at the election of Golden Mountain Partner at a price equal to 80% of the price for shares issued in connection with an equity financing of $20 million or more, or otherwise at a mutually agreed price.

 

The JV is planning to conduct an initial public offering on the Hong Kong Stock Exchange. The JV has hoped to conduct that in late 2026, but is now targeting the second or third quarter of 2027. . In connection with the planned public offering, the JV venture has retained a big four accounting firm as its independent accounting firm, and is in the process of securing audits of the financial statements that would be included in the public filings. The JV has also hired an investment banker and a valuation consultant to provide guidance on the potential pricing for the planned IPO. As of September 30, 2026, the Company owns 45% of GMP Bio.

 

The JV’s planned public offering is subject to a number of risks and uncertainties, some involving the JV’s ability to execute on its business plan, but others outside the JV’s control including market forces. Consequently, there is no assurance that the planned Hong Kong public offering will take place in 2027, or at all, and there is no assurance as to what enterprise value would be ascribed to the JV at that time. The JV’s planned public offering, if successful, will not provide direct funding to the Company. Any such funding would likely come through the sale or pledge of the Company’s interest in the JV, which will be subject to customary underwriter lockups and restrictions.

 

Under the fair value option, the Company periodically conducts a fair value assessment of the value of its investment in GMP Bio and records a change in the value when circumstances warrant. In late 2025, the Company hired the services of an independent, ASC-compliant valuation firm to review, perform and validate the assumptions considered by the Company and provide an ASC-compliant valuation of the JV under U.S. GAAP standards. The valuation conducted by the independent ASC-compliant valuation firm of the JV was based on various methods compliant with ASC and U. S. GAAP to derive the fair value. In its financial statements for the year ended December 31, 2025, the Company then utilized the fair value of GMP Bio, as assessed by the ASC-compliant valuation firm, attributed the ownership percentage of the Company in GMP Bio, to ascertain the Company’s interest in GMP Bio and recorded the resulting gain to the investment in GMP Bio at fair value of approximately $365.4 million. The Company relied on the inputs by the JV valuation, however, certain parameters like lack of marketability and lack of control discounts and other standard discounts, specific to the Company, have been applied to the independent valuation done by the Company to derive the ASC-compliant valuation. The Company will also appropriately adjust the fair value of the interest of the Company’s interest in the JV at the end of reporting periods and when key value inflection points are met. As the circumstances related to the JV have not materially changed since December 31, 2025, the Company assessed and determined that no additional fair value adjustment was required during the three and nine months ended September 30, 2026, and hence, the Company has not recorded a change in value of the Company’s interest in the JV.

 

46

 

 

PDAOAI

 

PDAOAI is the Company’s proprietary artificial intelligence–enabled knowledge platform, developed to support scientific, translational, and regulatory activities across its oncology pipeline. The platform was initially implemented by Oncotelic Therapeutics to streamline document search, synthesis, and analysis in knowledge-intensive environments, particularly within pharmaceutical research and development. Since its initial deployment, the Company has progressively expanded PDAOAI into a core infrastructure layer supporting research generation, biomarker discovery, and regulatory documentation across multiple programs. Unlike general-purpose artificial intelligence tools, PDAOAI has been designed specifically for pharmaceutical and biotechnology applications, with an emphasis on regulatory-grade documentation, scientific traceability, and reproducibility. The platform is intended to operate as an “evidence-interrogation” system rather than a black-box predictive engine, enabling structured ingestion, semantic indexing, and clustering of large biomedical corpora. This design allows users to query, retrieve, and synthesize information in a manner that is auditable and aligned with regulatory expectations for data provenance and scientific justification. During 2025, the Company significantly expanded the functional scope of PDAOAI and integrated it into its translational research workflow. This included the use of PDAOAI to support the preparation of peer-reviewed manuscripts, development reports, and regulatory documentation, as well as to enable interactive interrogation of scientific literature. The Company introduced interfaces that allow users to query individual publications and their associated reference networks, thereby facilitating deeper exploration of mechanistic hypotheses and clinical correlations within defined therapeutic areas. PDAOAI has also been applied to the assembly and interrogation of multi-omic and clinical datasets, particularly in the context of biomarker-driven oncology research. The platform has been used to identify, prioritize, and validate biomarkers associated with treatment response, disease progression, and survival outcomes. This capability has been most prominently demonstrated in the Company’s work on TGFB2 signaling and tumor microenvironment biology, where PDAOAI has supported analyses across multiple tumor types, including ovarian cancer, breast cancer, pancreatic cancer, hepatocellular carcinoma, and glioblastoma.

 

As disclosed in Company press releases, PDAOAI contributed to the generation of at least seven peer-reviewed publications during 2025. These publications collectively span bioinformatic biomarker discovery, tumor microenvironment analysis, nanoparticle drug delivery, and clinical outcome correlations, and include studies demonstrating prognostic and predictive roles of TGFB2 methylation and expression across multiple cancers. The Company believes that this body of work provides validation of PDAOAI’s utility as a research acceleration platform and supports its role in generating clinically relevant insights.

 

By late 2025, the Company had further evolved PDAOAI into a large-scale knowledge platform built around a comprehensive TGF-β–centric biomedical corpus, comprising over one hundred thousand curated abstracts and associated datasets. Within this framework, PDAOAI enables semantic retrieval, clustering of related concepts, and cross-referencing of molecular, clinical, and literature-derived data. The platform is designed to generate hypotheses that are not only computationally derived but also traceable to underlying evidence, thereby facilitating scientific validation and regulatory acceptance. The Company has now positioned PDAOAI as a cross-program decision-support system integrating molecular biology, pharmacology, clinical outcomes, and regulatory-grade literature. The platform is used to inform multiple aspects of the Company’s operations, including target identification, biomarker strategy, clinical trial design, and regulatory positioning. In particular, PDAOAI is intended to complement the Company’s nanomedicine and biomarker platforms by identifying patient subpopulations most likely to benefit from specific therapeutic approaches and by supporting the development of precision oncology strategies.

 

47

 

 

The Company believes that PDAOAI represents a differentiating capability within its integrated platform, enabling the convergence of artificial intelligence, molecular biology, and clinical data into a unified framework. By embedding PDAOAI across its discovery and development processes, the Company aims to accelerate insight generation, improve decision-making, and enhance the probability of clinical and commercial success across its pipeline.

 

On April 2, 2026, the Company announced that it had entered into a strategic partnership with TechForce Robotics, Inc. (“TechForce”) to advance the commercialization of its PDAOAI-enabled, GMP-compliant robotics platform. This milestone reflects the culmination of several years of research and development efforts, resulting in an integrated platform designed to combine Oncotelic’s proprietary PDAOAI capabilities with TechForce’s robotics hardware and manufacturing expertise. The system under development is designed to operate within GMP-regulated environments and is intended to enable automated material handling, real-time monitoring, and PDAOAI-enhanced compliance workflows across pharmaceutical manufacturing and related applications. The key highlights of the commercialization include:

 

  1. Integrated AI + robotics platform, combining the Company’s PDAOAI capabilities with TechForce’s scalable robotics systems to automate critical operational workflows;
     
  2. Form a GMP-Compliant Design, designed to support regulatory requirements, including data capture, audit readiness, and validation frameworks;
     
  3. Improve operational efficiency and compliance, intended to reduce human intervention, minimize contamination risk, and enhance process consistency through real-time monitoring and intelligent automation; and
     
  4. Achieve scalable manufacturing capability, intended to leverage TechForce’s hardware expertise and manufacturing network to support commercial deployment and future growth.

 

Joint Development, Manufacturing and Licensing Agreement with TechForce Robotics

 

In March, 2026, the Company entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Joint Development Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation. The Joint Development Agreement establishes a framework for the joint development, and manufacturing of AI-enabled, GMP-compliant robotic systems for use in pharmaceutical and related manufacturing environments. The integrated product to be developed combines TechForce’s robotic hardware with the Company’s proprietary PDAOAI Platform. The Company is currently testing the robotics platform.

 

Transactions with Lunai Bioworks

 

Intellectual Property Development and Services Agreement with Lunai Bioworks, Inc.

 

On April 17, 2026, the Company and Lunai Bioworks, Inc., a Delaware corporation (“Lunai”) entered into an intellectual property development and services agreement (“IP Services Agreement”), whereby the Company was to perform intellectual property development and business development services relating to a Nose-to-Brain (“N2B”) delivery platform. This includes applications in biodefense, Alzheimer’s disease (“AD”), and broader central nervous system (“CNS”) indications and excludes Parkinson’s disease and sexual dysfunction. The work shall focus on direct-to-CNS delivery to bypass the blood-brain barrier. The scope of services included scientific development, IP execution, technical data delivery, business development support and broadened biodefense focus. In connection with these services, Lunai agreed to compensate the Company a total compensation of $250,000, of which $62,500 was payable upon signing of the IP Services Agreement, $62,500 upon filing of provisional patents and $125,000 payable upon the execution of a biodefense and neurodegenerative platform IP acquisition agreement by Lunai, which was the agreement and plan for merger with Lunai, described below. The Company has completed all its obligations under the IP Services Agreement, has invoiced Lunai for the services and has recognized the revenue under the IP Services Agreement during the nine months ended September 30, 2026.

 

48

 

 

During the nine months ended September 30, 2026, the Company recorded services revenue of approximately $0.3 million in connection with the IP Services Agreement described above. No similar services revenue was recorded during the same period ended September 30, 2025.

 

Agreement and Plan of Merger with Lunai

 

On April 27, 2026, Oncotelic Inc., a wholly owned subsidiary of the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lunai, Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings Incorporated, a Delaware corporation (“Holdings”), and the holders of all of the issued and outstanding capital stock of Holdings, namely Oncotelic Inc. and Pelerin Therapeutics Inc., a corporation existing under the laws of the Province of British Columbia, Canada (“Pelerin” and, together with Oncotelic Inc., the “Holders”). Pursuant to the Merger Agreement, Holdings merged with and into Merger Sub in a triangular merger (the “Merger”), with Merger Sub continuing as the surviving corporation and as a wholly owned subsidiary of Lunai. The Merger was completed on May 1, 2026. Immediately prior to the effective time of the Merger, all of the issued and outstanding capital stock of Holdings was owned 62.5% by Oncotelic Inc. and 37.5% by Pelerin. The sole assets of Holdings at the effective time of the Merger consisted of a multi-jurisdictional patent portfolio (collectively, and as further defined in the Merger Agreement, the “Patents”), which the Holders had contributed to Holdings prior to the effective time. In consideration for the Merger, on May 1, 2026 Lunai issued to the Holders an aggregate of eight (8) shares of a newly designated series of preferred stock of Lunai, designated as “Series B Convertible Preferred Stock” (the “Series B Preferred Stock”), having an aggregate stated value (the “Stated Value”) of $20,000,000. The Series B Preferred Stock was allocated five (5) shares to Oncotelic Inc. (representing 62.5% of the Series B Preferred Stock and an aggregate Stated Value of $12,500,000). For more information on the Merger Agreement, refer to our Current Report on Form 8-K filed with the SEC on May 5, 2026.

 

The Company received Series B Preferred Stock from Lunai with a stated Value of $12.5 million in exchange for the Company’s 62.5% equity interest in Neurobridge IP Holdings Incorporated. The transaction was accounted for as a sale of nonfinancial asset under FASB ASC 610-20 since the Company transferred control of the nonfinancial asset. The Series B Preferred Stock received was recorded at its initial fair value of $1.1 million. Because the net book value of the contributed asset was $0, the Company recognized a pre-tax gain on derecognition of non-financial assets of $1.1 million, which is included within “Other Income” in the unaudited Condensed Consolidated Statement of Operations.

 

The subsequent remeasurement of the Series B Preferred Stock at fair value is governed by FASB ASC 321, Investments – Equity Securities. The Company holds its investment in publicly traded companies that have readily determinable fair value based on quoted market prices. Its investment is carried at fair value on the unaudited Condensed Consolidated balance sheets. Realized and unrealized gains and losses resulting from changes in the fair value are recognized each period in earnings within other income on the unaudited Condensed Consolidated Statements of Operations. The Company recognized $0.8 million and $0.5 million losses from the change in fair value of its equity investment during the three and nine months ended September 30, 2026.

 

IP Assignment Agreement

 

In connection with the Merger Agreement, on April 27, 2026, Oncotelic Inc. entered into an IP Assignment Agreement with Holdings, pursuant to which it agreed to contribute and assign certain assets relating to the intellectual property of the Company (collectively, the “Intellectual Property Assets”) to Holdings. For more information on the Merger Agreement, refer to our Current Report on Form 8-K filed with the SEC on May 5, 2026.

 

IP Grant-back Agreement

 

Further, on April 27, 2026, the Company and Holdings entered into an Intellectual Property Assignment and Grant-back Agreement (the “IP Grant-back Agreement”). The IP Grant-back Agreement grants back to the Company a perpetual, irrevocable, royalty-free, exclusive, non-terminable, and non-cancellable license to make, have made, use, offer to sell, sell, and otherwise exploit the Intellectual Property Assets in all fields of use except the Biodefense Field and the Alzheimer’s Disease Field as defined in the IP Grant-back Agreement, giving Holdings exclusive use of the Intellectual Property Assets in those fields. For more information on the Merger Agreement, refer to our Current Report on Form 8-K filed with the SEC on May 5, 2026.

 

49

 

 

Asset Transfer Agreement

 

Further, on April 30, 2026, Oncotelic Inc. on behalf of the Company, and Autotelic Inc. (“Autotelic”) entered into an asset transfer agreement (the “Asset Transfer Agreement”) pursuant to which Autotelic agreed to transfer all the rights, title and interest to certain assets (“Assets”), described below and owned by Autotelic to Oncotelic Inc. This Asset Transfer Agreement was entered into by both parties to effectuate the Merger Agreement. Dr. Trieu, Chairman and CEO of Oncotelic Therapeutics, Inc., is a partial owner and control person in Autotelic Inc. Autotelic Inc. currently owns less than 10% of the Company. The Assets transferred pursuant to the Asset Transfer Agreement include Peptide Y (including all variants, analogs, derivatives); Parathyroid Hormone (“PTH”), including PTH 1-34, PTH 1-84, and derivatives; Insulin (including intranasal and other formulations); Apomorphine (including intranasal and other formulations); Carbetocin (including intranasal and other formulations); any associated combination therapies, including multi-agent CNS, AD, metabolic, endocrine, or biodefense applications; and all delivery platforms, including nasal, injectable, and device-based systems and includes all patents, patent applications, know-how, trade secrets, data, formulations, manufacturing processes, regulatory filings, and all related rights associated with the Assets. In consideration for the transfer of the Assets, the Company shall issue equity of ten percent (10%) of the fully diluted outstanding shares of the Company, issuable on an uplisting of its capital stock to NYSE/NASDAQ. No cash was paid for the Asset Transfer Agreement.

 

The consideration payable to Autotelic is contingent on the Company uplisting its Common Stock to a nationally recognized stock exchange. Such shares of the Company have not been issued to Autotelic as of the date of this filing and are not due to be issued till the uplisting of the Company’s stock onto a nationally recognized stock exchange. If the uplisting does not occur, then the shares would not be issuable and neither would the transaction with Lunai be invalidated.

 

Recent Financing Transactions

 

Pacific Pier August 2026 Note

 

In August 2026, the Company entered into a Securities Purchase Agreement (the “2026 Pacific Pier SPA”), with Pacific Pier Capital II, LP (“Pacific Pier”), pursuant to which Company issued a convertible promissory note in the aggregate gross principal amount of $178,410 (the “August 2026 Pacific Pier Note”). The August 2026 Pacific Pier Note is convertible into shares of the Company’s common stock, par value $0.01 per share on or after six months following issuance date. For more information on the August 2026 Pacific Pier Note, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements.

 

The August 2026 Pacific Pier Note has an original issue discount of 12%, carries an interest rate of 12% per annum and matures on the earlier of (a) the one-year anniversary of the date of the August 2026 Pacific Pier Purchase Agreement, or (b) the acceleration of the maturity of the August 2026 Pacific Pier Note by Pacific Pier upon occurrence of an event of default or (c) on prepayment in full. The 2026 Pacific Pier Note contains a voluntary conversion mechanism whereby Pacific Pier may convert the outstanding principal and accrued interest under the terms of the 2026 Pacific Pier Note into shares of Common Stock (the “Conversion Shares”), following six (6) calendar months after the Issue Date, at a price that is lesser of (i) $0.06 (as adjusted for standard anti-dilutive events) or (ii) 85% of the lowest traded price of the Common Stock on the principal market on any trading day during the ten (10) trading days prior to the respective conversion date, subject to adjustments upon the occurrence of certain corporate events. The Company also issued 500,000 shares of Common Stock as commitment shares. For more information on the 2026 Pacific Pier Note, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements included in this report.

 

Pacific Pier June 2026 Note

 

In June 2026, the Company entered into a Securities Purchase Agreement with Pacific Pier, pursuant to which Company issued a convertible promissory note in the aggregate gross principal amount of $178,410 (the “June 2026 Pacific Pier Note”). The June 2026 Pacific Pier Note is convertible into shares of the Company’s common stock, par value $0.01 per share. For more information on the 2026 Pacific Pier Note, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements.

 

50

 

 

The June 2026 Pacific Pier Note has an original issue discount of 12%, carries an interest rate of 12% per annum and matures on the earlier of (a) the one-year anniversary of the date of the June 2026 Pacific Pier Purchase Agreement, or (b) the acceleration of the maturity of the June 2026 Pacific Pier Note by Pacific Pier upon occurrence of an event of default or (c) on prepayment in full. The June 2026 Pacific Pier Note contains a voluntary conversion mechanism whereby Pacific Pier may convert the outstanding principal and accrued interest under the terms of the June 2026 Pacific Pier Note into shares of Common Stock (the “Conversion Shares”), following six (6) calendar months after the Issue Date, at a price that is lesser of (i) $0.06 (as adjusted for standard anti-dilutive events) or (ii) 85% of the lowest traded price of the Common Stock on the principal market on any trading day during the ten (10) trading days prior to the respective conversion date, subject to adjustments upon the occurrence of certain corporate events. The Company also issued 500,000 shares of Common Stock as commitment shares. For more information on the June 2026 Pacific Pier Note, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements included in this report.

 

2026 Mast Hill Note

 

In January 2026, the Company entered into a Securities Purchase Agreement (the “2026 Mast Hill Purchase Agreement”), with Mast Hill Fund, LP (“Mast Hill”), and the Company issued a convertible promissory note in the aggregate gross principal amount of approximately $398,333 (the “2026 Mast Hill Note”). The 2026 Mast Hill Note is convertible into shares of the Company’s Common Stock. For more information on the 2026 Mast Hill Note, refer to Note 5 of the Notes to the unaudited Condensed Consolidated Financial Statements included in this report.

 

Short-term loans from related parties / families

 

As of January 1, 2025, approximately $2 million was outstanding and payable to Autotelic. During the year ended December 31, 2025 Autotelic Inc. provided additional short-term funding of approximately $1.0 million to the Company. During the nine months ended September 30, 2026, Autotelic Inc. provided additional short-term funding of $165,000 to the Company. As such, approximately $3.2 million was outstanding and payable to Autotelic at September 30, 2026.

 

As of January 1, 2025, approximately $76,000 was outstanding and payable to the Company’s CFO. During the year ended December 31, 2025, the CFO provided additional short-term funding of $10,000. As such, approximately $86,000 was outstanding and payable to the Company’s CFO at September 30, 2026.

 

In December 2023, the Company received $50,000 from the Company’s CEO. In December 2025, the amount due from PPM-2 payable to the CEO of $125,000 was converted into a short-term loan. During the nine months ended September 30, 2026 the Company repaid $70,000 to the CEO. As such, approximately $105,000 was outstanding and payable to the Company’s CEO at September 30, 2026. As of September 30, 2026, approximately $210,000 was outstanding as short-term advances from certain bridge investors.

 

Critical Accounting Policies and Significant Judgments and Estimates

 

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expense during the reporting periods. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances at the time we make such estimates. Actual results and outcomes may differ materially from our estimates, judgments, and assumptions. We periodically review our estimates considering changes in circumstances, facts, and experience. The effects of material revisions in estimates are reflected in the financial statements prospectively from the date of the change in estimate. Our significant accounting policies are more fully described in Note 2 to our condensed financial statements included elsewhere in this Quarterly Report.

 

51

 

 

We define our critical accounting policies as those accounting principles that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. We believe the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments are the following:

 

Intangible Assets

 

The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors.

 

Goodwill

 

Goodwill represents the excess of the purchase price over the estimated fair value of the identifiable net assets acquired in a business combination. Goodwill is not amortized but is tested for impairment at least annually, at the reporting unit level, or more frequently if events or changes in circumstances indicate that the asset might be impaired.

 

We have the option to first perform a qualitative assessment (commonly referred to as “Step 0”) to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If we determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, no further quantitative testing is required. If we choose to bypass the qualitative assessment, or if the qualitative assessment indicates it is more likely than not that the fair value of a reporting unit is less than its carrying amount, we perform a quantitative impairment test. The quantitative test compares the fair value of the reporting unit with its carrying amount, including goodwill. If the carrying amount of the reporting unit exceeds its estimated fair value, an impairment charge is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.

 

Fair Value of the Company’s equity investment

 

The Company accounts for its investment in the Series Preferred stock of Lunai Bioworks in accordance with ASC 321. Because the asset’s underlying common stock has a readily determinable fair value via an active public exchange, the investment is measured at fair value at each reporting date. The investment is measured using an as-converted basis, anchoring to the observable, quoted market price of Lunai’s underlying common stock on the Nasdaq. Because the preferred shares cannot be immediately liquidated on the open market, management applies a Discount for lack of marketability and other valuation discounts to reflect contractual and regulatory holding restrictions.

 

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”.

 

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards.

 

52

 

 

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note.

 

ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.

 

Derivative Financial Instruments Indexed to the Company’s Common Stock

 

We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants, which is as inherently subjective as they are for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Condensed Consolidated Statement of Income.

 

Investment - Equity Method (Fair Value Election)

 

The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares are included in the result from continuing operations. Refer to Note 6 of these Notes to the unaudited Condensed Consolidated Financial Statements.

 

Share-Based Compensation

 

We record the estimated fair value of all share-based payments issued to employees and other service providers. Our share-based payments consist primarily of stock options. The valuation of stock options is an inherently subjective process since market values are not available for any stock options in our equity securities. Market values are also not available on long-term, non-transferable stock options in other equity securities. With no market values on options to trade in our common stock and no comparable market values on any long-term non-transferable stock options, the process of valuing our stock options is even more uncertain and subjective. Accordingly, we use a Black-Scholes option pricing model to derive an estimated fair value of the stock options which we issue. The Black-Scholes option pricing model requires certain input assumptions, including the expected term of the options and the expected volatility of our common stock. Changes in these assumptions could have a material impact on the estimated fair value that we record for share-based payments that we issue. We determine the term of the options based on the simplified method, which averages the vesting period and the contractual life of the stock option. We determine the expected volatility based on the historical volatility of our common stock over a period commensurate with the option’s expected term. The Black-Scholes option pricing model also requires assumptions for risk-free interest rates and the expected dividend yield of our common stock, but we feel that these values are more objective and note that changes in these values do not have a significant impact on the estimated value of the options when compared to the volatility and term assumptions.

 

53

 

 

We are also required to estimate the level of award forfeitures expected to occur and record compensation expense only for those awards that are ultimately expected to vest. Accordingly, we perform a historical analysis of option awards that are forfeited prior to vesting, and record total stock option expense that reflects this estimated forfeiture rate.

 

Results of Operations

 

Comparison of the Results of Operations for the Three Months Ended September 30, 2026, to the Three Months Ended September 30, 2025

 

The following table sets forth key components of our results of operations for the periods indicated:

 

   September 30, 2026   September 30, 2025   Variance 
Operating expense:               
Research and development   1,622    426    1,196 
General and administrative   231,053    490,547    (259,494)
Total operating expense   232,675    490,973    (258,298)
                
Loss from operations   (232,675)   (490,973)   258,298 
Other income (expense)               
                
Interest expense, net   (286,727)   (231,338)   (55,389)
Loss from change in fair value equity investment   (750,000)   -    (750,000)
Gain (Loss) from change in fair value of derivatives on debt   108,804    (392,058)   500,862 
    -    -    - 
Net loss before controlling interests  $(1,160,598)  $(1,114,369)  $(46,229)

 

Net Loss before controlling interests

 

Net loss before controlling interests for the three months ended September 30, 2026, was approximately $1.2 million, an approximately $0.1 million increase from the $1.1 million recorded in the same period of 2025. The Company recorded lower operating expenses of approximately $0.3 million, of which approximately $0.1 million was related to lower stock-based compensation and approximately $0.2 million of lower other operational expenses, offset by approximately $50,000 of higher legal and professional expenses during the three months ended September 30, 2026, as compared to the same period of 2025. In addition, the Company recognized a gain of approximately $0.1 million from the change in fair value of derivative liabilities during the three months ended September 30, 2026, compared to a loss of approximately $0.4 million in the same period in 2025, which represents a net gain increase of $0.5 million. The gain recognized from the change in fair value of derivative liabilities during the period was primarily attributable to a decline in the Company’s common stock price, which reduced the estimated fair value of certain equity-linked derivative instruments that are remeasured at fair value each reporting period.

 

The gain was offset by higher interest expense of approximately $0.1 million following the additional convertible debts incurred in the period and a loss of approximately $0.8 million resulting from the fair value remeasurement, at September 30, 2026, of the Lunai Series Preferred Stock received in exchange for the Company’s equity interest in Neurobridge IP Holdings Incorporated.

 

Research and Development Expenses

 

Research and development (“R&D”) expenses remained similar for the three months ended September 30, 2026 compared to the same period in 2025.

 

We plan to continue, independently of the work of the JV, to increase research and development activities related to apomorphine, initiate new clinical trials for our other oncology indications as well as continue or expand on the trials and development of AI based tools and applications for OT-101; and Artemisinin for COVID-19 and other epidemics, and therefore anticipate that research and development expense may increase in the future, subject to our continuing ability to secure sufficient funding to continue planned operations.

 

54

 

 

General and Administrative Expenses

 

General and administrative (“G&A”) expenses decreased by approximately $0.3 million for the three months ended September 30, 2026, compared to the same period in 2025, primarily due to decrease in stock-based compensation of approximately $0.1 million, and approximately $0.2 million in lower operating expenses.

 

We anticipate that our G&A expenses will increase, if we are able to secure sufficient funding to continue planned operations.

 

Interest Expense, Net

 

We recorded interest expense, including amortization of debt costs, of approximately $0.3 million for the three months ended September 30, 2026 in connection with debt raised from various convertible notes, as compared to $0.2 million for the same period of 2025. For more information on debt raised from convertible notes and the JH Darbie Financing, see Note 5, Note 7 and Note 8 of the unaudited Condensed Consolidated Financial Statements of this Quarterly Report.

 

Change in value of equity securities of Lunai

 

During the three months ended September 30, 2026, the Company recorded total non-cash loss of approximately $0.8 million related to the period-end fair value remeasurement of its investment in Lunai.

 

This loss resulted from a subsequent downward fair value adjustment of the equity securities received in exchange for the Company’s interest in Neurobridge IP Holdings Incorporated. While the Series B Preferred Stock received from Lunai carries a stated value of $12.5 million, the Company recorded such consideration based on the fair value of these equity securities. No similar income was recorded during the three months ended September 30, 2025. For more information on the fair value of the equity securities in Lunai, refer to Note 2 of the unaudited Condensed Consolidated Financial Statement under “Fair Value Hierarchy – Lunai”.

 

Change in Value of Derivatives

 

During the three months ended September 30, 2026, we recorded a gain of approximately $0.1 million due to change in the value of the derivatives on the notes issued to our CEO and the bridge investors. Correspondingly, we recorded a loss of approximately $0.4 million due to change in value of the derivative on the notes issued to our CEO and a bridge investor in the comparable period in prior year.

 

Comparison of the Results of Operations for the Nine Months Ended September 30, 2026, to the Nine Months Ended September 30, 2025

 

The following table sets forth key components of our results of operations for the periods indicated:

 

   September 30, 2026   September 30, 2025   Variance 
Service Revenue  $250,000   $-   $250,000 
Total Revenue   250,000    -    250,000 
Operating expense:               
Research and development   2,762    1,020    1,742 
General and administrative   3,176,863    657,019    2,519,844 
Total operating expense   3,179,625    658,039    2,521,586 
                
Loss from operations   (2,929,625)   (658,039)   (2,271,586)
Other income (expense)               
Gain on derecognition of non-financial asset   1,100,000    -    1,100,000 
Interest expense, net   (900,830)   (642,917)   (257,913)
Loss from change in fair value equity investment   (450,000)   -    (450,000)
Gain from change in the value of derivatives on debt   121,592    32,772    88,820 
                
Net loss before controlling interests  $(3,058,863)  $(1,268,184)  $(1,790,679)

 

55

 

 

Net Loss before controlling interests

 

We recorded a net loss of approximately $3.1 million for the nine months ended September 30, 2026, as compared to a net loss of approximately $1.3 million for the same period ended September 30, 2025.

 

The higher net loss, of approximately $1.8 million, for the nine months ended September 30, 2026 as compared to the same period of 2025, was primarily due to the recording of approximately $0.3 million in revenue due to services provided to Lunai under the IP Services Agreement (See Transactions with Lunai Bioworks described in Note 9 of the unaudited Condensed Consolidated Financial Statements in this Report). No similar income was recorded during the same period ended September 30, 2025. The Company recorded higher general and administrative expenses of approximately $2.5 million of which approximately $2.3 million relates to higher stock-based compensation and approximately $0.5 million of higher legal and professional costs, offset by reduced operational costs of approximately $0.2 million. The Company also incurred higher interest expense of approximately $0.3 million and approximately $0.5 million of loss from the change in fair value of the Company’s equity securities as a result of the Series B Preferred Shares of Lunai received by the Company, offset by approximately $1.1 million non-cash gain on derecognition of non-financial asset and recording of a gain in the change in value of derivatives on debt of approximately $0.1 million

 

Service revenue

 

During the nine months ended September 30, 2026, we recorded service revenue of approximately $0.3 million as received from Lunai for certain services in connection with the IP Services Agreement. No similar revenues were recorded during the same period ended September 30, 2025.

 

Research and Development Expenses

 

R&D expenses increased marginally by approximately $2,000 for the nine months ended September 30, 2026 compared to the same period in 2025. The higher R&D cost was primarily related to higher operational costs.

 

We plan to increase research and development activities related to apomorphine, the initiation of new clinical trials for our other oncology indications as well continuing or expanding on the trials and development of AI based tools and applications for OT-101 and Artemisinin for COVID-19 and other epidemics, and therefore believe that research and development expense may increase in the future, subject to our continuing ability to secure sufficient funding to continue planned operations.

 

General and Administrative Expenses

 

G&A expenses increased by approximately $2.5 million for the nine months ended September 30, 2026 compared to the same period September 30, 2025, primarily due to higher stock-based compensation cost of approximately $2.3 million and higher legal and professional expenses of approximately $0.5 million, offset by lower operational expenses by approximately $0.2 million. The higher legal and professional costs are primarily attributed to the Company’s efforts to uplist the Company’s Common Stock to a nationally recognized stock exchange.

 

Gain on derecognition of non-financial asset and change in value of equity securities of Lunai

 

During the nine months ended September 30, 2026, the Company recorded total non-cash income of $0.7 million related to the Company’s transactions with Lunai, which comprised of a $1.1 million gain on the derecognition of a non-financial asset, alongside a subsequent $0.4 million downward fair value adjustment on the underlying Series B Preferred Stock equity securities from Lunai which carries a stated value of $12.5 million, the Company recorded these amounts based on the securities’ estimated fair value. No similar income was recorded during the nine months ended September 30, 2025. For more information on the fair value of the equity securities in Lunai, refer to Note 2 of the unaudited Condensed Consolidated Financial Statement under “Fair Value Hierarchy – Lunai”.

 

56

 

 

Interest Expense, Net

 

We recorded interest expense, including amortization of debt costs, of approximately $0.9 million for the nine months ended September 30, 2026, in connection with debt raised from various convertible notes, including the JH Darbie Financing and other debt financing, as compared to $0.6 million for the nine months ended September 30, 2025. Interest expense was higher in 2026 due to three additional notes. For more information on debt raised from convertible notes and the JH Darbie Financing, see Note 5 and Note 7 of the unaudited Condensed Consolidated Financial Statements of this Quarterly Report.

 

Change in Value of Derivatives

 

During the nine months ended September 30, 2026, we recorded approximately $0.1 million gain in value of derivatives on the notes issued to our CEO and the bridge investors. Correspondingly, we recorded a gain of approximately $32 thousand during the same period of 2025. The change in the gain is a direct result of changes to the input to the option pricing model used to value the Company’s derivatives.

 

Liquidity, Financial Condition and Capital Resources ($s in ‘000’s)

 

   September 30,
2026
  

December 31,
2025

 
Cash, including restricted cash  $84   $109 
Working capital  $(16,770)  $(16,945)
Total Oncotelic Therapeutics, Inc. Stockholders’ Equity  $263,469   $262,761 

 

Historically the Company has experienced net losses every year since inception barring a few years. Since inception, and at the end of the year ending December 31, 2024, the Company had an accumulated deficit of approximately $38 million. As of December 31, 2025, after giving effect to the re-valuation of the Company’s interest in the JV, the Company recorded net income of approximately $249 million after recording deferred taxes of $111.6 million, and as such had positive total stockholders’ equity, before non-controlling interests, of approximately $262.8 million. The Company incurred a net loss before non-controlling interest of approximately $3.1 million during the nine months ended September 30, 2026.

 

As of September 30, 2026, the Company had positive total stockholders’ equity, before non-controlling interests, of approximately $263.5 million, approximately $0.1 million in cash, approximately $1.2 million of prepaid and other current assets; and current liabilities of approximately $18 million, of which approximately $1.3 million are net assumed liabilities of the Company as part of the Oncotelic Inc. reverse merger, $12.4 million of short term debt including accrued interest, and $2.6 million is contingent liability to issue common shares of the Company to PointR shareholders upon achievement of certain milestones.

 

As of September 30, 2026 and December 31, 2025, the Company also had approximately $1.9 million and approximately $1.7 million, respectively, of long-term debt on account of the PPM-3 financing through J.H. Darbie, and $111.6 million of deferred income taxes. Management expects to incur significantly lower costs and losses, especially due to the transfer of costs over to the JV since April 2022, in the foreseeable future but also recognizes the need to raise capital to remain viable. The Company’s limited capital resources, history of recurring losses and uncertainties as to whether the Company’s operations will become profitable raise substantial doubt about its ability to continue as a going concern. The financial statements contained in this report do not include any adjustments related to the recoverability of assets or classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

57

 

 

During the past few years, the principal source of the Company’s working capital deficit has been from short term loans provided by related parties, officers and certain insiders, and issuance of convertible notes, a substantial part of which has been provided by officers and certain insiders. The Company will need to raise additional capital in order to fund its operations and continue development of its product candidates.

 

The Company received $0.3 million of revenue from services rendered to Lunai under the IP Services Agreement, but does not anticipate generating revenue from operations that will be sufficient to meets its operating requirements for the foreseeable future. Consequently, it plans to raise additional capital through the sale of equity securities and/or debt, but the Company is highly leveraged and there are no new financing arrangements are in place at this time. The Company’s principal asset is its investment in the JV. However, the interest in the JV is not an immediate source of liquidity for the Company. While the JV is planning an IPO, that will not provide capital directly to the Company. Any liquidity from the JV following an IPO will likely come through the sale of the Company’s interests in the JV, which will be subject to the timing and success of any IPO and contractual restrictions under any underwriting agreement.

 

The Company anticipates raising substantial additional capital through the sale of equity securities and/or debt, but no new financing arrangements are in place at this time.

 

If the Company is unable to access additional funds when needed, it may not be able to continue the development of these investigational drugs and the Company could be required to delay, scale back or eliminate some or all of its development programs and operations. Any additional equity financing, if available, would be dilutive to the current stockholders and may not be available on favorable terms. Additional debt financing, if available, may involve restrictive covenants and could also be dilutive. The Company’s ability to access capital is not assured and, if access is not achieved on a timely basis, would materially harm the Company’s financial condition, the value of its common stock and its business prospects.

 

Cash Flows

 

   Nine months ended September 30, 
($s in ‘000’s)  2026   2025 
Net cash used in operating activities  $(775)  $(600)
Net cash provided by financing activities  $750   $923 
Increase (decrease) in cash  $(25)  $323 

 

Operating Activities

 

Net cash used in operating activities was approximately $0.8 million for the nine months ended September 30, 2026. This was due to the net loss of approximately $3.1 million, the recording of a non-cash gain of $1.1 million from the derecognition of non-financial asset in exchange for equity investment and a non-cash gain in the fair value of the derivative of approximately $0.1 million. This was partially offset by approximately $2.5 million in stock based compensation, approximately $0.5 million from amortization of debt discounts, approximately $0.5 million loss from the change in fair value of its equity securities in Lunai (See Transactions with Lunai Bioworks described above), approximately $0.1 million for shares issued to investors and increase in operating assets and liabilities of approximately $0.1 million.

 

Net cash used in operating activities was approximately $0.6 million for the nine months ended September 30, 2025. This was due to the net loss of approximately $1.3 million and by approximately $33 thousand of change in fair value of derivative, offset primarily by changes in operating assets and liabilities of approximately $0.4 million, by approximately $0.1 million due to amortization of debt discounts, and approximately $0.2 million of stock-based compensation.

 

Financing Activities

 

For the nine months ended September 30, 2026, net cash provided by financing activities was approximately $0.7 million, primarily from net cash receipts from convertible notes with Mast Hill and Pacific Pier, approximately $0.2 million from short term loans, approximately $6,600 from sale of equity from the equity purchase agreement and offset by repayment of short term loans of approximately $70 thousand.

 

For the nine months ended September 30, 2025, net cash provided by financing activities was approximately $0.9 million, primarily due to receipt of a short-term loan from a related party of approximately $0.4 million and proceeds from a convertible debt of approximately $0.5 million.

 

58

 

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Effects of Inflation

 

We do not believe that inflation has had a material impact on our business, revenues or operating results during the periods presented.

 

Contractual Obligations

 

Our current drug development programs are based on a series of compounds called combretastatins, which we have exclusively licensed from Arizona State University, or ASU. If our current drug candidates are approved, we will be required to pay low to mid-single-digit royalties on future net sales of products associated with the ASU patent rights until these patent rights expire.

 

We also have an exclusive license from Bristol-Myers Squibb, or BMS, for certain patent rights to particular combretastatins, including CA4P. If CA4P is approved, we will be required to pay low-single-digit royalties on future net sales of products associated with the BMS patent rights until these patent rights expire.

 

As of September 30, 2026, the Company assessed that the variable rate financing June and August 2026 notes with Pacific Pier resulted in certain technical deficiencies in the provisions of the Mast Hills July 2025 and January 2026 notes, and related transaction agreements. Such deficiencies could also impact the Pacific Pier notes and agreements.  Neither lender has provided a notice of breach of the notes or agreements as of the date of this Report.  If either lender notified the Company of the breach, and the breach remained uncured for the applicable cure period, the lenders would be entitled to exercise remedies provided under the respective notes. Enforcement of these remedies could materially increase the Company’s near-term cash requirements, restrict access to financing and impair its ability to continue operations. For more information on the said notes, including remedies, refer to Note 5 to this Report. Further, as of September 30, 2026, the Company has not recorded an additional liability for incremental deficiency-related obligations. If the additional liability were to be recorded, the Company estimated an additional financial exposure, excluding principal and interest already recognized, to be approximately $0.2 to 0.7 million. The Company will reassess these obligations at each reporting date based on the contractual terms and all available information.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Our cash is maintained in U.S. dollar accounts. We have adopted a policy for the cash that we hold, and also for any cash equivalents and short-term investments that we may hold, the primary objective of which is to preserve principal, while also maintaining liquidity to meet our operating needs and maximize yields to the extent possible. Our cash equivalents and short-term investments can be subject to credit risk, and would be likely to decrease in value if market interest rates increase. However, due to the generally conservative nature of our investments and relatively short duration, we believe that interest rate risk is mitigated.

 

Although we may from time-to-time manufacture drugs and conduct preclinical or clinical trials outside of the United States, we believe our exposure to foreign currency risk to be immaterial. We do not use any type of hedging arrangement to mitigate any foreign currency risk.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

 

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”) conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our CEO and our CFO each concluded that our disclosure controls and procedures are not effective at that time as a result of certain material weaknesses in our internal control over financial reporting discussed below.

 

59

 

 

Material Weaknesses in Internal Control over Financial Reporting

 

Management conducted an assessment of the effectiveness of our internal control over financial reporting as of September 30, 2026, based on the framework established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has determined that the Registrant’s internal control over financial reporting as of September 30 2026, was not effective as a result of certain material weaknesses.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses which are observed in many small companies with a small number of accounting and financial reporting staff:

 

● Lack of adequate independent directors on the Company’s board of directors and committees to oversee financial reporting responsibilities;
   
● Inadequate or lack of segregation of duties;
   
● Lack of dedicated resources and experienced personnel to design and implement internal control procedures to support financial reporting objectives;
   
● Lack of risk assessment procedures on internal controls to detect financial reporting risks on a timely manner.

 

Management’s Plan to Remediate the Material Weaknesses

 

Management plans to implement measures, subject to the availability of resources required to design and maintain such controls, designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively. The implementation and remediation measures are subject to the availability of financial and therefore human resources. The remediation actions planned include:

 

● Continue to search for, evaluate and recruit qualified independent outside directors;
   
● Once independent directors are on Board, to augment or replace the non-independent directors to the Audit Committee and other committees.
   
● Identify gaps in our skills base and the expertise of our staff required to meet the financial reporting requirements of a public company; and
   
● Continue to develop policies and procedures on internal control over financial reporting and monitor the effectiveness of operations on existing controls and procedures.

 

Changes in Internal Control over Financial Reporting

 

During the three months ended September 30, 2026, we have not made any substantial progress in our planned remediation efforts, however, we are optimistic that the Company to complete its planned execution of internal controls over financial reporting upon the availability of resources.

 

We are committed to maintaining a strong internal control environment and believe that these remediation efforts will represent significant improvements in our control environment. Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

 

60

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. As of September 30, 2026, we are not involved in any legal proceedings. Historically, the outcome of all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity.

 

Item 1A. Risk Factors

 

For information about the risks and uncertainties related to our business, please see the risk factors described in our 2025 Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 15, 2026, and other SEC filings. The risks described below and in our 2025 Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

 

Item 2. Unregistered Sales of Equity Securities and Use Of Proceeds

 

All unregistered sales of equity securities during the three months ended September 30, 2026, were previously reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2026. Accordingly, no new or additional disclosures are required under this Item.

 

Item 3. Defaults upon Senior Securities

 

There have been no material changes to any previously disclosed defaults upon senior securities during the period covered under this Quarterly Report that would require disclosure under Item 1 of Part II of for 10-Q

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

Item 5. Other Information

 

None.

 

61

 

 

ITEM 6. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

In reviewing the agreements included as exhibits to this Quarterly Report, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the parties to the applicable agreement and:

 

  ● should not, in all instances, be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;
     
  ● have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;
     
  ● may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and
     
  ● were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

 

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the Company may be found elsewhere in this Quarterly Report and the Company’s other public filings, which are available without charge through the SEC’s website at http://www.sec.gov.

 

The following exhibits are included as part of this Quarterly Report and should not be considered as a complete list of exhibits. A more complete list of previously filed Exhibits can be found with our 2025 Annual Report on Form 10-K filed with the SEC on April 15, 2026:

 

        Incorporated by Reference
Exhibit Number   Description   Form   Filing Date   Exhibit Number   Filed Herewith
                     
10.1   Form of Restricted Stock Unit Grant Agreement   8-K   07/14/2026   10.1    
                     
10.2   Securities Purchase Agreement   8-K   08/04/2026   10.1    
                     
10.3   Convertible Promissory Note   8-K   08/04/2026   10.2    
                     
31.1   Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a).               X
                     
31.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a).               X
                     
32.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.               X
                     
32.2   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.               X
                     
101.1   Interactive Data Files for the quarterly period ended September 30, 2026               X
                     
101.INS   Inline XBRL Instance Document               X
                     
101.SCH   Inline XBRL Taxonomy Extension Schema Document               X
                     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document               X
                     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document               X
                     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document               X
                     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document               X
                     
104   The cover page from the Company’s Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2026 has been formatted in Inline XBRL (Inline Extensible Business Reporting Language)               X

 

* Confidential treatment has been granted for portions of this Exhibit. Redacted portions filed separately with the Securities and Exchange Commission.
+ Management contract or compensatory plan or arrangement.

 

62

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ONCOTELIC THERAPEUTICS INC.  
     
By: /s/ Vuong Trieu  
  Vuong Trieu, Ph.D.  
  Chief Executive Officer and Director (Principal Executive Officer)  
     
Date: November 16, 2026  
     
By: /s/ Amit Shah  
  Amit Shah  
 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 
     
Date: November 16, 2026  

 

63

 

Keep reading